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Abstract 
CD8+ T-cells target infected and dysregulated cells for deletion. Failure of this 
response can result in persistent challenge, such as cancer or chronic infection. CD8+ 
T-cells recognize peptides in the context of major histocompatibility complex class I 
(MHCI) molecules on the surface of host cells. The detection of T-cell antigens 
involves the binding of two receptors (TCR and CD8) to a single ligand (pMHCI). 
Individual TCRs cross-react with >106 different peptide antigens to ensure coverage 
of all possible pMHCI. As a result of this high level of T-cell crossreactivity the 
TCR/pMHCI interaction is usually suboptimal and significant scope exists in 
optimization for therapeutic benefit. The CD8 coreceptor enhances T-cell sensitivity 
through several mechanisms and has a potent ability to tune the antigen specific T-
cell response. The pMHCI/CD8 interaction is characterised by very weak affinity. 
Increasing the strength of the pMHCI/CD8 interaction by 15-fold has been shown to 
result in complete loss of antigen specificity. In this thesis, I have shown that loss of 
antigen specificity occurs at a defined pMHCI/CD8 threshold (KD ~ 27 µM). This 
finding suggests that there is scope to increase the strength of the pMHCI/CD8 
interaction for therapeutic benefit without non-specific CD8 T-cell activation. I 
demonstrated that increasing the strength of the pMHCI/CD8 interaction by 
engineering a point mutation into cell surface CD8 can result in improved T-cell 
antigen sensitivity. I have further classified the means by which CD8 can control T-
cell crossreactivity and how altering the strength of the pMHCI/CD8 interaction can 
alter the focus of the TCR. And finally, I demonstrated that the level of CD8 
expressed at the surface can have a dramatic effect on T-cell activation. Overall, I 
have demonstrated that cell surface CD8 can be engineered to enhance the 
therapeutic efficacy of adoptive T-cell transfer irrespective of antigen specificity. 
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Chapter 1  
Introduction 
1.1 The Immune System 
1.1.1 Overview of the Immune System 
The function of the immune system is to protect the host against damage; either in 
the form of infectious agent challenge or by dysregulation of self cells e.g. 
neoplasia. The immune system can be split into two parts, the innate and the 
adaptive systems, which are characterised by the speed of the response, and the 
specificity of targeting. 
All multicellular organisms have some form of innate (or natural) immunity (Fearon 
and Locksley, 1996). The more sophisticated adaptive, or acquired, response is 
found only in vertebrates, having evolved 400 million years ago, and involves a 
highly specific (targeted) response to challenges, which is increased with 
subsequent exposure owing to its capacity for ‘immunological memory’. The level 
of response changes throughout the host’s life as new pathogens are encountered. 
The different ways in which pathogens are recognised and responded to forms the 
main difference between the two systems. In order to mount an immune response, 
the host’s immune systems must first recognise a challenge, which in turn results in 
effector function activation to control or eliminate the infection. This response 
must be regulated i.e. kept under control to ensure damage to self does not occur, 
and, in the case of the adaptive immune response, remembered, so that a greater 
and more rapid response may be mounted upon repeated challenge. 
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1.1.2 The Innate System 
The innate immune system utilises germ-line encoded proteins, that recognise 
molecular patterns which are common to microbial pathogens (pathogen-
associated molecular patterns; PAMPs) via pattern recognition receptors (PRRs) 
(Medzhitov and Janeway, 1998), of which toll-like receptors (TLRs) are vitally 
important (Moser and Leo, 2010). The response is elicited immediately upon 
engagement of these receptors, and the response is the same upon repeated 
exposure to the pathogen. Activation of PRRs by PAMPs can elicit responses such 
as phagocytosis (by macrophages, neutrophils and monocytes), synthesis of anti-
microbial peptides (via eosinophils and basophils), and natural killer cell 
migration and activation, and complement release. The innate immune 
response may thus be considered to be the first line of defence against harmful 
agents. 
1.1.3 Adaptive Immunity 
The adaptive immune system is highly specialised, acquired, develops through the 
lifetime of the host, and is capable of recognising and responding to challenges 
presented by pathogens with rapid mutation rates, which have evolved to evade 
the innate response (Moser and Leo, 2010). One hallmark of the adaptive response 
is its capacity for immunological memory, whereby response is both quicker and 
greater upon repeated challenge (Vischer et al., 1967, Klaus, 1978). It is organised 
around lymphocytes, which express a vast array of unique antigen-specific 
receptors. Lymphocytes develop in two distinctly different anatomical locations; 
the thymus and the bone marrow (Boehm, 2011), giving rise to two different 
lineages (T- and B-cells, respectively). The adaptive immune system may therefore 
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be further sub-divided in to the humoral (B-lymphocytes) and cell-mediated (T-
lymphocytes) responses. 
1.1.4 B-lymphocytes
The humoral response, named from the ancient medical term ‘humors' (Nutton, 
2005), recognises antigen via the B-cell receptor (BCR), a membrane-bound 
immunoglobulin (Ig), which upon activation, causes B-cells to terminally 
differentiate into plasma cells, and secrete antibody (Ab), an immunoglobulin of 
the same specificity as the B-cell receptor, into the extra-cellular space (Hardy 
and Hayakawa, 2001, McHeyzer-Williams and Ahmed, 1999, Shapiro-Shelef and 
Calame, 2005). Antibodies bind pathogens and toxins, in some cases marking them 
for phagocytosis or complement destruction by the innate immune system (Cohen, 
1991, Savill et al., 1993, Kerr et al., 1972). Antibodies can also recruit other cells 
of the immune system to the site of infection, facilitating destruction and removal 
by T-cells (Cohen et al., 1985, Kerr et al., 1972). 
1.1.5 T-lymphocytes
T-cells are responsible for the cellular immune response, or ‘cell mediated
Immunity’. T-cells are thymically derived from a common progenitor cell, and 
express a unique T-cell receptor (TCR) at their cell surface. In response to 
challenge, a single T-cell may proliferate thus giving rise to a clonal population of 
T-cells, all expressing the appropriate TCR, in a process termed, ‘clonal expansion’
(Denizot et al., 1986). There are several different functional subsets of T-cell, and 
a degree of plasticity can exist between some of these T-cell subsets (Table 1.1).
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Type Phenotype (cell surface) Effector molecules 
CD4 Naïve αβTCR, CD3, CD4, 
CCR7, CD45RA, CD62LHI, 
IL-7R(CD127) 
- 
Helper, TH1 αβTCR, CD3, CD4, 
IL-12R, IFNγR, CXCR3 
IFNγ, IL-2, LTα 
Helper, TH2 αβTCR, CD3, CD4, 
IL-4R, IL-33R, CCR4, 
IL-17RB, CRTH2 
IL-4, IL-5, IL-10, 
IL-13 
Helper, TH9 αβTCR, CD3, CD4, IL-9, IL-10 
Helper, TH17 αβTCR, CD3, CD4, 
CD161, IL-23R, CCR6, 
IL-1R, 
IL-17A, IL-17F, 
IL-21, IL-22, 
CCL20 
Helper, TH22 αβTCR, CD3, CD4, 
CCR10 
IL-22 
Helper, TFH αβTCR, CD3, CD4, 
CXCR5, SLAM, OX40L, 
CD40L, ICOS, IL-21R, PD1 
IL-21 
Natural Treg αβTCR, CD3, CD4, 
CD25, CTLA4, GITR 
IL-10, TGFβ, 
IL-35 
Inducible Treg αβTCR, CD3, CD4, 
CD25, CTLA4, GITR 
IL-10, TGFβ 
Central memory αβTCR, CD3, CD4, 
CCR7HI, CD44, CD62LHI, 
IL-7R(CD127), IL-15R 
IL-2, CD40L,  
(IL-4, IFNΥ, IL-17A) 
Effector memory αβTCR, CD3, CD4, 
CD62LO, CD44, IL-
7R(CD127), 
IL-15R, CCR7LO
Inflammatory 
cytokines+++
CD8 Naïve αβTCR, CD3, CD8ΑΒ,  
CCR7, CD45RA,  
CD62LHI, IL-7R(CD127) 
 - 
Cytotoxic 
effector 
αβTCR, CD3, CD8αβ, Perforin, Granzyme, 
IFNγ 
Central memory αβTCR, CD3, CD8αβ, 
CCR7HI, CD44, CD62LHI, 
IL-7R(CD127), IL-15R 
IL-2, CD40L,  
(IL-4, IFNΥ, IL-17A) 
Effector memory αβTCR, CD3, CD8αβ, 
CD62LO, CD44, IL-
7R(CD127), 
IL-15R, CCR7LO
Inflammatory 
cytokines+++
Exhausted CD3, CD8αβ, PD1, TIM3, 
1B11, LAG3 
- 
others Γδ γδTCR, CD3 IFNγ, IL-17A, 
IL-17F, IL-22 
NKT Vα24Jα17-αβTCR, CD3, 
NK1.1, SLAMF1, TGFβR 
IL-4, IFNγ, IL-17A 
MAIT Vα7.2Jα19-αβTCR, CD3, 
NK1.1, SLAMF1, TGFβR 
IL-4, IFNγ, IL-17A 
IEL ΑβTCR or γδTCR, 
CD3, CD8αα, B220 
IL-10, TGFβ 
Anergic αβTCR, CD3, CTLA GRAIL, CBL-B, ITCH, 
NEDD4 
Table 1:1 T-cell subsets (Martinez, 2010). 
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The TCR may be comprised of either α and β (αβ TCR), or, γ and δ (γδ TCR) sub-
units, giving rise to an αβTCR or a γδTCR, the αβTCR usually being the more 
abundant. During thymic maturation, αβ T-cells become committed to expressing 
either the CD4 or the CD8 co-receptor. 
1.1.6 CD8+ T-cells 
Occasionally referred to as cytotoxic T-cells (Tc) due to their function, CD8+ T-cells 
recognise intracellular challenge in the context of target cell surface expressed 
peptide-major histocompatibility complexes class I (pMHCI), which are 
constitutively expressed on most nucleated mammalian cells. pMHCI are comprised 
of small peptide fragments (8-14 amino acids in length) presented in the context of 
major histocompatibility complex class I molecules (MHCI) (Davis and Bjorkman, 
1988, Bjorkman et al., 1987b, Bjorkman et al., 1987a). Naïve CD8+ T-cells are 
capable of recognising this challenge if their specific TCR can bind the target 
pMHCI, triggering expansion, however differentiation into an effector phenotype is 
required to elicit cytotoxicity (Trifari et al., 2013, Pennock et al., 2013). Effector 
CD8+ T-cells bring about target cell death by secretion of perforin and granzymes 
(Trapani and Smyth, 2002, Trapani, 2012). This thesis is concerned mostly with 
CD8+ T-cells, thus their function will be discussed in further detail later.  
1.1.7 CD4+ T-cells 
CD4+ T-cells recognise antigen presented via MHCII, which are only expressed on 
professional antigen presenting cells (dendritic cells, macrophages and B-cells), 
and present slightly longer peptide fragments, typically 15-24 amino acid length, of
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extracellular origin. CD4+ T-cells may be further sub-divided into regulatory T-cells 
(TReg), which may be natural (generated in the thymus and committed to this 
function) or inducible (differentiate into this phenotype from naïve CD4+ T-cells), or 
helper T-cells (TH), of which there are several further subsets. Both subsets of TReg
cells are responsible for promotion of tolerance and immunosuppression by both 
contact-dependant and contact-independent means, although there exists slight 
differences in their phenotypes and effector function (Table 1.1). The first 
described further differentiation of T-cells sub-sets from that fixed by their thymic 
ontogeny was of naïve CD4+ T-cells into TH1 and TH2 (Sad and Mosmann, 1994, 
Mosmann and Sad, 1996). Further sub-sets of helper T-cells have since been 
described; TH9, TH17, TH22 and follicular helper T-cells (TFH) (Bluestone et al., 
2009). Broadly speaking TH1 cells promote cell-mediated immunity to intracellular 
challenges. They secrete IFNγ and induce macrophage activation by up-regulation of 
inducible nitrous oxide synthase (iNOS). TH2 cells promote humoral immunity; they 
stimulate antibody release and eosinophil activation (thus are also important in 
parasitic disease). They have also been implicated in many CD4+ T-cell mediated 
allergic conditions, e.g. asthma (Ray and Cohn, 1999). TH9 cells are involved in 
clearance of parasitic disease, particularly gastro-intestinal nematodes, and have 
been implicated in allergic disease and are characterised by their potent production 
of IL-9 (Kaplan, 2013). TH17 cells promote immunity against fungi and bacteria and 
are found mainly at mucosal surfaces (Annunziato et al., 2007). They are anti-
inflammatory and, again, have been implicated in CD4+ T-cell mediated 
autoimmune disease (Park et al., 2005). TH22 cells have only recently been 
classified and whether they are a true independent subset remains unclear, however 
this phenotype is found in inflammatory skin disease (Eyerich et al., 2009, Fujita, 
2013). TFH cells are found in lymphoid follicles and promote germinal centre immune 
responses. They provide help for B-cell class switching (Crotty, 2014). Plasticity, or 
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the potential to alter phenotype from one to another, exists between the TH subsets 
and also inducible TReg cells, especially in the case of the TH17 and TFH subsets (Zhou 
et al., 2009, Bluestone et al., 2009, O'Shea and Paul, 2010, Murphy and Stockinger, 
2010). Experimentally some authors have demonstrated that cells possess the 
ability to induce phenotype change, however it has been argued whether true 
plasticity and the ability of these cells to switch phenotype as required exists in 
vivo or whether there is merely normal differentiation down a terminal pathway 
(Hirahara et al., 2013). 
1.1.8 γδ T-cells 
The function of γδ T-cells is less clearly understood, however they are found 
enriched at epithelial surfaces and appear to have some characteristics of both 
innate and acquired immunity (Wencker et al., 2014). γδ T-cells are, like αβ T-cells, 
differentiated in the thymus from a common lymphoid progenitor, with their TCR 
being formed by a similar re-arrangement process to the αβ TCR. Indeed the TCRδ 
gene locus is embedded within the TCRα gene locus (Vantourout and Hayday, 2013), 
and recent work has identified a TCR comprised of a variant δ chain combined with 
the VJα, paired with the β chain (Pellicci et al., 2014). 
γδ T-cells make up 2-5% of circulating T-cells in man, however some individuals 
have considerably more than this as their resting normal, and in the context of some 
immunological challenge this can increase to over 50%, suggesting that they are 
capable of undergoing expansion in the face of challenge similarly to αβ T-cells. 
Abundance of γδ T-cells also varies greatly across species, with, for example, 
farmyard ungulates having 70-80% of their CD3+ population being γδ+ (Baldwin and 
Telfer, 2015).  
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There is a small variation of Vδ arrangements, of which Vδ1, Vδ2 and Vδ3 are the 
most common (Adams et al., 2015). Vδ1 γδ T-cells have been shown to recognise 
certain lipids such as supfatide and α-Galactosylceramide (α-GalCer), in the context 
of CD1d (Uldrich et al., 2013). Other ligands recently identified include other CD1 
ligands, phosphatate activating Vδ9 TCRs, and members of the butyrophilin family, 
BTN3A activating Vγ9Vδ2 TCR. Whilst the structure of a γδ TCR complexed with 
CD1d-αGalCer has recently been solved (Uldrich et al., 2013), the exact role and 
function of γδ T-cells remains uncertain. 
1.1.9 Other T-cell subsets 
In addition to the well-characterised CD4+ and CD8+ αβ T-cells, there are other 
subsets which are less well characterised. Intraepithelial lymphocytes (IELs) are 
found only in the intestinal mucosa (Sheridan and Lefrancois, 2011, Sheridan and 
Lefrancois, 2010). They may express either an αβ or a γδ TCR. They express CD8αα 
and are thought to have a regulatory function (Leishman et al., 2001). Natural Killer 
T-cells (NKT cells) express an αβ TCR, but no co-receptor. They are CD1d restricted,
and do not recognise Major Histocompatibility Complex (MHC). They have been 
shown to have both anti-inflammatory and pro-inflammatory functions, but their 
exact role is as yet uncertain. Mucosal associated invariant T-cells (MAIT cells) 
express an αβ TCR with an invariant α-chain, and no associated co-receptor 
(Sheridan and Lefrancois, 2011). MAIT cells are MR1 restricted, but are otherwise 
similar to NKT cells, and both may be considered innate-like T-cells (Bennett et al., 
2015). 
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1.2 Surface Molecule Interactions of T-cells 
1.2.1 The T-cell Receptor (TCR) 
The TCR is a heterodimer which consists of an alpha (α-) and a beta (β-) chain, and 
associates at the cell surface with CD3, which in turn is made up of the sub-units 
CD3-gamma (CD3γ), CD3-delta (CD3δ), CD3-epsilon (CD3ε) and CD3-zeta (CD3ζ) 
(Figure 1.1). The αβTCR recognizes small antigenic peptide fragments presented in 
the context of MHC molecules at the cell surface; and is therefore responsible for 
the specificity of T-cell activation. Both αβ and γδ T-cells are thymically derived, 
and their TCRs are formed by RAG-mediated V(D)J recombination (discussed in more 
detail in section 1.5.2). αβ T-cells are frequently described in the literature as 
‘conventional’ T-cells, although this largely seems to be because more is known 
about their function, and, in man at least, they are usually more frequent.  
The TCR is generated through somatic re-arrangement (including mutation on 
recombination) of a limited number of genes, giving rise to a vast repertoire of 
recognition receptors (n = 1018)(Mason, 1998, Arstila TP, 1999). Of this potential 
repertoire diversity, it has been shown that the actual number of different TCRs 
which may be present in the blood at any given time is a minimum of 25 x 106, with 
the maximum number being dictated by the number of α-chains available (Arstila 
TP, 1999). Artsilla et al found that in naïve T cells, they were able to demonstrate 
106 β-chain possibilities, and 25 α-chains, however this reduces to 1-2 x 105 β-chains 
and a single α-chain in the memory pool. Other authors have shown different 
estimates of TCR diversity; Nikolich-Žugich et al calculated 2.5 x 107 TCR clonotypes 
in man (Nikolich-Zugich et al., 2004), and demonstrated more variety in the alpha 
chain. 
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Figure 1.1: The TCR/CD3 complex. 
The heterodimeric αβTCR can only be expressed at 
the cell surface in association with the six sub-
units that comprise the CD3 complex. There are 
ten ITAMs within the cytoplasmic tails of the CD3 
sub-units, which must be phosphorylated by 
kinases such as lck in order to initiate TCR 
triggering. An essential function of the co-
receptor, be it CD4 or CD8, is thought to be to 
recruit these kinases to the CD3 complex 
facilitating triggering. 
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It is estimated that there are around 1012 T-cells in the adult host’s blood (in man) 
at any one time, although the number of different specific TCRs and the frequency 
of repetition is uncertain. In the mouse, it has been shown that there are less TCRs 
available in the blood, as would be expected owing to the smaller circulating 
volume and thus smaller number of T-cells circulating, and this has been shown to 
be in the region of 1-2 x 106 (Armanda Casrouge, 2000). 
1.2.2 The γδTCR 
The γδTCR is derived by somatic recombination of the γ and δ gene loci in the 
thymus, in an identical manner to the αβTCR. As has already been discussed, less is 
known about the structure and function of the γδTCR, although it is known that 
they are not co-receptor dependent, or MHC-restricted. The recent discovery of a 
TCR comprised of a pairing of part a δ-chain with an αβTCR, the δ/αβTCR (Pellicci 
et al., 2014) may suggest the existence of other combinations.   
1.2.3 Major Histocompatibility Complex (MHC) 
MHC genes are highly diverse. Indeed they are one of the most polymorphic genes 
expressed (Okamura et al., 1997), with over 12,500 MHCI alleles and over 4,600 
MHCII alleles having thus far been identified in man (Robinson et al., 2015). They 
are also co-dominant and polygenic, i.e. all genotypes present are concurrently 
expressed. There are two different classes of MHC molecules: MHC class I (MHCI) 
and MHC class II (MHCII) (Neefjes et al., 2011, Amadou et al., 1999, Maenaka and 
Jones, 1999). MHCI molecules are expressed on the surface of most nucleated cells 
within the body (Maenaka and Jones, 1999, Shatz, 2009, Corriveau et al., 1998, Joly 
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et al., 1991), and they present small (8-14 amino acids in length), linear peptide 
fragments, which have been processed from intracellular proteins (Okamura et al., 
1997, Amadou et al., 1999, Maenaka and Jones, 1999, Praveen et al., 2010, 
Germain, 1994). TCRs capable of recognising these peptide-MHCI complexes (pMHCI) 
are co-expressed at the cell surface with the co-receptor molecule CD8 (Germain, 
1994). These CD8+ T-cells recognise and result in death of infected or damaged and 
dysfunctional cells, i.e. they are necessary for the control of intracellular challenges 
(Harty et al., 2000). Nucleated cells may express up to 106 MHCI on their cell surface 
(Yewdell et al., 2003), although some cell populations express far less, and certain 
diseases or conditions such as neoplasia, may result in down-regulation leading to 
potential immune system evasion.  
In contrast, MHCII molecules are predominantly expressed by professional antigen 
presenting cells (APCs) and the peptide fragments presented are slightly larger (>13 
amino acid length) and processed from extracellular proteins (Cella et al., 1997, 
Germain, 1994, Cresswell, 1994). The cell surface co-receptor found on T-cells that 
co-engages with pMHCII complexes is CD4. Whilst the majority of αβTCRs are 
restricted to either MHCI or MHCII (Van Laethem et al., 2012), there are exceptions 
that are capable of recognising antigens presented in the context of both; however, 
their specificity is determined by their co-receptor phenotype (Pearce et al., 2004, 
Matechak et al., 1996). 
1.2.4 MHC structure 
MHCI comprises two glycoprotein chains, an α chain which is associated with β2-
microgloubulin (β2m). The α-chain (or ‘heavy chain’) consists of three domains (α1, 
α2 and α3), and spans the cell membrane. The smaller and non-polymorphic β2m 
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sub-unit is associated with the heavy chain, but is not anchored to the cell 
membrane. The peptide is presented in a closed-ended peptide-binding groove, 
formed by the α1 and α2 domains. The MHCII glycoprotein comprises an α and β 
chain, which both consist of two domains, and both span the cell membrane. The 
peptide-binding groove is open ended, facilitating the presentation of larger 
peptides (Figure 1.2). MHCs are hugely polymorphic, with each MHC able to present 
a range of different peptides in its peptide-binding groove. Whilst not all of the 
thousands, or in some cases millions, of possible peptides which may be presented 
exist in nature (Wooldridge et al., 2012), a great many do, giving rise to the vast 
array of peptides which are presented to the immune system at the cell surface. It 
is estimated that there are of the order of 1015  different pMHCs expressed in the 
human host (Wooldridge et al., 2012). It has already been stated that a single cell 
may express up to 106 MHCI at its cell surface (Yewdell et al., 2003), and whilst 
some of these may present the same peptides, the vast majority will differ, creating 
a very complex environment at the cell surface for the immune system to survey in 
order to identify anomalous cells.  The potential number of different peptide 
possibilities can be mathematically calculated (>1015 (Wooldridge et al., 2012)). 
Each individual will express 6 different MHCI (two HLA-A, two HLA-B, and two HLA-
C) on the surface of their cells, and up to 6 different MHCII (two HLA-DR, two HLA-
DQ and two HLA-DP) giving rise to their individual tissue type, or MHC restriction 
(Sewell, 2012); HLA (Human Leucocyte Antigen) being the specific human MHC. This 
restriction is genetically pre-determined, however the TCRs that recognise them are 
selected during development in the thymus
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Figure 1.2: MHC class I and MHC class II 
MHCI molecules are expressed on most nucleated 
cells. They comprise two polypeptide chains; a 
single ‘heavy chain’ made up of a cytoplasmic 
domain, a trans-membrane domain, and three 
extracellular domains (α1, α2 and α3), associated 
with the much shorter, single-domained and non-
polymorphic β2m. The peptide-binding groove is 
formed between the α1 and α2 domains at the 
membrane distal part of MHCI, and is highly 
variable between MHCI alleles. 
MHCII are expressed only on professional APCs 
(dendritic cells, macrophages and B-cells). They 
also are comprised of two polypeptide chains, α 
and β, however here they are similarly sized and 
each comprise of a cytoplasmic domain, a trans-
membrane domain and two extracellular domains 
(α1 and α2, and β1 and β2 respectively). Despite 
the differences thus far described, there are 
similarities to MHCI, the peptide is presented in a 
binding groove at the membrane distal part of the 
molecule, in this case between the α1 and β1 sub-
units. Again, this region varies between MHCII 
alleles.
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1.2.5 Antigen Processing and Presentation by MHCI 
As has been previously mentioned, this thesis focuses on CD8+ T-cells, which are 
MHCI-restricted. MHCI are expressed on most nucleated mammalian cells. MHC are 
polygenic, therefore the individual host can express up to 6 different MHCI alleles, 
capable of presenting a multitude of different small peptide fragments on the cell 
surface (Germain, 1994, Janeway CA Jr, 2001). For the most part, these peptide 
fragments are of intracellular origin, derived from the cell’s own translational 
machinery, allowing the immune system to scan the proteins present inside that 
cell, thus facilitating immune surveillance. There does however exist evidence of 
extracellular peptides being processed and presented in this manner in a process 
termed cross-presentation (Harding and Song, 1994, Cao et al., 2002, Accapezzato 
et al., 2005). 
Protein is degraded in the cytosol via the ubiquitin proteasome pathway, a process 
conserved in the eukaryotic cell from yeast to mammal. Proteins in the cytosol are 
flagged for degradation and polyubiquitinated, which in turn allows binding of the 
proteasomal 19S regulatory cap (Adams, 2003), resulting in denaturation of the 
protein, allowing it to feed into the proteasomal core where enzyme degradation 
occurs (Gaczynska et al., 1993, Rock et al., 1994). The peptide fragments generated 
during this process are then transported into the endoplasmic reticulum via the 
Transporter Associated Processing (TAP) complex where it binds to the newly 
synthesised MHCI molecules. Chaperone proteins such as calnexin, tapasin, 
calreticulin and ERp57 associate with the MHCI forming the Peptide Loading 
Complex (PLC), which in turn facilitates the loading of peptides into the peptide-
binding groove. Tapasin also has a role in peptide editing, allowing a range of 
peptides to be presented at the cell surface (Praveen et al., 2010). Vesicles 
containing the newly formed pMHCI may then traffic to the cell surface (Figure 1.3
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Figure 1.3: Antigen Presentation by MHCI 
Proteins in the cytosol are denatured and are thus 
able to feed into the core of the proteasome 
where they are degraded by enzymes (A). The 
resultant peptide fragments enter the endoplasmic 
reticulum (ER) via the Transporter Associated 
Processing (TAP) complex. Chaperone protein and 
the immature MHCI form the peptide-loading 
complex (PLC), loading the peptide onto the 
peptide-binding groove (B). β2m associates, and 
the fully formed pMHCI move through the ER and 
traffics to the cell membrane via vesicles (C). The 
pMHCI are expressed on the cell surface, where 
they may be recognised by specific CD8+ T-cells 
(D).
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It should also be noted that viral antigens are presented on the cell surface very 
rapidly after infection, far faster than the half-life of the viral peptide would 
permit, and even several hours before functional viral proteins are first detected in 
the cell (Neefjes et al., 2011, Vyas et al., 2008, Schubert et al., 2000). This anomaly 
is because of degraded ribosomal products (DRiPs) within the cell (Schubert et al., 
2000, Berglund et al., 2007). These DRiPs are protein fragments resultant from 
anomalous protein synthesis (e.g. deletions, insertions or mutations in translation 
etc.), which are rapidly degraded to prevent the formation of protein aggregates 
within the cytosol that would otherwise be damaging to the cell (Neefjes et al., 
2011). 
MHCI molecules are unstable in the absence of peptide, meaning that all MHCI at 
the cell surface are pMHCI complexes. The peptide is bound as the MHC forms in the 
endoplasmic reticulum (ER) and is trafficked to the surface in this form. There is 
however evidence that high concentrations of peptide in the surrounding fluids can 
allow the bound peptide to be ‘exchanged’ and this has been utilized in 
experimental design (Praveen et al., 2010). 
1.2.6 TCR recognition of MHC 
The αβTCR is highly variable and exhibits overall structural similarity to 
immunoglobulins (Ig). Disulphide bonds link the α- and β-chains of the TCR, and 
each chain contains a constant region (membrane proximal) and a variable region 
(membrane distal). It is this distal variable region that allows for recognition of 
different MHC-presented antigenic peptides (Wucherpfennig et al., 2010, Rudolph et 
al., 2006). The variable regions of the α-and β-chain, Vα and Vβ respectively, 
mediate recognition of the peptide-binding platform of pMHCI. This peptide-binding 
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region of the TCR is formed by 3 complementarity-determining loops (CDR1, CDR2 
and CDR3), the latter of which makes contact with the peptide, with CDR1 and CDR2 
making contact with the MHC. The orientation of the TCR is such that the Vα domain 
sits over the N-terminus of the peptide, with the Vβ domain overlies the C-terminus 
of the peptide (Bjorkman et al., 1987a, Hennecke et al., 2000). TCR binding of the 
pMHC is diverse, however, in general, the TCR engages with the α and β chains 
orientated diagonally across the compound surface created by the peptide and the 
flanking α helices of the MHC (Ferber et al., 2012). It is thought that this rotation 
could be to facilitate the binding of the co-receptors CD4 or CD8 to the invariant 
region of the MHC (Wucherpfennig et al., 2010), however there can be considerable 
variation (35°) in the degree of rotation (Ferber et al., 2012). In addition to the 
diversity of the TCR repertoire, each TCR is highly cross-reactive, recognising 
between 102 and 108 different peptides (Mason, 1998, Wooldridge et al., 2010b, 
Wooldridge et al., 2012). 
1.2.7 The co-receptors: CD4 and CD8 
T-cells that possess TCRs that recognise MHCI express the CD8 co-receptor on their
surface, whereas TCRs that recognise MHCII are found on T-cells that express CD4, a 
restriction imposed on the T-cell during thymic ontogeny (Van Laethem et al., 
2012). These two molecules, whilst similar in function, are structurally quite 
different (Leahy, 1995). CD4 is a single chain glycoprotein consisting of four 
domains, whereas CD8 exists as a dimer of two chains linked by a disulphide bond. 
In its co-receptor form, CD8 exists as a heterodimer, comprising two different 
chains; α and β. CD8 can also form a homodimer of two α chains, CD8αα, which is 
found largely on other cell lineages such as dendritic cells (DCs), IELs and γδ T-cells 
(Konkel et al., 2011, Maldonado-Lopez et al., 1999, Sato et al., 1993). In contrast, 
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CD8αβ is expressed only on double positive (DP)(CD4+CD8+) thymocyes and MHCI-
restricted, mature αβ T-cells.  
The TCR recognises and engages pMHC, causing the CD3 sub-units to initiate the 
cascade of signalling events within the T-cell, leading to cell activation. In most 
cases the co-receptors (CD4 or CD8) are required to enhance early intracellular 
signalling in order for this to occur. Once the TCR has engaged pMHC, the co-
receptor molecules localise to the TCR-pMHC contact region, and bind to the 
invariant region of the MHC, a distinctly separate location to the TCR binding 
platform, which acts to stabilise the TCR/pMHC interaction (1.4). Some authors 
argue, that whilst CD8 has been shown to stabilise this interaction, CD4, which binds 
with a much weaker affinity, does not, acting only to recruit kinases to the 
signalling complex intracellularly (Artyomov et al., 2010). 
1.2.8 The CD8 Co-receptor 
CD4 and CD8 were initially identified as phenotypic markers based on MHC 
restriction, however once it had been shown that antibody blockade of these 
molecules results in failure of T-cell activation, their function in T-cell activation 
was realised (Miceli and Parnes, 1993, Daniels and Jameson, 2000, Miceli and 
Parnes, 1991). CD8 binds the same pMHCI molecule as the TCR, and acts to stabilise 
the TCR/pMHCI complex (Borger et al., 2014). This in turn facilitates TCR triggering 
thus in some cases increasing the specific sensitivity of the T-cell by over a million 
fold (Holler and Kranz, 2003). Evidence that CD8 binds the same pMHC 
simultaneously to the TCR, and has an important role in facilitating the T cells
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Figure 1.4: The Tri-partite structure. 
At the cell: cell interface, TCR signalling usually 
requires formation of a triple structure; 
TCR/pMHCI/CD8. The highly variable and specific 
TCR binds the peptide-binding platform of the 
pMHCI complex, having contacts with both the 
peptide, which is held in the peptide binding 
groove, and the variable regions of the 
polymorphic MHCI (α1 and α2 domain). The CD8 
co-receptor is non-polymorphic and binds the 
invariant region of the MHCI, making contacts 
largely with the α3 domain. 
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response led to the use of the term ‘co-receptor’ (Janeway, 1992, Miceli et al., 
1991, Meuer et al., 1982). 
1.2.9 Structure of CD8 
CD8 is expressed on the cell surface either as a homodimer (CD8αα) or a 
heterodimer (CD8αβ) (Norment and Littman, 1988). The heterodimer is 
constitutively expressed on CD8+ T-cells and double positive thymocyes. Both dimers 
may serve as a co-receptor, albeit with a limited capacity in the case of CD8αα 
(Zamoyska, 1994, Van Laethem et al., 2007). Each chain of the dimer comprises four 
regions; a short cytoplasmic tail, the trans-membrane domain, and longer 
glycosylated ‘stalk’ region which is rich in serine, threonine and proline residues to 
allow the immunoglobulin- like head to reach the invariant region of the target 
MHCI (Zamoyska, 1994). A di-sulphide bond in the stalk-region links the two sub-
units of the CD8 dimer. The stalk, or ‘hinge’, region comprises 50 residues in the 
case of CD8α and 30 residues in the case of CD8β (Delves and Roitt, 1998) i.e. CD8β 
is shorter. The ‘head’ is a globular glycoprotein, formed from the 113 N-terminal 
amino acids, which shares homology with the variable region of immunoglobulin (Ig), 
and binds the constant region of the MHCI. Some authors have suggested further di-
sulphide linkage between cysteine residues in the α and β chain in this membrane 
distal region of the dimer (Cole et al., 2012) others, however report this C36 as un-
paired (Delves and Roitt, 1998), and that the corresponding cysteine (C31) in CD8β 
is replaced with isoleucine (Chang et al., 2005).  
The role of the cytoplasmic tail region has been heavily implicated in facilitating co-
receptor function. It is believed that palmitoylation of the free cysteine residue in 
the cytoplasmic tail of CD8β allows for partition into lipid rafts, and recruitment of 
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the receptors therein, which are important for stronger and sustained signal 
transduction (Arcaro et al., 2001, Arcaro et al., 2000). This explanation goes 
someway to explain why CD8αβ can serve as a better co-receptor for the TCR than 
CD8αα (Zamoyska, 1994, Cheroutre and Lambolez, 2008). A regulatory role has been 
ascribed to CD8αα by some authors, hypothesising that CD8αα acts to sequester lck 
thus inhibiting signalling (Cheroutre and Lambolez, 2008). Indeed, there exists some 
evidence of some cell populations transiently up-regulating CD8αα in order to 
suppress or temporarily dampen signalling (Cheroutre and Lambolez, 2008).  
Cells expressing CD8αβ recognise antigen at lower concentrations than similar cells 
expressing CD8αα (Arcaro et al., 2000), however, given that similar pMHCI-binding 
affinities have been demonstrated between murine CD8αα and CD8αβ and it is likely 
that the same is true in man (Garcia et al., 1996, Kern et al., 1999), it follows that 
differences in co-receptor function are likely to be due to other features of the 
heterodimer, rather than differences in affinity for the MHCI, thus differences are 
likely to be intracellular. The cytoplasmic tail of CD8α binds the kinase p56lck (lck) 
via two vicinal cysteine residues and a common zinc ion (Zn2+) (Davis and Berg, 
2009), thus upon MHCI engagement by CD8, it is recruited to the CD3 complex in 
the region of CD3ε (Beddoe et al., 2009, Kjer-Nielsen et al., 2003), where it can act 
to bring about phosphorylation of the ITAMs. Whilst the triple structure is 
maintained, being stabilised by CD8, phosphorylation of all ITAMs can continue, 
allowing further phosphorylation by CD3ζ-associated protein 70 (ZAP70), and 
downstream signalling, which will be discussed in more depth in later sections. 
It has been suggested that because the homodimer CD8αα may bind two lck 
molecules, there exists steric hindrance of this interaction inhibiting 
phosphorylation, thus the heterodimer, recruiting a single lck at a time, may recruit 
lck more effectively, although little evidence exists for this theory (Gascoigne et 
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al., 2011, Cheroutre and Lambolez, 2008). Whilst this argument may have some 
merit, Arcaro et al demonstrated enhanced antigen recognition in the presence of 
CD8αβ, as compared to both CD8αα and CD8αβ where the cytoplasmic tail of the β-
chain were lacking (Arcaro et al., 2000), suggesting that the cytoplasmic tail of 
CD8β is important to co-receptor function. The cytoplasmic tail of CD8β is thought 
to promote effective lck binding (Bosselut et al., 2000) 
1.2.10 The pMHCI/CD8 Interaction 
Human CD8 is largely non-polymorphic in nature and binds to the invariant region of 
the MHCI, making contact primarily with the α3 domain of the MHCI heavy chain, 
but also to a lesser extent with the α2 domain of MHCI and β2m (Norment and 
Littman, 1988, Cole et al., 2007, Chang et al., 2005, Xu et al., 2001). 
Polymorphisms have been identified in the CD8α gene, although not expressed at 
the cell surface as they result in either failed expression (de la Calle-Martin et al., 
2001), or a secretory form (Giblin et al., 1989, Norment et al., 1989), thus they do 
not affect MHCI contact and interaction. Variation in the CD8β gene is seen only in 
the trans membrane and cytoplasmic region (DiSanto et al., 1993, Thakral et al., 
2013, Thakral et al., 2008), and these splice variants will be discussed in more 
detail in the final discussion, and in Appendix E.  
The crystal structure of human MHCI in complex with CD8αβ is thus far unsolved. If, 
however, solved structures of the murine CD8αα and H2-Kb and human CD8αα and 
HLA-A*0201(Gao et al., 1997a, Kern et al., 1998) are compared it is observed that 
CD8αα binds MHCI in a similar manner in both the mouse and in man, thus our 
assumptions as to the spatial relationships of CD8αβ and MHCI are based upon these 
structures, and that of the murine CD8αβ (Shore et al., 2008). Gao et al 
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demonstrated that CD8αα binds to MHCI asymmetrically, with the subunits binding 
in what can be considered the proximal and distal positions, relative to the cell 
membrane, with one sub unit occupying around 70% of the contact residues (Gao et 
al., 1997a, Chang et al., 2006). Residues 51-55 of the CD8α form the main contact 
with residues 223-229 α3 domain of the MHCI heavy chain. The structure of CD8αα 
has been demonstrated to contain flexible loops (complementarity determining 
region (CDR)-like) which clamp to bind a finger-like projection of the α3 heavy chain 
(Gao et al., 1997a). The resulting conformational changes are limited to the α3 
domain of the pMHCI and do not extend to the peptide binding platform. Murine 
CD8αα, whilst binding in similar locations, has been shown to have more contact 
points with the MHCI, a feature which likely explains the higher binding affinity of 
the murine system as compared with man (Purbhoo et al., 2001, Wooldridge et al., 
2010a). 
Gao et al predicted from the structure of human CD8αα complexed with pMHCI that 
the CD8β would occupy the position of the CD8α-2 subunit (Gao et al., 1997a). 
However, Wang et al solved the structure of murine CD8αβ complexed with H-2Dd 
and demonstrated that the CD8β subunit was membrane-proximal; the position 
occupied CD8α-1 subunit (Wang et al., 2009). It has been argued that both may be 
true, that CD8αβ may bind in either orientation (Chang et al., 2006), however to 
date there is little structural evidence for this. 
1.2.11 The CD4 Co-receptor 
CD4+ T-cells are MHCII-restricted. CD4 is the co-receptor to the TCR/pMHCII 
interaction. The structure of CD4 is markedly different to that of CD8. CD4 is a 
monomer comprised of four extracellular immunoglobulin-related domains (D1-D4), 
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a hydrophobic trans membrane domain, and a cytoplasmic tail. The cytoplasmic tail 
is highly basic, and contains 3 serine residues, which may be phosphorylated 
(Pitcher et al., 1999) and motifs which facilitate association with Lck in a zinc-
dependent manner, similarly to those residues found on the cytoplasmic tail of CD8 
(Kappes, 2007b). CD4 binds the conserved region of the MHCII, with the N-terminal 
Ig-like domains having contacts with the α2 and β2 subunits (Wang et al., 2001, Li et 
al., 2013). As with pMHCI/CD8, there are no induced conformational changes to the 
peptide-binding platform when CD4 binds the pMHCII. Studies suggest that the 
affinity of the pMHCII/CD4 interaction is even weaker than that of the pMHCI/CD8 
interaction. Xiong et al suggested a dissociation constant (KD) of greater than 200 µM 
for the murine system (Xiong et al., 2001), however more recent studies 
demonstrate that this is incorrect, that it is not possible to detect CD4 binding of 
MHCII in solution, and demonstrating a far weaker association (>2.5 mM) (Jonsson 
et al., 2016). 
1.2.12 Co-receptor Function of CD8 
Early studies examining the apparent ability of CD8 to enhance T-cell antigen 
sensitivity proposed a role for CD8 as an accessory molecule, binding the pMHCI 
independently of TCR. It was postulated that CD8 at the cell surface increased 
effector: target adhesion thus allowing the T-cell to respond to lower levels of 
antigen. It has since been shown that CD8 binds the same pMHCI at the same time as 
the TCR in what was first termed the ‘co-receptor model’ by Charles Janeway 
(Janeway, 1992). In the case of all but the strongest TCR/pMHCI interactions, this 
co-engagement of CD8 is essential for TCR triggering and subsequent T-cell 
activation. High affinity TCR/pMHCI interactions, which do not absolutely require 
CD8 engagement in order to facilitate T-cell activation, are said to be CD8-
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independent (Laugel et al., 2011), however some authors have demonstrated that 
full cytotoxic function of the CD8+ T-cell is not possible without CD8 engagement 
(Knall et al., 1995). It has also been shown that if pMHCI/CD8 affinity is super-
enhanced, TCR engagement is not required to achieve triggering (Wooldridge et al., 
2010a), however, owing to the non-polymorphic nature of CD8, this is an 
experimental rather than a physiologically normal phenomenon. This would suggest 
that for the majority of antigens, both receptors are required to simultaneously 
engage the pMHCI in order to initiate activation. The relative kinetics of these 
interactions would suggest that the TCR docks first and when CD8 co-engages TCR 
triggering is initiated. Recent mathematical modelling would suggest that this 
ordering is not essential; if the TCR/pMHCI interaction exhibits more rapid kinetics 
and a weaker interaction then the reverse may be true, and likewise if the 
pMHCI/CD8 interaction strength is increased (Szomolay et al., 2013). 
1.2.13 Kinetics of TCR/pMHCI/CD8 tri-molecular complex 
The interaction kinetics of cell surface receptors can be analysed by producing 
soluble versions of these receptors and collecting measurements using surface 
plasmon resonance (SPR) techniques, for example using BIAcore instrumentation. 
This typically involves the immobilization of a ligand to the surface of a SPR chip 
and flowing over soluble receptor at multiple concentrations, allowing detection of 
binding in real time and calculation of interaction kinetic parameters. It has been 
shown that the TCR binds the pMHCI complex with moderate affinity, usually KD = 
1-90 µM (Irving et al., 2012). This varies between different TCRs, and between
different peptide ligands ‘seen’ by the same TCR. Stronger agonists with a KD of 1-5 
µM and ‘super-agonists’ (KD<1 µM) are able to trigger a TCR response without the 
need for CD8 engagement and can be referred to as ‘CD8 independent’ (Irving et 
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al., 2012, Purbhoo et al., 2004). The half life (t½) of this interaction is ~10 s, 
however it has recently been suggested that on-rate (Kon) for TCR/pMHC binding is 
faster than that of the off-rate (Koff), thus the same TCR can immediately re-bind 
pMHC, facilitating stable complex formation (Irving et al., 2012). 
The CD8/pMHC interaction is characterised by low affinity (KD ~90-220 µM), 
significantly lower than that of the TCR/pMHC interaction (Wyer et al., 1999). The 
kinetics of this interaction are extremely rapid, characterised by a Koff in the region 
of 18 s-1. It has been demonstrated that if the strength of the pMHC/CD8 interaction 
is increased sufficiently, the TCR is effectively bypassed, resulting in T-cell 
activation irrelevant of the preference of the TCR or the nature of the presented 
peptide ligand (Wooldridge et al., 2010a). 
1.2.14 TCR Signalling; recognition of pMHCI 
In vivo, cells are constantly interacting with each other, and thus TCRs and pMHC 
come into contact with each other, forming short-lived connections. These are 
termed immunological kinapses (IK) when they are fleeting, and immunological 
synapses (IS) when they persist for longer (Fooksman et al., 2010). A single APC will 
likely express many different pMHC, presenting an array of antigenic peptide 
fragments. There may be considered to be 3 phases to signalling; during the first 
phase, early signals are initiated though the transient immunological kinapse. 
Aggregation of these kinapses leads to small protein clusters forming the more 
stable and organised immunological synapse (phase 2) (Billadeau, 2010). TCRs are 
up-regulated and recruited to the site, resulting in many TCR clusters forming in an 
IS. Many of the surface molecules on T cells and APCs separate themselves into 
distinct clusters or supramolecular activation clusters (SMACs) (Monks et al., 1998). 
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The cell surface molecules are organised into a ‘bull’s-eye’ pattern, with a central 
cluster of TCR/pMHC (cSMAC) and a peripheral region packed with adhesion 
molecules (pSMAC) (Anton van der Merwe et al., 2000). It can take many signalling 
events within the same cell to induce activation. The IS has been traditionally 
thought to be required for sustained TCR triggering, however subsequent literature 
suggests that cSMAC formation is not required (Alarcon et al., 2011). For T-cell 
activation to occur a second signal is also required. This is received from co-
stimulatory molecules, such as CD28 (Lichtenfels et al., 2012). The distal SMAC 
(dSMAC) is rich in CD45 and other accessory molecules, and also is the site of 
formation of TCR microclusters (MCs), which contain large amounts of CD28 bound 
to CD80, its primary ligand, initiating the co-stimulatory signal (Yokosuka et al., 
2008). TCR MCs are constantly forming here in the dSMAC and then migrating to the 
cSMAC, thus perpetuating the IS (Fooksman et al., 2010). The organisation of the 
surface molecules into the regions that make up the IS is dependent of the actin 
filament cytoskeleton (Grakoui et al., 1999). 
1.2.15 CD3 
The TCR α and β sub-units can only be expressed at the cell surface in association 
with the CD3 sub-units, γ, δ and ε (Weiss and Stobo, 1984). The CD3 sub-units have 
long cytoplasmic tails, are involved in early signalling events once the TCR has 
engaged cognate pMHCI, communicating the signal across the plasma membrane. All 
six sub-units (γ, δ, 2 ε, and 2 ζ) span the surface membrane, and contain 
Immunoreceptor tyrosine-based activation motifs (ITAMs): one in the case of the γ, 
δ, and ε sub-units, and three in the case of CD3ζ. These are conserved sequence 
motifs common to the cytoplasmic region of molecules within the immunoglobulin 
superfamily, with the form YXXLX(7-12)YXXL (Fooksman et al., 2010), i.e. each ITAM 
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has two aliphatic and two tyrosine residues (Wucherpfennig et al., 2010). Upon 
peptide recognition, these common motifs become phosphorylated by lck, thus 
propagating the signal through the cell membrane and amplifying the signals from 
the TCR. This is essential for signal propagation, as has been demonstrated by 
mutation of tyrosine residues abrogating signal transduction (Sunder-Plassmann et 
al., 1997). There is enrichment of the complex with ZAP70, however both tyrosines 
must be phosphorylated before ZAP70 can bind (Janes et al., 2000). Complete 
phosphorylation of these motifs is necessary for T cell activation. It has been 
suggested that premature phosphorylation (i.e. without TCR engagement) is 
prevented by the insertion of the CD3ε tyrosines into the hydrophobic core of the 
plasma membrane (Aivazian and Stern, 2000), although other authors argue that the 
CD3 ITAMs are in a constant flux of phosphorylation and de-phosphorylation and that 
triggering is prevented in the resting cell by de-phosphorylation occurring at a 
greater rate than phosphorylation (Davis and van der Merwe, 2006). Lck is largely 
associated with the co-receptors CD4 and CD8, and as such the dominant role of the 
CD4 and CD8 co-receptors is to recruit lck to the pMHCI/TCR/CD3 complex 
(Artyomov et al., 2010, Kappes, 2007a), although some sources argue that it is the 
lck which recruits the co-receptors to the complex (van der Merwe and Cordoba, 
2011, Gao and Jakobsen, 2000).  
It has been demonstrated that the cytoplasmic tail of CD3ζ is, when associated with 
lipid, folded in such a way as to prevent phosphorylation, thus the association of 
these tails with the hydrophobic, lipid-rich membrane prevents phosphorylation, in 
what has been termed the ‘conformational change model’, or ‘ITAM sequestration’. 
In aqueous solution lck phosphorylation is favoured. It has been postulated that TCR 
engagement facilitates conformational changes in the internal sub-units, releasing 
the cytoplasmic tails from the membrane and thus facilitating phosphorylation by 
lck (Aivazian and Stern, 2000). What triggers this release, or how it comes about is 
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unclear. It has been suggested that TCR aggregation and an associated 
multimerisation of receptors may play a role, as has the effects of the mechanical 
force of the TCR binding the pMHCI. This hypothesis has not thus far been tested; it 
remains to be explained how the formation of the tri-partite complex results in the 
phosphorylation events that take place in the intracellular regions of the CD3 
complex (‘TCR triggering’), and other authors have demonstrated that in vivo ITAMs 
are largely and constitutively phosphorylated (Chakraborty and Weiss, 2014, van 
Oers et al., 1993). Another theory, the kinetic segregation model (KS), suggests that 
the IS promotes and facilitates the formation of a pro-signalling environment. 
Segregation of phosphatases such as CD45 from the IS allows for phosphorylation by 
lck, thus triggering downstream signalling (van der Merwe and Davis, 2003, Davis 
and van der Merwe, 2006). Whilst these theories have been put forward as 
alternative explanations, they may not be mutually exclusive. 
1.2.16 The Kinetic Segregation Model 
Davis and Van der Merwe propose an alternative model for the initiation of cell 
signalling, summarised in Figure 1.5, which is based around the spatial re-
organisation of signalling proteins (Davis and van der Merwe, 2006). Proteins are 
very abundant in the cell membrane, making up around 20 - 25% by mass of the cells 
surface membrane (Cooper, 2000, Nicolson, 2014). These proteins are wide varying 
and diverse, and perform many different functions, and include proteins involved in
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Figure 1.5: Kinetic Segregation model  
(Davis and van der Merwe, 2006) 
At the cell surface large, de-phosphorylating CD45, 
phosphorylating kinases such as lck and TCR/CD3 
complexes are present in approximately 
4:2:1 ratios (A). Phosphorylation of the 
TCR/CD3 complex iTAMs are is a state of constant 
flux, with constant phosphorylation (P) by lck 
being in turn countered by constant de-
phosphorylation (dP) by CD45. In the resting T-
cell, phosphorylation of the CD3 ITAMs occurs 
randomly, however the relative numbers of lck is 
approximately half of that of CD45, thus net 
de-phosphorylation is greater and the TCR cannot 
trigger (B). CD45 is appreciably larger than the 
TCR/pMHCI, thus when an APC is held is close 
contact with the T-cell by this interaction, 
CD45 is excluded, thus net 
phosphorylation occurs facilitating TCR triggering 
(C). 
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cell: cell interactions and signalling. Proportionally, phospho-kinases such as lck 
make up about twice as many of these proteins as the TCR, and phosphatases, 
primarily CD45, up to twice as many again (Davis and van der Merwe, 2006). In 
addition, diffusion and thus protein movement within the cell membrane is very 
rapid, constantly shifting, meaning that by random bumping of intracellular proteins 
is frequent (Nicolson, 2014, Singer and Nicolson, 1972, Nicolson, 1976). There is a 
large super-family of membrane proteins with cytoplasmic tails bearing tyrosine 
motifs. The TCR-CD3 complex possesses 10 ITAMS, which are constantly being 
phosphorylated by lck and de-phosphorylated by CD45, however, the ratio of Lck: 
CD45 is such that overall de-phosphorylation is favoured, thus triggering is 
suppressed in the resting cell. 
CD45 is a large, rigid molecule whose prominence from the cell surface is 
significantly larger than the gap afforded by the TCR/pMHCI interaction. When the 
IS is formed, CD45 is excluded by this narrow gap, and is unable to move back in, 
meaning that de-phosphorylation cannot occur. This model would suggest that the 
role of the co-receptor is likely to recruit lck, and that the absence of CD45 
facilitates signalling, i.e. dephosphorylation is prevented by steric exclusion, CD45 
being too large to enter the IS when TCR is bound to presented pMHCI. TCRs which 
have not engaged pMHC, because of their small size and rapid diffusion are able to 
leave the IS. Whilst they are likely to have become phosphorylated whilst in the IS, 
the authors postulate that they are able to exit and become de-phosphorylated 
before downstream signalling occurs. 
They have demonstrated that truncation of the CD45 molecule suppresses signalling, 
presumably by allowing this molecule to enter the IS and de-phosphorylate the 
ITAMS. Similarly, enlarging the intracellular gap by increasing the size of the 
TCR/pMHC complex, thus allowing phosphatase in to the IS also affords signalling. 
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1.3 T-cell Signalling
1.3.1 T-cell signalling Pathways
Activated ZAP70 phosphorylates the linker of activated T cells (LAT) and lymphocyte 
cytosolic protein 2 (SLP-76) (Smith-Garvin et al., 2009). These substrates of ZAP70 
function as scaffold (adaptor) proteins and aggregates of scaffold proteins form 
microclusters within the IS. LAT is a membrane protein which, when it interacts 
with Lck, becomes palmitoylated and interacts with the cholesterol and sphingolipid 
rich lipids rafts. The lipid rafts are the platform for later signalling events within the 
cell, leading to transcription and thus effector function (Pang et al., 2007). Lipid 
rafts are micro domains within the cell membrane, spanning ~20 nm, which are used 
to bring proteins necessary for signal transduction together in this highly specialised 
domain, once they have undergone post-translational addition of lipids by processes 
such as palmitoylation (Nicolson, 2014). CD45 is excluded from lipid rafts, probably 
because it would act to inhibit phosphorylation. This is further evidenced by its 
likely role in the regulation of lck activity (Chichili et al., 2012). 
Following tyrosine phosphorylation of kinases, there follows activation of 
phospholipase C (PLC), calcineurin and Ras, which in turn leads to the 
transcriptional activation of the IL-2 gene. PLC causes breakdown of the membrane 
protein PIP2 (Phosphatidylinositol 4,5-bisphosphate) into diacylglycerol (DAG) and 
inositol 1.4.5-triphosphate (IP3). DAG remains membrane-bound and activates 
protein kinase C-θ (PKCθ), leading to activation of the transcription factor NFKB. 
DAG also activates RasGRP, causing a kinase cascade, ultimately resulting in 
activation of the Fos component of the transcription factor Activation Protein-1 (AP-
1) (Smith-Garvin et al., 2009). IP3 is released into the cytosol of which in turn binds
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the IP3 receptors on the endoplasmic reticulum (ER) causing release into the cytosol 
of the Ca2+ stored therein (Robert et al., 2011). The resulting depletion in ER stored 
calcium causes opening of calcium release activated calcium channels (CRAC 
channels) in the plasma membrane, allowing further Ca2+ to flood the cell. Increase 
intracellular calcium causes activation of the phosphatase calcineurin, which itself 
activates nuclear factor of activated T cells (NFAT), another transcription factor. 
NFkB, AP-1 and NFAT all induce nuclear events, such as transcription of the IL-2 
gene, causing effector activity and proliferation of the T-cell (Figure 1.6). 
In a secondary pathway, activation of the PLC pathway by TCR engagement causes 
an influx of free cytosolic calcium ([Ca2+]) and activation of protein kinase C (PKC). 
This phosphatidylinositol (PI) pathway causes transcriptional events and thus IL-2 
production. Activation of the T cell without engagement of this secondary PI 
pathway have been observed (Sussman et al., 1988). Calcineurin release is also 
regulated by [Ca2+] flux, with the phosphatise activity of this molecule contributing 
to transcription factor activation and therefore nuclear events. 
1.3.2 Down-regulation of cell surface TCR upon Activation 
Following TCR engagement of pMHCI, cell surface TCRs are down regulated. This 
cycling of the TCR is considered by some to be a crucial part of T-cell activation, 
involving internalisation of the TCR following engagement (Itoh et al., 1999, 
Valitutti et al., 1996b). This remains to be proven, however, and indeed others 
argue that non-engaged TCRs are also internalised (San Jose et al., 2000). It is 
known that the TCR/CD3 complex is very stable and is constantly being internalised 
and recycled in the normal resting T-cell (Valitutti et al., 1997, Cai et al., 1997, Liu 
et al., 2000). It is also known that internalisation and recycling of surface molecules
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Figure 1.6: Signalling pathways following 
TCR triggering. 
Following phosphorylation of CD3 ITAMs, activated 
ZAP70 causes further downstream phosphorylation 
of LAT and PLC within the lipid rafts. This causes 
activation of the Ras, calcineurin and NFκβ 
pathways, and a net influx of calcium, resulting in 
transcriptional activation of the IL-2 gene, which 
in turn results in activation of other effector 
pathways and the initiation of a positive feedback 
loop causing further signal amplification. 
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is a feature common to cell membrane receptors, mediated via a tyrosine-based 
motif (Pandey, 2009). Liu et al demonstrated that the stable TCR/CD3 complex is 
constantly being internalised and recycled in resting cells, however, following T-cell 
activation, recycling to the cell surface is blocked resulting in down-modulation of 
TCR and associated CD3 (Liu et al., 2000). This study would suggest that there is no 
increase in the rate of internalisation following activation, but that recycling is 
blocked following the activation process, possibly by transcriptional inhibition of 
expression, thus involving TCRs which were internalised as part of an on-going 
process and may or may not have individually themselves been part of triggering 
(Liu et al., 2000). 
1.3.3 CD8+ T-cell Activation 
T-cells express large numbers of TCRs at the cell surface. In most cases this is the
same TCR formed of identical α and β subunits. Allelic exclusion favours only a 
single Vα and Vβ recombination, however it is possible for a cell to produce more 
than one of either chain, allowing for the expression of 2 or more different TCRs at 
the cell surface (Matis et al., 1988, Hardardottir et al., 1995). In this instance, one 
of the TCRs will dominate, making up the majority of the TCRs at the cell surface. 
In contrast, an APC may express up to 6 different MHCI alleles at the cell surface, 
which can present a multitude of different peptides. This vast array of different 
pMHCIs is constantly being scanned, but the huge number of different possible 
combinations means that only a tiny proportion of these are the same. Indeed it is 
possible, given the plethora of different peptides presented in the context of MHCI 
by the APC, that some pMHCI may be unique events. A single pMHCI can trigger up 
to ~200 TCRs at the cell surface (Valitutti et al., 1995) meaning that a low number 
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of pMHCIs can achieve high TCR occupancy leading to a sustained and amplified 
signal. 
During an infectious challenge APCs engage and prime T-cells in the accessory 
lymphoid organs such as the lymph nodes and spleen. Naïve T-cells are present in 
low numbers in the host, too low to effectively rise to infectious challenge. 
Additionally, they are incapable of effector function such as inducing target 
cytolysis or IFNγ production. Therefore specialised APC such as DCs present pMHCI 
to naive T-cells in the accessory lymphoid tissue, initiating proliferation and 
differentiation. This activation of naïve T-cells induces intense proliferation giving 
rise to a large pool of effector T-cells. The vast majority of these are ‘short-lived 
effector cells’ (SLEC) which die off once the challenge has been cleared. 
Approximately 5% are memory T-cells, and remain in the circulation in case of a 
repeat challenge. The replicative drive of the memory population is much slower 
and thus burnout is not achieved, or rather is delayed, allowing these cells to 
remain. It has been shown that a single naïve T-cell may divide to give rise to both 
effector and memory subsets (Stemberger et al., 2007, Gerlach et al., 2010) 
although other authors have argued that this is not the case, that the eventual 
phenotype of the naïve T-cell is pre-programmed before the antigenic challenge 
(Beuneu et al., 2010). In the instance of different antigenic challenge (viral, 
bacterial, parasite, dysregulated cell etc.) different innate populations producing 
different cytokines are present adding increased complexity. 
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1.3.4 Co-stimulation of T-cells; A Three signal Process 
In order for a naïve T-cell to become fully activated, the signal generated by the 
TCR/pMHCI interaction is insufficient; a second ‘co-stimulatory’ signal is required 
(Figure 1.7).  
This signal, termed ‘signal 2’, the TCR/pMHCI interaction being ‘signal 1’, is 
delivered only when the T-cell encounters pMHCI presented by a ‘professional’ APC 
(Bretscher, 1999, Pardigon et al., 1998). The professional APC possesses at its 
surface B7.1 (CD80) and B7.2 (CD86), which are ligands to CD28. CD28 is the only 
receptor to B7.1 and B7.2 which is expressed on naïve T-cells. Following 
engagement of the TCR to the pMHCI, the APC and the T-cell are held in close 
proximity, enabling CD28 to engage with its ligand. The ‘close contacts’ are 
essential for CD28 engagement, thus the specificity of the interaction is generated 
by the TCR/pMHCI interaction, with the non-specific CD28-B7.1/2 interaction only 
occurring after the TCR/pMHCI complex has formed. Whilst signal 1 is insufficient 
for full activation, it has been demonstrated that if the close contacts may be 
formed by another means, such as by exclusion of CD45, then signal 2 may be 
sufficient to bring about T-cell activation (Chang et al., 2016), an observation 
which may account for the observed loss of specificity of the TCR when the pMHCI/
CD8 interaction affinity is super-enhanced (Wooldridge et al., 2010a, Dockree et 
al., 2017). In the absence of signal 2, the T-cell becomes anergic (Yamamoto et al., 
2007, Appleman and Boussiotis, 2003). It has been postulated that the requirement 
for two signals exists in order to differentiate between self- and non-self 
stimulation, i.e. weak self-stimulation is required for maintenance of the naïve 
population, whereas full and robust activation is necessitated in the face of 
challenge (Bretscher, 1999), however it should be remembered that the strength of 
the TCR/pMHCI interaction has a quantitative effect on the T-cell response, and 
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Figure 1.7: Co-stimulatory signals. 
Activation of naïve T-cell requires both stimulation 
through the TCR (signal 1) and co-stimulatory 
pathways (signal 2).  The effect of these signals is 
to drive IL-3 release, resulting in positive feedback 
(signal 3). 
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some authors have suggested that T-cell activation may still occur in the absence of 
signal 2 if signal 1 is particularly strong (Sharpe and Freeman, 2002, Yamamoto et 
al., 2007). 
Only professional APCs possess on their surface B7.2 and may be induced to up-
regulate B7.1 following engagement (Chen and Flies, 2013), thus professional APC 
are absolutely required to initiate the immune response. These are usually 
encountered in the draining lymph nodes or associated lymphoid tissue rather than 
the local environment, however following activation the activated T-cells migrate to 
target tissue where clonally expanded effector T-cells target anomalous or infected 
cells for deletion. In order for professional APCs to present antigenic peptide in the 
context of MHCI in the secondary lymphoid tissue, these peptides must have been 
internalised at the site of the challenge, however the criteria for presentation of 
exogenous peptide by MHCI have not been fully realised. 
A third signal is provided to the CD8+ T-cell by the APC in the form of cytokine 
release. Following TCR engagement and co-stimulation, the APC releases pro-
inflammatory cytokines such as IL-2. In the absence of this third signal, the T-cell 
may fail to develop full effector functions, and a memory pool is not generated 
(Curtsinger and Mescher, 2010, Mescher et al., 2006). Inactivated naïve T-cells do 
not express IL-2 nor its receptors, thus initiation of signalling is considered to take 
place in the order which is described; 1) TCR engagement, 2) Co-stimulatory signal 
transmission, 3) IL-2 mediated signalling. Further IL-2 may be supplied by TH1-cells, 
in the event that insufficient is produced by the APC(Chen and Flies, 2013). The 
anergy resulting from the absence of signal 2 may be reversed or ‘rescued’, by IL-2 
(Appleman and Boussiotis, 2003). 
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Knowledge of the 3 signals required to induce T-cell activation is utilised by 
researchers; Dynabeads™ are impregnated with CD3 and CD28, and may be 
used in IL-2 enriched culture media to expand T-cells in vitro (Trickett and 
Kwan, 2003). 
1.3.5 Other Co-stimulatory and Co-inhibitory Molecules 
Whilst the only receptor to B7.1/2 expressed by naïve T-cells is CD28, effector T-
cell may also express Cytotoxic T-lymphocyte Antigen 4 (CTLA-4). Following priming 
of the naïve T-cell, CTLA-4, which is accumulated in lysosomes, is trafficked to the 
cell surface at the APC close contact zone (Saito and Yamasaki, 2003). When CTLA-4 
engages B7.1/2, the signal generated is inhibitory. The inhibitory signal generated 
results in down-regulated endocytosis and thus expression of CD28 at the cell 
surface. This in turn reduces the activation signal that the CD28-B7.1/2 interaction 
induces, whilst the inhibitory signal generated by The CTLA-4-B7.1/2 interaction 
persists, in a negative feedback process. CTLA-4 accumulates in the cSMAC, and has 
been shown to physically exclude CD28 from this region, further dampening the T-
cell response (Yokosuka et al., 2010).  
Programmed Death 1 (PD-1) has been shown to have an inhibitory response on T-cell 
activation, following engagement with its ligand PD-L1 (B7-H1) (Riley, 2009). It has 
an additional ligand, PD-L2 (B7-DC), which is only present on professional APCs, 
whereas PD-L1 is widely expressed, and has also been found to engage B7-1 (Butte 
et al., 2007). PD-1 engagement results in recruitment of SH-domain containing 
tyrosine phosphatase-2 (SHP-2), and as a consequence, down-regulation of PI3 
activity, as well as inhibiting phosphorylation of the CD3 and ZAP70, and inhibiting 
phosphorylation of other TCR signalling components (Chen and Flies, 2013, Saito 
and Yamasaki, 2003, Riella et al., 2012).  
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PD-1 has a vital role in regulation of the T-cell response and in maintaining 
peripheral tolerance. It inhibits alloreactive responses, and it has been shown that 
PD-1 up-regulation in transplanted tissue is associated with a favourable prognosis 
in graft survival. The PD-1 pathway has been usurped by pathogens and neoplastic 
processes resulting in chronic infection and tumour survival (Carreno et al., 2006). 
In cancer immunology, tumours with high levels of PD-1L are associated with a less 
favourable prognosis for the host (Wang et al., 2017, Muenst et al., 2014). 
The ligands to these inhibitory receptors are collectively known as the B7 ligand 
family, and there is crossover between ligands and receptors. There are further B7 
homologues which have been found, many of which have unknown receptors, thus 
their effects are uncertain (Sharpe and Freeman, 2002). In addition to those 
described above, the receptor Inducible Co-stimulator (ICOS) has an unique B7-like 
receptor, B7RP-1 (ICOSL, B7-H2). ICOS is the third member of the CD28 superfamily 
(after CD28 and CTLA-4), and is rapidly up-regulated following TCR engagement. Its 
effect is stimulatory, however rather than promoting expansion like CD28, its main 
effect is to induce differentiation to an effector phenotype and upon regulation of 
cytokine production (Sharpe and Freeman, 2002). Its effects on proliferation are 
mild, and whilst it can promote IL-2 release in the low levels, this is insufficient to 
that which is required for a fully robust response.  
The combine effects of these co-stimulatory and co-inhibitory pathways are shown 
in Figure 1.8.
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Figure 1.8: Co-stimulatory and Co-
inhibitory Pathways in T-cell Activation. 
Additionally to the TCR/pMHCI/CD8 interaction, 
the T-cell receives signals from other concurrent 
molecular interactions with the APC (professional 
APC or tumour). These interactions may be 
stimulatory or inhibitory. Early co-signals provided 
by the APC are stimulatory, and necessary for 
complete activation. Inhibitory signals are 
necessary to damp down and control the T-cell 
response. Tumour cells may hijack these pathways 
in order to evade the immune system. 
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1.4 T-cell Activation
1.4.1  Activated Antigen-specific T-cells 
Upon activation, the naïve T-cells become activated antigen-specific T-cells. Naive 
T-cells become committed to clonal expansion within 2-14 hours of antigen
exposure, and are committed to expansion and differentiation without the need for 
further antigenic stimulation (van Stipdonk et al., 2001). This is thought to alleviate 
the need for prolonged confinement to peripheral lymphoid tissue, releasing the 
effector cells to the periphery. They expand and differentiate, acquiring the 
abilities to kill and to produce cytokines. The expansion is rapid, with a single naïve 
T-cell being capable of undergoing several divisions in the first few days, giving rise
to a several-thousand-fold expansion (Kaech et al., 2002, Badovinac and Harty, 
2006). They also undergo phenotypic changes, expressing different cell-surface 
molecules, which have different roles in T-cell biology corresponding to their new 
differentiated function. The expanded effector cell population is heterogenous and 
contains both CD4+ T helper (TH) cells and cytotoxic CD8+ T-cells. Because MHCI are 
expressed on most cells throughout the body, infected cells will present the target 
antigen in the context of their MHCI, and thus mark themselves for deletion by the 
effector CD8+ T-cells. These effector T-cells are capable of producing IFN-γ, tumour 
necrosis factor (TNF) and IL-2, and of deleting infected cells via cytolysis. 
A typical viral challenge will be cleared in a few days following this expansion, and 
there follows a contracture of the active effector population, with over 90% of these 
cells dying as the cells become exhausted. The remaining population are memory T-
cells that are capable of undergoing slow divisions over the life of the host. These 
cells are phenotypically different again, and are able to respond rapidly in the case 
of a second challenge. The exact origin of the memory population is not yet fully 
understood. It remains uncertain whether memory T-cells arise from the effector 
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pool, or whether they originate via a separate lineage. Some authors have 
presented data which suggest that the memory pool are a daughter population, 
directly descended from the effector T-cells (Jacob and Baltimore, 1999), however 
other authors have demonstrated the reverse, outlining a ‘central’ memory 
population which differentiates separate from effector cells (Iezzi et al., 2001). The 
memory cells persist following the exhaustion and deletion of the effector 
population, and may generate a more rapid and robust response in the event of 
secondary challenge. 
CD8+ T-cell expansion is dependent on repeated antigen exposure, however the MHCI 
receptor required for this is ubiquitous within the host, which may be a reason why 
CD8+ T-cell expansion is more rapid that that observed with CD4+ T-cells (Kaech et 
al., 2002). 
1.4.2 Extracellular feedback: the role of IL-2 
For extracellular feedback via cytokines to occur the cytokine must be present in 
the extracellular fluid, however the responding cell must also have up-regulated the 
specific cytokine receptor. Upon T-cell activation, IL-2 is produced and secreted by 
the activated T-cell (Boyman and Sprent, 2012). In addition to this, T-cell activation 
also causes up-regulation of the alpha subunit of the IL-2 receptor, IL-2Rα, to be 
mobilized to the cell surface (Boyman and Sprent, 2012, Busse et al., 2010). This 
results in positive feedback, increased activation, and thus further amplification of 
the signal (Busse et al., 2010). Signals via the IL-2 receptor also result in down-
regulation of the receptor, causing negative feedback (Popmihajlov and Smith, 
2008). The effector population contracts and reduces, despite the antigen levels 
remaining high for longer periods (Mitchell et al., 2010). Effector population 
contraction is thought to be important to avoid excessive immunopathology during 
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prolonged antigenic challenge (Mitchell et al., 2010, Sheridan and Lefrancois, 2011). 
The extent of cell death (and the size of the initial expansion) will determine the 
size of the memory population (Sheridan and Lefrancois, 2011, Obar and Lefrancois, 
2010). 
1.4.3 The role of Tumour Necrosis Factor (TNF) 
A role in memory pool formation has been suggested for the TNF receptor (TNFR) 
and other similar receptors (the TNFR family) and their ligands (e.g. CD27 and 
CD154 (CD40L)). It has been shown that CD154 knock-out mice have greatly 
increased CD8+ effector cell death and a reduced resultant memory population 
(Whitmire and Ahmed, 2000). There is no effect on the initial clonal expansion 
suggesting that CD154 interactions may regulate memory formation by interfering 
with effector population contracture. Both Fas (CD95) and TNFR1 cause little effect 
on effector cell death, suggesting that other pathways influence apoptosis of the 
effector T-cells (Zimmermann et al., 1996). It is very likely that multiple 
mechanisms contribute and overlap causing contraction, since disruption to no 
single pathway has thus far been shown to inhibit Activation Induce cell death 
(AICD). 
1.4.4 Down-regulation and the switch to memory Phenotype 
It has been shown that the cytolytic activity of a common pool of effector T-cells 
directly affects the resultant memory cell population, namely that the more 
targeted cytolysis which a CD8+ T-cell has induced, the less likely it is to develop 
into a memory cell (Schluns and Lefrancois, 2003). This would suggest that memory 
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cell development is dependent not on the naive cells pre-cursor, but on the extent 
of granule-mediated cytolysis which the T-cell has induced (Opferman et al., 2001). 
It is, however, unclear whether this is a direct effect (perforin ultimately causing 
cytolysis of the parent cell) or indirect due to increased antigen exposure when 
target killing is reduced.  
The role of IFN-γ in down-regulation of the effector T-cell population and in AICD 
regulation is even less well understood, although it has been suggested that this 
may be achieved by regulation of controlling the expression of death factors, death 
receptors, or survival receptors such as the interleukin-15 receptor (IL-15R) 
(Badovinac et al., 2000). 
1.4.5 The Importance of T-cell memory 
As has already been discussed, memory T-cells exist in low numbers following a 
challenge, dividing slowly, providing the host with the ability to respond more 
rapidly in the event of a recurrence of challenge (Sheridan and Lefrancois, 2011, 
Ariotti et al., 2012). Upon stimulation with specific antigen a naïve T-cell undergoes 
rapid and robust proliferation and differentiation (Figure 1.9). The resultant 
effector pool phenotype continues to respond to the challenge, however memory 
cells may be generated in as little as a day following antigenic stimulation (Arens 
and Schoenberger, 2010). It may be argued that memory is not essential to the host 
given that for the memory pool to exist requires the infectious agent having been 
encountered and successfully controlled previously. This is however taking an over-
simplified view. The outcome of infectious challenge, both in terms of mortality and 
morbidity are very often dose-dependent. In addition, other factors such as
49 
Adapted from (Arens and Schoenberger, 2010) 
Figure 1.9: Upon stimulation, a naïve T-
cell undergoes expansion and proliferation  
On stimulation with specific antigen, the naïve T-
cell undergoes proliferation and differentiation 
into an effector phenotype. Early clearance of the 
challenge (>24h) allows for generation of a 
memory pool. Elimination of challenge causes 
apoptosis of the effector pool, whilst the memory 
phenotype persists in the case of repeated 
challenge. Effector function of effector cells 
increases up to day 14, and then begins to tail off 
as the effector pool becomes exhausted. Following 
prolonged infection, the effector pool is unable to 
sustain rapid proliferation and much of this 
exhausted population undergoes apoptosis. 
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concurrent disease and/or the general health status of the host will also play an 
important role. In addition, prompt and effective clearance of challenge will result 
in a lesser degree or morbidity and so is evidently beneficial to the host. Memory 
CD8+ T-cells demonstrate a clear survival advantage to the host when compared to 
naïve T-cells, especially at higher doses (Badovinac and Harty, 2006, Kaech et al., 
2002). These facts are utilised for patient advantage when developing vaccination 
strategies, enabling us to provide immunity to patients without them having to 
physically encounter the disease. This fact has enabled us to provide preventative 
medicine for diseases with a naturally high mortality rate and to protect those who 
would otherwise be more susceptible e.g. infants, the elderly and the 
immunocompromised. In addition, vaccination of a high percentage of the 
population will provide so-called ‘herd immunity’, protecting the small percentage 
who cannot themselves be vaccinated with a degree of protection by reducing the 
endemic levels of the challenge.  
Memory CD8+ T-cells are phenotypically different from both naïve T-cells and 
effector T-cells, however they are capable of rapidly elaborating their responses in 
terms of cytokine production and target killing, and of robust proliferation 
generating a clonal expansion of secondary effector cells. These will expand, 
respond to challenge before and either undergo activation induced cell death (AICD) 
or leave a memory pool once again, in the same manner as the primary insult. The 
response time of the memory population is very much faster, thus the challenge is 
cleared more quickly. The memory T-cells are present in the periphery, meaning 
that the antigenic challenge may be detected by the immune system very rapidly in 
the target tissue, rather than be required to be presented by professional APC in 
accessory lymph nodes. This also means that the infection may be less severe or 
widespread before a response is elicited. In addition the memory T-cells tend to be 
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found in greater numbers in the tissues where the infectious challenge may be 
encountered (Ariotti et al., 2012, Mackay and Gebhardt, 2013). 
1.4.6 Target Killing by CD8+ T-cells 
There are two main cytotoxic pathways in CD8+ T-cells: Ca2+-dependent 
perforin/Granzyme-mediated apoptosis, and Ca2+-independent Fas ligand/Fas-
mediated apoptosis, both of which are initiated via TCR signalling.  CD8+ T-cells 
possess excretory cytolytic granules within their cytosol. These lysosomes are 
comprised of an electron dense core surrounded by several vesicles, within which 
are stored lytic proteins in inactive form. Upon activation, these lysosomes are 
directed towards the cell surface by migrating along the cell’s microtubular 
apparatus and are polarised close to the IS, where their contents may be exocytosed 
into the synaptic cleft (Trapani, 2012). The two proteins, perforin and granzyme, 
may act in cohort or alone to bring about target cell lysis (Peters et al., 1991).  
1.4.7 Perforin 
Perforin is stored within the lysosome as a monomer, and is released into the 
extracellular space as such, where it inserts into the target cells membrane. The 
target receptor facilitating this is currently un-identified, and it appears likely that 
one is not required, with perforin monomers inserting into the target membrane 
without the presence of any specific partner protein. Once integrated into the 
target cell membrane, the perforin molecules coalesce to form polymers, excluding 
the lipid bilayer, thus forming pores within the membrane of approximately 16 nm 
diameter (Podack et al., 1985). This in turn causes an uncontrolled influx of Ca2+, 
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resulting in the osmotic collapse of the cell. These pores may also act as a conduit 
for other killing proteins such as granzymes (Lowin et al., 1995). Bystander cells 
may be protected from perforin activity by the presence of proteoglycans and 
lipoproteins in their cell membranes (Lowin et al., 1995). In addition the release of 
perforin into the tightly controlled environment of the synaptic cleft may offer 
some protection, however it remains uncertain how the CD8+ T-cell itself avoids 
lysis. Müller and Tschopp demonstrated evidence that The CD8+ T-cell was able to 
block perforin entry (Muller and Tschopp, 1994), however these findings have not 
proven to be repeatable (Trapani, 2012). 
1.4.8 Granzymes 
Granzymes were first described by Jürg Tschopp in 1987 (Masson and Tschopp, 
1987). Five have to date been described in man (A, B, K, H, and M), all of which can 
be found in CD8+ T-cells (Bovenschen and Kummer, 2010, Grossman et al., 2003). 
Further gene loci (C, D, E, F, G L, and N) have been identified in the mouse (but not 
in man), however most of these (all but C) are ‘orphaned’; the gene locus has been 
identified but the granzyme itself has not been isolated in the host (Grossman et 
al., 2003). Granzymes A and B have been the most studied. Granzyme A was initially 
thought to act extracellularly by inducing IL-6 and IL-8 production and cleaving 
matrix proteins (Barry and Bleackley, 2002), and whilst these remain important 
modes of action, more recently intracellular targets have been identified. 
Granzymes are capable of entering the cytoplasm in a receptor dependent fashion 
(receptor-mediated endocytosis), but it is likely that the main mode of entry is via 
pores created by perforin polymers (Catalfamo and Henkart, 2003). Heparan 
sulphate proteoglycans and the mannose-6-phosphate receptor have been identified 
as likely receptors for granzymes. They were initially first thought to be receptors 
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for perforin monomer insertion too (Veugelers et al., 2006), but it has since been 
shown that perforin inserts without receptor protein assistance. Once inside the 
cell, granzymes are capable of mediating apoptosis in the target cell via both 
caspase-dependent and caspase-independent mechanisms.  Of the human 
granzymes, granzyme B is the most studied and is responsible for rapid induction of 
caspase-dependent apoptosis. Human granzyme B-mediated apoptosis is in part 
mediated by the target cells’ mitochondria. Mitochondrial changes are induced by 
granzyme B by causing cleavage of the BH3-only pro-apoptotic protein, Bid. The 
truncated Bid migrates to the mitochondria alongside Bax and/or Bak, where it 
causes mitochondrial outer-membrane permeablisation and release of other pro-
apoptotic proteins, including cytochrome c, which is crucial for the formation of 
apoptosomes and the activation of caspase-9, which in turn cleaves other caspases 
downstream. Granzyme B may also cleave Mcl-1, a member of the anti-apoptotic 
family Bcl-2, which in turn also causes cytochrome c release. Other caspases such 
as effector caspase 3 and initiator caspase 8 are also processed by granzyme B. 
Several other granzyme B substrates have been reported, however these 
interactions have not been as rigorously tested.  
Other granzymes have been less well studied. Granzymes H and K are so-called 
‘orphan-granzymes’, owing to the fact that their substrate is as yet unidentified 
(Bots and Medema, 2006), although some authors have hinted that their mode of 
action is caspase independent and similar to that of granzyme A (Johnson et al., 
2003). Granzyme M-induced cell death is rapid and independent of both caspase 
and the mitochondria (Kelly et al., 2004). It induces large vacuole formation within 
the target cells which may be suggestive of induced autophagy, although the exact 
mechanism is still unclear (Bots and Medema, 2006).  
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1.4.9 Fas-mediated cytotoxicity: 
Target cells express on their surface Fas molecules, which is also known as CD95 or 
Apo-1. Fas is a member of the TNFR superfamily, and is expressed in a variety of 
different cell types, both immune and non-immune. It possesses an intracellular 
‘death’ domain, which can initiate caspase-dependent apoptosis upon binding to its 
ligand (Chinnaiyan et al., 1995, Cleveland and Ihle, 1995, Accapezzato et al., 2005). 
TCR signaling induces up-regulation of Fas ligand (CD95L) to the cell surface in a 
Ca2+-independent manner (Waring and Mullbacher, 1999). These molecules are 
enriched in lipid rafts, thus are recruited to the immunological synapse during TCR/
pMHCI complex formation and are held in tight junction with the target cell 
allowing for Fas activation. Fas ligand is also expressed within the endocytosed 
cytolytic granules (He et al., 2010, He and Ostergaard, 2007). Fas-mediated 
apoptosis may also be involved in homeostasis and cell proliferation among other 
populations (Cleveland and Ihle, 1995). 
1.5 Development of T-cells 
1.5.1 Thymic development of T-cells 
In order to provide protection against all possible pathogens that a host may 
encounter in its lifetime the T-cell repertoire is required to be as diverse as 
possible. In addition it must remain unresponsive to normal healthy self-tissue and 
retain a robust response to dysregulated self. To this end T-cells are developed and 
then undergo a rigorous selection and maturation process in the thymus during 
development, from which less than 5% emerge. Lymphoid progenitors develop from 
stem cells in the bone marrow and migrate to the thymus. They begin their 
maturation in the sub-capsular cortex, migrating deeper into the medulla as they 
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mature into thymocytes (Figure 1.10). Initial maturation into functional T-cells is 
antigen-independent. First they develop their specific T-cell cell-surface markers 
such as the TCR, CD3, CD4, CD8, and CD2. Initially, the immature cells begin to 
express CD2, followed by the adhesion molecule, CD44. At this stage they have not 
yet re-arranged their TCR genes, nor do they express other phenotypic cell surface 
molecules and are CD4- CD8- double negative, or DN1. DN2 cells then express CD25-
Rα and begin to re-arrange the β chain of the TCR genes. Once productive re-
arrangement of the β chain has occurred, this is expressed, alongside the CD3 
molecule, with a surrogate α-chain, pTα. Signalling via this receptor causes the 
cessation of β-chain re-arrangement and a brief period of proliferation. During this 
proliferative period, the cells become CD4+ CD8+ double positive (DP) and lose their 
cell surface CD25. They re-express RAG-1 and RAG-2 in order to re-arrange the α-
chain, which will continue until the cell either undergoes positive selection, or dies. 
The DP TCR+ thymocytes have now migrated to the cortico-medullary junction, 
where they undergo positive and negative selection. Cells that are unable to 
recognise self-MHC within 3-4 days remain in the thymic cortex and die by neglect. 
The positively selected DP thymocytes migrate to the medulla where they undergo 
negative selection. APCs presenting self-peptide in the context of either MHCI or 
MHCII interact with the DP thymocytes; those that recognise self-antigen strongly 
receive a strong signal for apoptosis, thus are selected for deletion. The co-receptor 
molecules are essential at this stage, and once a T-cell has recognised either MHCI 
or MHCII, the DP thymocyte is then committed to become either CD4+ or CD8+, and 
the redundant co-receptor is then lost. In the absence of either co-receptor, the 
resultant T-cell repertoire is skewed in favour of the other T-cell phenotype, and if 
both are absent thymic selection results in T-cells that recognise non-MHC ligands 
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Figure 1.10: Thymic Ontogeny 
Double negative (DN) thymocytes progress through 
four distinctly separate phenotypes in the thymic 
cortex. They undergo RAG (recombination-
activating gene) re-arrangement of the TCR β-
chain and generate a preTCR with pre-α-chain 
(pTα) in order to undergo expansion. The α-chain 
is then re-arranged by a similar process. The 
immature double positive (DP) thymocytes that fail 
to recognise self-MHC die by neglect. MHC-
restriction is imposed at this stage. The co-
receptor committed thymocytes migrate to the 
medulla, where those that recognise MHC too 
strongly are marked for deletion. The single 
positive (SP) thymocytes migrate to the periphery 
where they circulate as naïve T-cells. 
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(Van Laethem et al., 2007, Trobridge et al., 2001). It should be noted that both 
positive and negative selection are directed under self-antigen. Positive selection 
ensures that self-MHC are recognised, negative selection ensures that self-
recognition is not strong enough to trigger autoimmunity. No pathogenic antigen has 
been encountered, relying on the promiscuity of the TCR to recognise foreign 
peptides with much greater affinity.  
1.5.2 VDJ Rearrangement 
The TCR repertoire is highly diverse. Unlike MHC, this is achieved by 
recombination, rather than polymorphism, however, in contrast to antibody 
generation, there is no somatic hypermutation. This allows the selection of 
appropriate and robust TCRs during thymic selection. This process is ligand-
independent and thus the selection process in the thymus is essential to ensure only 
appropriate (neither auto-reactive, nor non-functional) TCRs enter the periphery. 
Only around 5% of those TCRs originally generated recognise self-MHC at an 
appropriate level and are matured following positive and negative selection in the 
thymus. In order to achieve this huge range of potential TCRs, known as the primary 
repertoire, from which the final repertoire is selected, the thymocytes undergo a 
series of re-arrangement events of the α and β chains of the TCR. This ‘somatic 
recombination’ of the Variable (V), Diversity (D, only present in some loci), and 
Joining (J), gene segments, known as VDJ recombination, are mediated by VDJ 
recombinase enzymes such as Recombinase Activating Genes 1 and 2 (RAG1 and 
RAG2) (Schatz and Ji, 2011). The enzymes cleave and recombine the V, D and J 
segments at specific sites, where the double stranded DNA is repaired by the 
enzyme DNA-dependent protein kinase complex (DNA-PK), before recruiting a 
further enzyme, terminal deoxynucleotidal transferase (TDT). This enzyme then 
randomly adds nucleotides to the DNA ends, 
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giving rise to junctional and thus TCR diversity. This process is summarised in Table 
1.2 and Figure 1.11. 
As has previously been discussed, the β-chain is first re-arranged. The newly re-
arranged β-chain is expressed with the pre-existing α-chain, which acts as a 
surrogate α-chain in order to form the pre-T receptor (pTα). This allows for 
activation through the pTα, which causes the β-rearrangement to stop once a viable 
chain has been produced, and instigating proliferation before α-chain re-
arrangement, which occurs in a similar manner. There is no signal to stop α-chain 
re-arrangement, rather if recognition of self-MHC has not happened within 3-4 days, 
death by neglect occurs. 
Whilst most TCR chain transcripts arise from fully rearranged gene loci, some germ 
line transcripts have been identified (Abbey and O'Neill, 2008). 
V(D)J recombination is essential for the development of the adaptive immune 
system in most vertebrate hosts, and gives rise to an extraordinarily diverse array of 
antigen receptors. It must be noted that occasional genome instability and lymphoid 
malignancies can arise. 
1.5.3 T-cell Maturation
Around 5% of the initial lymphoid progenitor cells emerge as single positive (SP) 
thymocytes having successfully undergone positive and negative selection. In order 
to achieve functional competency they must still undergo a final stage of T-cell 
maturation; a series of steps is required in order for them to be competent naïve T-
cells capable of participating in an immune response.
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Figure 1.11: V(D)J re-arrangement of TCR 
α and β loci to generate novel TCR 
The β-chain is re-arranged first during thymic 
generation. Firstly the Dβ1 may combine with one 
of six Jβ, or Dβ2 may combine with one of seven 
Jβ. The DJ is then re-combined with a Vβ. The 
resultant locus is transcribed from the leader 
sequence (L) and any additional material is spliced 
out, giving rise to an mRNA transcript, L VβDβJβCβ. 
Splicing out is under the enzymes RAG1 and RAG2, 
and the repair is by DNA-PK and TDT. A preTCR, 
pTα, is expressed through pairing with the germ 
line β-chain. Stimulation through the pTα initiates 
thymocyte expansion prior to α-chain 
rearrangement.
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Stage Process Features 
1 Synapsis Binding the enzyme to the 
conserved sequences 
2 Cutting Precise double-stranded breaks at the 
nucleotide preceding and following  
the recognition sequences 
3 Trimming Nucleotide deletions from the 
coding regions 
4 Addition Nucleotide insertions 
5 Repair Polymerisation 
6 Joining Ligation 
Table 1.2: The stages of the V(D)J recombination reaction 
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Firstly, they must be capable of proliferation and expansion when antigen 
stimulated through the TCR. ‘Semi-mature’ lymphocytes are still susceptible to 
programmed apoptosis when stimulated through the TCR (Kishimoto and Sprent, 
1997). MHCI up-regulation by these cells has been shown to be a useful indicator of 
competency to divide (Hogquist et al., 2015). Down-regulation of CD69 and up-
regulation of CD62L and S1P1 is seen with tissue egress, and by this stage the 
maturing thymocytes are acquiring resistance to death receptor signalling. Thymic 
egress is noted after approximately 4 days of maturation in the medulla, and is via 
the blood vessels rather than lymphatics, although why this should be so remains 
uncertain.  
Once in the periphery, the thymocytes gain the ability to produce cytokines, and 
may respond to antigen presented by APCs as mature naïve T-cells. Naïve T-cells are 
thought to survive and persist owing to weak stimulation via contact with self-
ligands presented in the context of MHC, and by anti-apoptotic signals from low 
levels of the cytokine IL-7 (Surh and Sprent, 2008, Kishimoto and Sprent, 1997). This 
weak stimulation of the TCR by self-peptides may also enhance sensitivity to foreign 
antigens. 
1.6 Cancer Immunology 
1.6.1 Cancer Immunology Overview 
Despite improved understanding and earlier detection of pathology, cancer 
remains a massive global health issue, and a leading cause of death worldwide. 
With many cancers remaining refractory to traditional treatment approaches, and 
world-wide cancer mortalities increasing by several million each year, researchers 
have 
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increasingly looked for novel approaches to treatment, including harnessing and/or 
augmenting the natural ability of the immune system to target cancer.  
Cancer immunotherapy has yielded many positive results for patients with late 
stage cancers, traditionally considered to be untreatable. The expanded T-cell may 
be infused back into the patient in high numbers following ex vivo expansion in a 
process called Adoptive Cell Transfer (ACT). In addition to this, greater 
understanding in the field of cancer immunology has enabled us as researchers and 
clinicians to better understand to pathology and behaviour of tumours, and the 
ways in which they evade the immune system, and in doing so devise novel ways of 
treating them and/or optimising our treatments.  
1.6.2 T-cells and Cancer
CD8+ T-cells have a pivotal role in anti-tumour immunity. CD8+ T-cells recognise and 
target infected and dysregulated cells for deletion, indeed this is a key role of the 
immune system, thus cancer itself may be considered to be a disease resulting from 
failure of the immune system to do so (Swann and Smyth, 2007, Finn, 2012). CD8+ T-
cells do exist which recognise cancer antigens, however cancer is observed and 
persists in the host (Topalian et al., 1987, Kawakami et al., 1994, Hicklin et al., 
1999, Jager et al., 1998). Researchers have recognised the potential power of the 
cytotoxic CD8+ T-cell to eliminate cancer for many years, yet in order to harness 
this power for the benefit of the host, one must first appreciate reasons why the 
immune system may have initially failed to clear this disease. 
Firstly, we must consider the possibility that the cancer we observe in the host is 
the cancer that has already evaded the immune system. It is possible, indeed likely, 
that many cancers are recognised and eliminated by the immune system before they 
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reach a level that is detectable in the host. Anti-cancer T-cells are identified in 
individuals with no previous history of cancer (Vella et al., 2009, Boon and van der 
Bruggen, 1996), and many cancers are observed at increased rates in 
immunocompromised patients (Kubica and Brewer, 2012, Schulz, 2009), although it 
is recognised that there are multiple reasons as to why this should be so.  
Demonstrably, cancers do successfully evade the immune system, persist, and 
become deleterious to the host, and researchers have devoted much time to 
understanding why this should be so; if one could create an environment where the 
immune system had the greater advantage, then the prognosis is likely to be more 
favourable. It is well recognised that established tumours employ multiple strategies 
in order to evade the immune system (Costello et al., 1999, Igney and Krammer, 
2002, Topfer et al., 2011, Seliger, 2005). Tumours are capable of down-regulating 
MHCI, thus reducing the available target ligands that may be recognised by anti-
cancer T-cells, and also of creating a hostile microenvironment, which inhibits, 
discourages, or fails to provide help to these cells. Not only are tumour cells and 
the surrounding environment abnormal, but the bloods vessels which supply tumours 
are too; they may grow abnormally, flow abnormally, or even change direction of 
flow readily, thus normal mechanisms by which T-cells which are potentially 
protective to the host are cut off once the tumour is established. The larger and 
more established the tumour becomes, the more alien and hostile the 
microenvironment within, and thus the more difficult it becomes for the immune 
system to infiltrate, thus traditionally oncologists have considered early 
recognition, intervention and treatment to be the key to treating cancer. However 
many cancer immunologists believe that harnessing the power of the CD8+ T-cell 
and other anti-cancer immune response could hold the key to future cancer 
therapies. 
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1.6.3 Tumour Immune Surveillance 
There exists strong supporting evidence that the immune system plays a pivotal role 
in controlling neoplastic processes in the host. Cancer exists in immunocompetant 
hosts, suggesting a failure of immune surveillance. The immune system may act to 
control and shape the tumours behaviour, for example by targeting and deleting cells 
which break free from the tumour, thus delaying the spread of malignancy.  
T-cells are likely to have a key role in tumour immune surveillance. RAG deficient 
mice, which lack both B- and T-cells, and NK cells, have been used in models to 
demonstrate the importance of these populations. It has been demonstrated that 
mice lacking IFNγ, IFNγ receptors, and perforin fail to suppress malignancies (Kaplan 
et al., 1998, Shankaran et al., 2001, Smyth et al., 2000, Street et al., 2002). 
Increased rates of cancer have been reported in human hosts with either congenital 
or acquired immunodeficiency (Penn and Starzl, 1973, Mayor et al., 2017, Chapman 
et al., 2013, Boshoff and Weiss, 2002). This is particularly true of viral-driven 
malignancies.  
Additionally, it has been demonstrated that tumours derived from 
immunocompromised hosts are of increased immunogenicity, even when transplanted 
into an immunocompetant host, suggesting that the immune system plays a role in 
shaping the behaviour of the tumour (Kaplan et al., 1998).  
The ‘immunoediting’ hypothesis was first suggested in 2002 (Dunn et al., 2002), and 
described 3 possible outcomes for the cancer host; elimination of the tumour, the 
establishment of equilibrium between the tumour and the host’s immune system, 
and tumour escape from immune control (Arum et al., 2010). In a malignant process, 
these three stages are progressive; initially the host’s immune system is capable of 
identifying, targeting and deleting neoplastic cells, however this 
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progresses to a state of equilibrium where growth is contained however the 
cancer cells are not fully eliminated. During this phase, however, the 
malignant cells undergo changes in gene expression and mutations, possibly 
due to the mounting selectional pressure from the immune response, and are 
increasingly able to evade the immune response. This results in uncontrolled 
proliferation of the malignancy, or immune escape. 
1.6.4 Immune Evasion and Tumour Escape 
Cancer cells employ numerous mechanisms to evade the immune system. Broadly, 
these involve evading recognition by the immune system, induction of immune 
tolerance, or resistance to cytotoxic mechanisms employed by the immune system. 
The tumour antigen self may be lost or expression reduced, therefore this is less 
available in the cytosol for proteasomic degradation and so loading and expression 
in the context of MHCI (Yee and Greenberg, 2002). The intracellular machinery 
required for antigen processing and presentation (the proteasome, tapesin and TAP, 
MHCI and β2M) may be compromised in cancer cells, resulting in failure of antigen 
expression at the surface of the cell (Tertipis et al., 2015, Bicknell et al., 1994, 
Bubenik, 2004). Proteasome aberrations result in a lack of peptide for loading and 
presentation. TAP deficits disallow peptide entry to the ER. MHCI are unable to 
exist without β2M. 
Tumour cells may release cytokines which can induce T-cell death, or disrupt the T-
cell’s signalling pathways e.g. chemokine ligand 12 (CXCLI2), Transforming growth 
factor β (TGFβ), IL-10, receptor binding cancer antigen (RCAS1). CXCL12 promotes 
neovascularisation and is associated with a poor prognosis (Salmaggi et al., 2004). In 
the early phase of immunosurveillance and pre-malignancy, TGFβ is suppressive of 
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the tumour, anti-inflammatory and promotes homeostasis, however once the 
tumour has entered the malignant and proliferative stage the tumour’s TGFβ 
signalling pathways become inactive. Now, paradoxically, TGFβ actively aids in 
tumour spread and growth, and facilities metastasis (Massague, 2008, Jakowlew, 
2006).  
Additionally, the tumour may protect itself from apoptosis by the up-regulation of a 
mutated form of FasL, which inhibits this pathway, or molecules such as FLICE 
(FADD-like interleukin-1β-converting enzyme)-like inhibitory protein (FLIP), and 
protein inhibitor-9 (PI9), which can protect from granzyme degradation and 
promote resistance to death receptors (Kataoka et al., 1998, Hahne et al., 1996, 
Soriano et al., 2012). 
Tumours can up-regulate PD-L1, thus utilising the T-cells own inhibitory 
mechanisms to dampen down the T-cell response (Juneja et al., 2017). It has 
been shown that high levels of PD-L1 are associated with a less favourable 
outcome for the host (Zhao et al., 2017). If the tumour possesses professional APC 
properties, it can also down-regulate B7.1 and B7.2 expression on the tumour 
surface can be reduced or absent, resulting in T-cell anergy (de Charette et al., 
2016) (Figure 1.8). 
Indeolamine 2,3 dioxygenase (IDO, INDO) can be overproduced by tumour cells, or 
by local DCs, which can the activity of CD8+ T-cells and promote the activity of Tregs 
(Uyttenhove et al., 2003, Moon et al., 2015).  
DCs in the draining lymph nodes can be incompletely activated, thus inducing 
tolerance rather than robust activation of CD8+ T-cells (Cuenca et al., 2003). 
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1.6.5 Cancer Immunotherapy 
Cancer immunotherapy is the use of the host’s own immune system to treat cancer. 
Strategies act to counter ways in which the cancer cells evade and edit the immune 
system, or exploit the cell surface molecules expressed by cancer cells that may be 
recognised by the immune system. Broadly, strategies may be divided into active or 
passive approaches. Active approaches either prime the host’s own immune system 
to target the cancer cells (e.g. cancer vaccines), or involve the infusion of immune 
cells into the patient which will target the cancer (Adoptive cell transfer, ACT). 
The other approach aims to target the mechanisms employed by the tumour to 
evade the existing immune response with the use of antibodies or cytokines.  
Several monoclonal antibodies (mAb) are currently in therapeutic use for the 
treatment of both solid and haematological tumours, with many more currently 
under development or trial (Corraliza-Gorjon et al., 2017).  
Pro-inflammatory cytokines have been successfully used to treat cancer. Currently 
in use are IL-2 and IFNs (Antony and Dudek, 2010, Parker et al., 2016). Down-
regulation of MHCI by the tumour has the effect that T-cells fail to recognise the 
tumour, thus effectively rendering the adoptive arm of the immune system 
ineffective. Innate NK cells are still able to target the tumour, however in the 
absence of MHC they become anergic. Pro-inflammatory cytokines have been 
demonstrated to be effective at rescuing this response (Ardolino et al., 2014, 
Ardolino et al., 2015). 
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1.6.6 Monoclonal Antibody Therapy 
Antibodies have long been considered a possible therapeutic agent, and the 
creation of the first hybridoma in 1975 has facilitated the manufacture of mAbs. 
The first mAbs were murine in origin and therefore immunogenic, however as 
technologies advanced, chimaeric, humanised and then fully human mAbs were 
created. mAbs may trigger cytotoxic destruction of tumour cells by NKs (antibody-
dependant cell-cytotoxicity (ADCC)), phagocytosis of tumour cells by macrophages 
(antibody-dependant cell-phagocytosis (ADCP)), facilitate complement targeting of 
the tumour (complement-dependent cytotoxicity (CDC)), block ligands and 
receptors at the tumour cell surface, or bind tumour antigens to induce apoptosis.  
Most mAbs target immune checkpoints rather than the tumour itself, acting to 
arrest the tumours immune evasion mechanisms, thus re-programming and rescuing 
the immune system’s anti-tumour response.  
There are currently over 50 mAbs in therapeutic use (Ayyar et al., 2016), with 20 
specifically licensed for solid tumours, 13 for haematological tumours (correct as of 
2017 (Corraliza-Gorjon et al., 2017)). Many are bi-specific or multi-specific, listed as 
targeting 21 different antigens (Corraliza-Gorjon et al., 2017). Many more are under 
development or currently in therapeutic trials (Corraliza-Gorjon et al., 2017, Ayyar 
et al., 2016). Currently there is a large focus upon modulating immune function and 
redirecting T-cell responses. mAbs targeting the B7-CD28 superfamilies have proven 
to be extremely effective at reducing the tumours ability to evade the host’s T-cells 
(Ni and Dong, 2017, Corraliza-Gorjon et al., 2017, Assal et al., 2015). Blockade of 
the PD-1 or PD-L1 interaction, which is frequently utilised by the tumour to limit 
the host T-cell response, has yielded positive results, at least in the short term, for 
several aggressive and metastatic cancers (Balar and Weber, 2017, Sunshine and 
Taube, 2015, Homet Moreno and Ribas, 2015, Mahoney et al., 2015, Wang and Wu, 
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2017, Ni and Dong, 2017). Another molecule successfully targeted is CTLA-4 (Assal 
et al., 2015, Mocellin and Nitti, 2013, Wolchok and Saenger, 2008). 
As with many anti-cancer treatments, the tumour can become resistant to therapy 
(Wang and Wu, 2017, Sharma et al., 2017), and side-effects have been reported 
(Wolchok and Saenger, 2008, Naidoo et al., 2015, Naidoo et al., 2016, Kahler et al., 
2016, Baldo, 2013), however overall the response to such therapies, particularly in 
late stage disease which has traditionally considered to be refractory to treatment 
has been extremely encouraging, and further B7-CD28 superfamily targets are 
currently under trial (Assal et al., 2015). 
1.6.7 Adoptive Cell Transfer and Gene Therapy 
ACT involves the expansion of anti-tumour cell populations, and the re-infusion back 
into the patient. Expansions may be of directly ex vivo cells, or cells which have 
been modified in some way to improve their efficacy. Modifications may be the 
creation of a chimaeric antigen receptor (CAR) in order to introduce a de novo 
receptor. Usually this is created using the internal machinery from an existing 
receptor of the cell, fused with the external receptor to a desired ligand, thus the 
resulting receptor is fused of two parts (chimaera). Alternatively, the cells own 
receptors can be modified in order to enhance the cell’s response; these are said to 
be ‘engager-modified’. 
Different immune cell populations have been considered for ACT cancer therapies, 
however, the focus of this thesis is CD8+ T-cells, and so these approaches will be 
discussed in greater depth. 
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NK cells are part of the innate response, and are considered to be the host’s ‘first 
line of defence’ against cancer.  Mixed results have been reported, with earliest 
trials eliciting disappointing responses, however improvements have been seen in 
recent studies (Davis et al., 2015, Rezvani and Rouce, 2015, Besser et al., 2013). 
Most other approaches have utilised lymphocytes, mostly T-cell, however B-cell 
ACT has also been trialled (Besser, 2013). B-cells may act as APCs, Ab producing 
cells, and as immune effectors cells, so have their place in cancer treatment where 
they can augment the T-cell response, or directly target the cancer. 
Tumour infiltrating lymphocytes (TILs) have also been used for ACT (Goff et al., 
2010, Kvistborg et al., 2012, Rosenberg et al., 1986, Topalian et al., 1987). TILs are 
derived from solid tumours, and comprise of a mixed cell population; all 
lymphocytes found in the tumour – CD8+, CD4+, B-cells and γδ T-cells. Owing to the 
nature of the acquisition of these cells, one cannot be certain which target the 
cancer, provide help, are incidental, or may even hinder the response, and it is 
also possible that some important populations are ‘grown out’ or lost in the 
expansion process, however extremely positive responses have been reported in 
some trials, with some patients achieving lengthy remissions (Geukes Foppen et al., 
2015). Additionally, this sampling technique has been used to then prime and 
select clones for expansion, or to select TCRs for gene transfer. Owing to the nature 
of the techniques required for this, i.e. the use of a whole solid tumour from which 
to obtain the TILs, target cancers are limited to those which may be easily 
biopsied, with skin cancers such as melanoma being ideal candidates. TILs were 
one of the first conceived ACTs to treat cancer, with a murine model being 
pioneered in 1986 (Rosenberg et al., 1986). Clinical trials using this technique had 
begun the following year (Topalian et al., 1987, Rosenberg et al., 1988). 
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Many ACT therapies for cancer utilises the cytotoxic properties of CD8+ T-cells to 
directly target the tumour cells. Initial trials using a clonally expanded population of 
T-cells that recognise anti-cancer antigens showed were encouraging. Remission 
(partial or complete) rates of 50% or more have been reported for metastatic 
melanoma patients (Besser et al., 2010, Dudley et al., 2008, Khammari et al., 2009). 
Increasingly, genetically modified T-cells have been considered. Strategies utilised 
include the creation of CARs in order to target ligands not naturally recognised by T-
cells (Bridgeman et al., 2010b). CARs are created by the hinging of a single chain 
variable fragment (scFv) specific for the antigen of choice, to the cytoplasmic 
elements of either CD3 or CD28, thus linking the specificity of the antibody from the 
scFv is derived to the signalling machinery of the cell. The scFv is a fusion protein, 
created of the variable heavy (VH) and light (VL) of the specific immunoglobulin (Ig). 
The removal of the constant regions maintains the specificity of the Ig, whilst 
generating a small protein for the extracellular part of the CAR.  An example of this 
is the creation of a CAR recognising CD19, thus targeting B-cells, which has been 
successfully used to treat lymphoma (Klebanoff et al., 2014, Ramos et al., 2014, 
Lipowska-Bhalla et al., 2012). 
Another modification strategy employed to enhance ACT is to enhance of the TCR 
for the cancer ligand. It has already been discussed that the affinity with which 
some anti-cancer TCRs recognise tumour antigen may be sub-optimal, thus the 
resulting antigen-specific T-cell response to the tumour can be less than adequate, 
therefore efforts to enhance the TCR/pMHCI interaction be beneficial to the patient. 
It has been discussed that some cancer antigens are of a not dissimilar order to some 
pathogenic TCRs, however it has been suggested that the ‘ideal’ affinity for TCR/
pMHCI interactions is 10 µM (Zhong et al., 2013). Few anti-cancer TCRs of this 
affinity are recorded, with most falling short, thus scope for enhancement exists, 
and TCR gene therapy is increasingly important. 
73 
Recently, media attention has been given to reports of the use of donor T-cells to 
treat two babies with acute and refractory leukaemia. The T-cells in question were 
described as ‘off the shelf’, for use in un-matched donors, and had been gene-
edited using TALENs, and engineered to express CARs. The initial research appears 
to be flawed, in that the patients had also received chemotherapy, however, this 
may represent a new strategy in the future (Qasim et al., 2017). 
1.6.8 Principles of TCR Gene Therapy 
An effective anti-cancer TCR should maintains its specificity for the tumour, 
recognise the target with sufficient affinity to initiate a robust response against the 
target cell. The T-cell itself must be capable of evading the tumours inherent 
suppression mechanisms, countering the tumour’s immune editing and reversing 
the immune tolerance of the tumour that occurs in the metastatic patient. The TCR 
itself should be specific to the tumour antigen, without promiscuous recognition of 
autoreactive or allo-antigens, thus rigorous screening of the TCR is required to 
avoid auto- and allo-reactivity, which could be deleterious to the patient. Ideal 
antigens are tumour-specific and expressed only on the tumour such as onco-
antigens, mutated antigens or neo-antigens, or related to viruses that may drive 
some tumour. 
Using multimer technology, T-cells that recognise known onco-antigens may be 
isolated from ex vivo PBMC for clonal expansion (Wooldridge et al., 2009), 
whereupon their ability to lyse target cells either pulsed targets, or tumour lines) 
can be tested in vitro. Following identification of a high-affinity clone, the TCR can 
be clonotyped, the α- and β-chain sequenced, and cloned into a retroviral vector, 
enabling the manufacture of retroviral particles for transduction into T-cells. 
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Mutations to enhance the affinity of the TCR for the pMHCI can be introduced for 
testing (Robbins et al., 2008). As has been previously stated, the ideal affinity for 
these TCRs has been suggested as around 10 µM. Above this affinity, further 
increase has minimal effect on the avidity of the T-cell. It has also been 
demonstrated that very high affinity TCRs recognise the TCR contribution to the 
TCR binding platform such that the peptide presented becomes less relevant, and 
autoreactivity ensues 
(Cole et al., 2014).  
Retroviral particles can only infect actively dividing cells, thus ex vivo T-cells must 
be induced to proliferate with the use of Dynabeads™, which induce T-cell 
proliferation by providing signals 1 and 2 with anti-CD3 and anti-CD28 antibodies 
(Brimnes et al., 2012). T-cells can then be enriched for the transduced populations 
for rigorous testing, before they can be considered for adoptive transfer (Tan et al., 
2015). Testing involves testing the efficacy of the transduced lines; response to 
targets and if possible tumour lines, and for antigen-driven proliferation, and also 
for autoreactivity and alloreactivity with the use of combinatorial peptide library 
screening (Wooldridge et al., 2012). 
1.6.9 The lentiviral Vector Gene Delivery System 
Lentiviridae are members of the family Retroviridae, characterised by a long 
incubation period (‘lenti’, Latin for ‘slow’). Examples of such are Human 
Immunodeficiency Virus (HIV) and Feline Immunodeficiency Virus (FIV). 
Retroviruses are capable of inserting viral DNA (or RNA) into the host cell DNA in 
significant quantities, and replicating themselves by utilising the replication 
system of the host cell. However lentiviridae are unique amongst retroviridae in 
that they can infect non-dividing (quiescent) cells. For this reason lentiviral 
vectors (LVs) are commonly 
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used tools in research for Gene Transfer (GT) (Klimatcheva et al., 1999). In 
addition, they have been widely used in clinical trials (196 trials at the time of 
publishing, 7.5% of trialled systems) (ABEDIA, 2017) (Figure 1.12). LVs may stably 
integrate expression vector inserts into host DNA; expression is prolonged and 
phenotype is maintained (Wanisch and Yanez-Munoz, 2009). They are also 
relatively well tolerated and of lower toxicity compared to other delivery systems, 
and may be utilised to deliver up to 8kb of transgenic DNA (Matrai et al., 2010). 
Earlier LV delivery systems have the potential to revert to pathogenic retrovirus 
(Klimatcheva et al., 1999, Matrai et al., 2010). In order to overcome this, the 
lentiviral system utilised in this thesis is a replication-deficient HIV-1 derivative, 
grown in human embryonic kidney (HEK293T) packaging cells, with four distinct 3rd 
generation lentiviral plasmids; a transfer plasmid, two packaging plasmids and an 
envelope plasmid. These plasmids contain genes encoding only the relevant 
structural proteins, and the enzymes involved in lentiviral infection and DNA 
integration of the host; pol, gag, and rev. These enzymes are separately expressed 
by two different packaging plasmids, thus increasing the safety of the system by 
vastly increasing the number of random recombination/mutation events required 
to revert to a wild type virus. Of these essential viral genes, pol encodes for 
reverse transcriptase and other essential translation enzymes, gag encodes the 
capsid, and rev encodes a structural protein that serves to bind the viral mRNA, 
facilitating export from the nucleus and thus protein transcription.
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Figure 1.12: Viral vectors used in 
clinical trials 
Taken from the Gene Therapy Clinical Trials 
Database (ABEDIA, 2017).
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1.6.10 Lentiviral Plasmids 
The lentiviral expression vector: Transgene expression is mediated by elongation 
factor-1α (EF-1α). The virion particles contain DNA encoding only for the designated 
transgene, and the ψ packaging signal, preceded by the primer binding site (PBS), 
where reverse transcription starts. Long terminal repeat sequences (LTR) are 
found at either end of the genes encoding for lentiviral function (3’ and 5’ LTRs). In 
order to enhance safety and reduce the potential for insertional mutagenesis, these 
have been mutated to an alternate open reading frame (ORF), and mutations 
inserted to eliminate endogenous enhancer activity of the transfer vector. In 
addition to the transgene and the ψ sequence (lentiviral machinery), the vector also 
incorporates the Woodchuck hepatitis virus (WHV) post-transcriptional regulatory 
element 
(WPRE) and the central polypurine tract (cPPT) (Barry et al., 2001). The WPRE is 
situated immediately downstream of the transgene and acts to enhance expression 
(Higashimoto et al., 2007, Schambach et al., 2006). The cPPT acts to enhance 
transduction by enhancing nuclear import, thus facilitating better insertion (Van 
Maele et al., 2003). The rev response element (RRE) binds the mRNA, promoting 
nuclear export and translation (Barry et al., 2001).  
The lentiviral packaging plasmids The rev enzyme is encoded in a separate 
plasmid, pRSVrev. This enzyme is derived from respiratory syncytiovirus (RSV) 
rather than HIV in order to further enhance the safety of the system. The other two 
enzymes necessary for lentiviral generation, pol and gag are encoded in the pMLDg/
pRRE plasmid, which also encodes for the RRE.  
The envelope plasmid: The third packaging plasmid is pVSV-G which encodes for 
the viral envelope.  
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The expression plasmid, pELN, encodes the inserted transgene 
expression cassette, and additional promoter sequences. 
1.6.11 Summary 
As one might expect, the responses have been variable, depending on the trial, the 
strategy, and the nature of the target cancer. Due to the massive variability in both 
host and pathology, direct comparison of these approaches is extremely difficult, 
and it seems likely that, rather than a ‘cure for cancer’, a targeted approach to 
each tumour is necessary. These trials have largely been conducted on patients with 
large, aggressive and seemingly intractable cancers, thus any response should be 
considered a positive sign, yet many studies report some degree of response in most 
patients, with a percentage achieving complete remission (Rosenberg and Dudley, 
2009, Rosenberg et al., 2008, Rosenberg et al., 1986, Dudley and Rosenberg, 2003, 
Hinrichs and Rosenberg, 2014, Kvistborg et al., 2012, June, 2007, Besser, 2013, 
Perica et al., 2015).  
This exciting field of research represents the shape of the future in targeted cancer 
treatment. Whilst it is recognised that poor sub-optimal TCR/pMHCI affinity is not 
necessarily the reason why tumours escape the immune system and persist in the 
host, the success of some attempts to create enhanced affinity TCRs, suggests that 
this is an important feature for at least some cancers. One downfall to this approach 
is the need to be targeted to both ligand and specific MHCI. Moreover, the timescale 
required to create such a ‘designer TCR’ can be lengthy; at a recent workshop 
considering TCR gene therapy, Adaptimune suggested 2 – 2.5 years, from bench to 
bedside. This thesis considers the possibility that the non-polymorphic CD8 molecule 
may be considered as a novel way of enhancing the TCR response to cancer ligand. 
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1.7 Aims of this Thesis 
1.7.1 Hypothesis 
Co-receptor mediated optimisation of the antigen specific T-cell response may be 
achieved by either tuning the strength of the pMHCI/CD8 interaction, or altering 
the level of CD8 expressed at the cell surface. 
1.7.2  Aims 
Specifically, I intend to: 
1) Define the optimal pMHCI/CD8 interaction strength required which affords
enhanced T-cell immunity by introducing point mutations into MHC at the
CD8 binding site in order to examine this response.
2) Design and optimise a system for the stable transduction of CD8αβ and a
known TCR into immortalised and primary cell systems.
3) Define the effect of introducing point mutations into the α chain of CD8,
specifically examining the kinetics of this interaction in vitro, and the effect
on the T-cell response in vivo.
4) Examine the T-cell response of altering the splice variant expressed on the
cytoplasmic tail of the CD8β chain.
Define the effect of altering cell surface CD8 expression levels on 
pMHCI recognition, and subsequent CD8+ T-cell activation. 
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Chapter 2 
Materials and Methods 
2.1 Mammalian Cell Culture 
2.1.1  Cell Culture Media 
The following cell culture media were used: 
R10: Roswell Park memorial Institute 1640 media (RPMI-1640) (Life Technologies, 
ThermoFisher Scientific, U.K.) supplemented with 10% heat inactivated foetal 
bovine serum (FBS) (Life Technologies, ThermoFisher Scientific, U.K.), 2 mM L-
glutamine (Life Technologies, ThermoFisher Scientific, Paisley, U.K.), 100 IU/ml 
penicillin and 100 µg/ml streptomycin (Life Technologies, ThermoFisher Scientific, 
Paisley, U.K.). 
R0 (PSG): RPMI-1640 supplemented with 2 mM L-glutamine, 100 IU/ml penicillin 
and 100 µg/ml streptomycin. 
R2: RPMI-1640 supplemented with 2% heat inactivated FBS, 2 mM L-glutamine, 100 
IU/ml penicillin and 100 µg/ml streptomycin. 
R20: RPMI-1640 supplemented with 20% heat inactivated FBS, 2 mM L-glutamine, 
100 IU/ml penicillin and 100 µg/ml streptomycin. 
CK media: R10 supplemented with 2.5% Cellkines (Helvetica Healthcare, Geneva), 
200 IU/ml IL-2 (Proleukin®, aldesleukin, Novartis, U.K.) and 25 ng/ml IL-15 
(PeproTech, London, U.K.). 
T-cell media: R10 supplemented with 200 IU/ml IL-2 and 25 ng/ml IL-15.
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D10: Dulbecco modified Eagle’s medium (DMEM) (Life Technologies, ThermoFisher 
Scientific, U.K.) supplemented with 10% heat inactivated FBS, 2 mM L-glutamine, 
100 IU/ml penicillin and 100 µg/ml streptomycin. 
D0: DMEM supplemented with 2 mM L-glutamine, 100 IU/ml penicillin and 100 
µg/ml streptomycin. 
Freezer mix: FBS supplemented with 10% sterile dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, Poole, U.K.).  
FACS Buffer: Phosphate buffered saline (PBS) supplemented with 0.5% Bovine 
Serum Albumen (BSA) and 0.1% NaN3 sodium azide. 
MACS Buffer: PBS supplemented with 0.5% BSA and 2 mM EDTA. 
2.1.2 Separation of Peripheral Blood Mononuclear Cells (PBMCs) 
50 ml of whole blood, obtained from the Welsh Blood Transfusion Service or 
directly ex vivo from healthy donors, was collected into a sterile 50 ml falcon 
tube (BD Biosciences) with 50 µl preservative-free heparin (Unihep, Leo®) at a 
final concentration of 1000 IU/ml. PBMC were generated by Axis-shield density 
gradient centrifugation. Peripheral blood was gently layered onto an equal volume 
of Axis-shield density gradient media (LymphoprepTM, STEMCELL Technologies, UK) 
and centrifuged for 10 minutes at 1800 rpm (561 g) with the brake off (Hireaus 
Megafuge 1.0). The buffy coat was removed from the interface using a sterile 
Pasteur pipette and placed into a sterile 50 ml falcon. Cells were washed twice in 
R0: 1800 rpm (561 g) for 10 minutes, followed by 1500 rpm (389 g) for 5 minutes. 
Cells were then suspended in R10 media and kept at 37 °C/5% CO2. Cells intended 
for use as human γ-irradiated (30 Gy) allogeneic feeders were stored at 4 °C prior 
to use. 
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2.1.3 Counting cells with Trypan blue 
Cells were counted and analysed for viability by combining 10 µl of cell suspension 
with an equal volume of 0.1% Trypan blue in phosphate-buffered saline (PBS) 
(Sigma-Aldrich) and loaded on to an improved Neubauer haemocytometer (Weber 
Scientific International Limited, Lancing, U.K.). Viable cells remain colourless, 
whilst non-viable cells appear blue at 100 times magnification on a light 
microscope (Nikon Eclipse TS100). The percentage of total cells counted that 
remained white equates to the viability of the cell culture. 
2.1.4 Culture of Human CD8+ T-cell clones 
CD8+ T-cells were grown from cryopreserved stocks in T25 tissue culture flasks, in 
CK media for 2 weeks following re-stimulation using 1 µg/ml Phytohaemagglutinin 
(PHA) with γ-irradiated allogeneic feeders (12 x 106 irradiated allogeneic PBMC 
from 2-3 different individuals in 12 ml of media per flask). The flask was upright 
and tilted at an angle for the first 5 days, before returning to vertical. Media was 
topped up on day 5 and changed on day 7, taking care not to disturb the pellet. 
Cells were counted and plated out into 24-well tissue culture plates on day 10. 
After 2 weeks, cells were maintained in CK media, or T-cell media. 
2.1.5  Human CD8+ T-cell clones used in this thesis 
The following CD8+ T-cell clones were used in this study (Table 2.1): 
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• ILA1, specific for the human telomerase reverse transcriptase
(hTERT)-derived epitope ILAKFLHWL (residues 540-548) restricted by
HLA A*201 (A2 hereafter) (Laugel et al., 2007b, Purbhoo et al.,
2007).
• MEL2, MEL5 and MELc5, specific for the Melan-A-derived epitope
ELAGIGILTV (residues 26-35) restricted by HLA A2 (Purbhoo et al.,
2007, Laugel et al., 2007b).
• LC13, specific for the Epstein-Barr virus (EBV) EBNA3A-derived
epitope FLRGRAYGL (residues 339–347) restricted by HLA B*0801 (B8
hereafter) (Macdonald et al., 2009, Burrows et al., 1994, Bridgeman
et al., 2012).
• SB10, specific for the EBV BZLF1-derived epitope LPEPLPQGQLTAY
(residues 52–64) restricted by HLA B*3508 (B35 hereafter) (Green et
al., 2004, Tynan et al., 2005).
2.1.6 Separation of CD8+ T-cells from fresh, directly ex vivo PBMC 
Directly ex vivo PBMC were counted and resuspended in MACS buffer, before 
magnetically labelling with CD8 MicroBeads (human)(MACS® Technology, Miltenyi 
Biotec Ltd.), as per manufacturers instructions. The cells were then loaded onto a 
MACS MS column, which is placed in the magnetic field of a MiniMACS cell 
Separator. The MiniMACS cell Separator was then removed from the magnetic field, 
thus facilitating elution of the positively selected CD8+ fraction, as per
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Name MHCI restriction Epitope Residue Origin 
ILA1 A*0201 ILAKFLHWL 540-548 hTERT 
MEL2 A*0201 ELAGIGILTV 26-35 Melan-A 
MEL5 A*0201 ELAGIGILTV 26-35 Melan-A 
MELc5 A*0201 ELAGIGILTV 26-35 Melan-A 
LC13 B*0801 FLRGRAYGL 339-347 EBV EBNA3A 
SB10 B*3508 LPEPLPQGQLTAY 52-64 EBV BZLF1 
Table 2.1:  Human CD8+ T-cell clones used 
in this thesis. 
85 
manufacturer’s instructions. Cells were then washed, and resuspended in R10 
media. 
2.1.7 Generation of TCR-transduced CD8+ T-cell lines 
1 x 106 CD8+ T-cells, separated directly ex vivo, were counted, and resuspended in 
1ml R10 media. Cells were plated in a 24-well tissue culture coated plate. 25 µl 
resuspended Dynabeads® (Dynabeads® Human T-Activator CD3/CD28, ThermoFisher 
Scientific Inc., Invitrogen Life Technologies), were washed in an equal volume of 
MACS buffer. A MiniMACS cell Separator was used to facilitate buffer removal, 
before resuspending in 25 µl R10, which was subsequently added to the counted 
cells. IL-2 was supplemented at 30 IU/ml. Cells were incubated overnight at 37 
°C/5% C02, and examined the next day for active proliferation. 500 µl Lentiviral 
particles (generated as described in section 2.1.13)(Table 2.2), resuspended in R10 
supplemented with IL-2 at 30 IU/ml were added. Cells were incubated and 
examined every 24 hours. The media was changed/virus particles removed after 
24-48 hours, dependant on cell health. Cells were cultured in CK media after 5
days, and sorted for transgene expression (rat CD2 (rCD2 hereafter) expression) 
using a modified FACSAriaIITM (BD Biosciences). Cells were sorted into R20 media, 
and rested overnight before expansion by re-stimulation using 1 µg/ml PHA with γ-
irradiated allogeneic feeders. Cells were maintained in CK media and regularly 
stained to demonstrate maintained transgene expression.
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Name 
of transTCR 
MHCI 
restriction Epitope Residue Origin 
ILA1 A*0201 ILAKFLHWL 540-548 hTERT 
C12C* B*2705 KRWIILGLNK 263-272 HIV p24 Gag 
* (Iglesias et al., 2011)
Table 2.2:  Transduced CD8+ T-cell lines 
generated in this thesis. 
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2.1.8 Cryopreservation storage of cells 
5 x 106 cells were centrifuged at 1500 rpm (389 g) for 5 minutes then re-suspended 
in 1 ml freezer mix and transferred to a cryovial (Nunc). Cryovials were stored in 
100% Isopropyl, Propan-2-ol (Mr.Frosty™, ThermoScientific) storage containers at 
-80 °C for 48 - 72 hours before being transferred to liquid nitrogen containers for 
long-term storage.  
2.1.9 Thawing of frozen stocks 
Cell stocks were rapidly thawed at 37 °C to minimize cell death, washed in 
R0 (1500 rpm (389 g), 5 minutes) to remove the DMSO before re-suspension in 
the appropriate culture media.  
2.1.10 Generation of stable HLA A2-expressing C1R B-cell line 
Endotoxin free pcDNA3.1 mammalian expression vectors (Life Technologies) with 
inserts encoding either the full length of the HLA A2, or one of its mutants: A2 
DT227/8KA (Purbhoo et al., 2001), A2 A245V (Wooldridge et al., 2005), A2 Q115E 
(Wooldridge et al., 2007), A2/Kb A245V (Dockree et al., 2017), and A2/Kb 
(Wooldridge et al., 2010a), were generated and linearised, before inserting into 
the C1R B-cell line by electroporation. The C1R B-cell line is an Epstein-Barr Virus 
(EBV)–transformed, class I MHC negative immortal cell line (Storkus et al., 1987). 
C1R cells were split and fed with R10 media 24 hours before transfection because 
transfection efficiency is increased when B cells are actively dividing, and the 
population is >90% viable. For each transfection 10 x 106 C1R B cells were washed 
twice in R0 by centrifuging at 1500 rpm (389 g) for 5 minutes at room 
temperature, before resuspension in 500 µl of R0 and transfer to a sterile 0.4 cm 
electroporation 
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cuvette (Bio-Rad, Herts, UK) with 10 µg endotoxin-free linearised DNA (10 µl of 1 
µg/µl). After gently mixing the cell suspension and DNA using a Pasteur pipette the 
cuvette was placed on ice for 5 minutes. Electroporation was performed using the 
following conditions for each DNA construct; Voltage = 250 V, Capacitance = 400 
µF. 
Electroporation was performed using a Gene Pulser Xcell™ electroporation system 
(Bio-Rad). The electroporated cells were then rested at room temperature for 10 
minutes. After the addition of 500 µl warm R10, the suspension was gently 
transferred into a T25 flask with a further 12 ml R10 and subsequently cultured at 
37 °C/5% CO2. Stable transfectants were selected by adding 0.5 mg/ml G418 
(Sigma-Aldrich) 72 hours after transfection. Cell health and viability was examined 
daily, as significant death was expected in the first 3 days following G418 addition, 
prior to recovery. The transfected C1R cell lines were sorted for A2 expression 
using a modified FACSAriaIITM (BD Biosciences) following staining with FITC-
conjugated mouse anti-human HLA A2 antibody, specific clone BB7.2 (Biolegend®), 
before cloning by limited dilution. The clones were maintained in culture in R10 
media, and regularly tested for HLA A2 and analysed by flow cytometry. All clones 
showed 100% HLA A2 expression, staining with similar MFIs. 
2.1.11 Generation of C1R B-cell Clones by limited dilution 
Cells were counted and resuspended at a concentration of 1 cell per 400 µl culture 
media. Cells were plated up in a round-bottomed 96-well tissue culture plate, 200 
µl/well (i.e. 1 cell ever 2 wells). Control wells at 10 and 100 cells/well were also 
added. Plates were cultured at 37 °C/5% CO2, replacing media as required and 
examined for growth after 10 - 14 days. Clones were stained with FITC-conjugated 
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mouse anti-human HLA A2 antibody, and examined by flow cytometry. Data 
acquired were compared in order to compare A2 expression levels. Clones 
expressing similar levels of A2 for each mutation were selected for expansion. 
Once expanded, C1R B-cells were maintained in culture in T200 tissue culture 
flasks. Clones were regularly stained for A2 expression whilst in culture. 
2.1.12 The HEK 293T lentiviral packaging cell line 
The HEK 293T cell line is a derivative of HEK 293 cells, a line originally derived 
from normal human embryonic kidney (HEK) cells by transformation with sheared 
Adenovirus-5 DNA (Graham et al., 1977). HEK 293T has been stably transfected to 
express the SV40 large T antigen (DuBridge et al., 1987), and, like its parent cell, is 
efficiently transducible with retroviruses. HEK 293T is an adherent cell line, 
maintained in culture in D10 media. Cultures reaching 100% confluence were 
washed in PBS to remove traces of serum (which contains a trypsin inhibitor), 
before incubation for 5-10 minutes with 0.5% trypsin in HBSS (Life Technologies). 
Flasks were gently agitated to encourage cells to detach from the plastic tissue 
culture surface. Cells were removed by gentle pipetting, washed to remove 
trypsin, and split. 
2.1.13 CaCl2 Transfection of HEK 293T cells and Production of Lentiviral 
particles 
Lentivirus (LV) was generated by CaCl2 transfection of HEK 293T packaging cells 
with four distinct plasmids of a 3rd generation LV packaging system. The pELN 3rd
generation transfer vector was used in combination with pRSV.rev, pVSV-G, and 
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pMDLg/pRRE. HEK 293T cells were split, counted, and plated at 106 /ml, in 15 ml 
of D10 in a T175 flask. Following 24 hours, cell health and confluence were 
checked, and the media was removed and replaced with 12 ml of pH 7.9 media. 
Transfection mix (comprising 15 µg pELN, 18 µg pRSV.rev, 7 µg pVSV-G, and 18 µg 
pMDLg/pRRE), made up to 3 ml with pH 7.1 media (Table 2.3), was slowly added 
taking care to contact only the surrounding media rather than the adherent cells 
on the tissue culture surface. Following 12 - 18 hours, the media were removed, 
and replaced with 15 ml of D10. Virus was harvested, stored at 4 °C, and media 
replaced at 48 and 72 hours post transfection. The supernatant collections were 
pooled, and passed through a 0.45 µm filter. Pooled supernatant was added to 38.5 
ml thin-walled ultracentrifuge tubes (Beckmann Coulter), topping up with media to 
ensure the tube is filled, and placed in a Beckmann Coulter SW28.1 rotor for ultra-
centrifugation (Beckmann Coulter Optima L-100 XP) at 20,000 g for 2 hours at 4 °C. 
Following centrifugation, the supernatant was discarded, the pellet allowed to dry, 
and the virus resuspended in 2 ml of R10 media. Virus was aliquotted, snap frozen 
on dry ice, and stored at -80 °C. 
2.1.14 Immortal T-cell Lines 
Immortal cell lines used in this thesis are; the J.R.T3-T3.5 line (ATCC, 2014b, 
Schneider et al., 1977), the J.RT3-T3.5 NFAT GLuc line (provided by Dr. John 
Bridgeman), and the HUT78 H9 derivative (ATCC, 2014a, Chen, 1992, Beddoe et 
al., 2009). These lines are maintained in culture in R10 media. Cells were 
resuspended at a concentration of 106 /ml, and plated up in a 24 well tissue culture 
plate, 1 ml/well. 500 µl Lentiviral particles (generated as described above), 
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pH 7.1 media D0 
25 mM HEPES 
pH adjusted to pH 7.1 
0.22 µm filtered 
pH 7.9 media D10 
25 mM HEPES 
pH adjusted to pH 7.9 
0.22 µm filtered 
Transfection mix 15 µg pELN 
18 µg pRSV.rev 
7 µg pVSV-G 
18 µg pMLDg/pRRE 
50 mM CaCl2
made up to 3 ml with pH 7.1 media 
Table 2.3:  CaCl2 Transfection Media. 
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resuspended in R10, were added to each well. Either one or 2 viruses were added, 
and the well topped up to 2 ml with R10. Cells were incubated and examined every 
24 hours. The media was changed/virus particles removed after 48 hours, 
dependant on cell health. Cells were expanded, and sorted for transgene 
expression using a modified FACSAriaIITM (BD Biosciences), into R20 media. 
Transgene expression was examined by staining for rCD2 expression, (FITC 
conjugated anti-ratCD2, specific clone OX-34, Biolegend®) which indicates 
transfection with TCR transgene, and CD8β (anti-CD8β, specific clone 2ST8.5H7, 
Beckman Coulter), which indicates CD8αβ heterodimer expression. Cells were 
washed and expanded in R20 media, and then maintained in culture in R10 media, 
and regularly stained to ensure maintenance of phenotype. A list of immortal T-cell 
lines generated in this thesis is listed in Table 2.4. 
2.2 Bacterial Culture 
2.2.1  Bacterial Culture media 
The following culture media were utilised in production of this thesis: 
Luria-Bertani (LB) Broth: Tryptone 10 g/l, Yeast extracts 5 g/l and NaCl 10 g/l. pH 
adjusted to 7.0 with NaOH 
LB Agar: Tryptone 10 g/l, Yeast extracts 5 g/l, NaCl 10 g/l and Agar 15 g/l. Media 
were poured into plates whilst still warm and fluid.  
TYP Broth: Tryptone 16 g/l, Yeast extracts 16 g/l, NaCl 5 g/l and K2HPO4 1 g/l. pH 
adjusted to 7.0 with NaOH.
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Parent Cell line Trans-TCR CD8 variant 
J.RT3-T3.5 ILA1 CD8-
J.RT3-T3.5 ILA1 CD8αβ 
J.RT3-T3.5 ILA1 CD8αS53Nβ 
J.RT3-T3.5 NFAT GLuc ILA1 CD8- 
J.RT3-T3.5 NFAT GLuc ILA1 CD8αβ 
J.RT3-T3.5 NFAT GLuc ILA1 CD8αQ2K/S53Nβ 
J.RT3-T3.5 NFAT GLuc ILA1 CD8αS53Nβ 
J.RT3-T3.5 NFAT GLuc ILA1 CD8αβM2 
J.RT3-T3.5 NFAT GLuc ILA1 CD8αβM3 
J.RT3-T3.5 NFAT GLuc ILA1 CD8αβM4 
J.RT3-T3.5 NFAT GLuc MEL5 CD8- 
J.RT3-T3.5 NFAT GLuc MEL5 CD8αβ 
J.RT3-T3.5 NFAT GLuc MEL5 CD8αQ2K/S53Nβ 
J.RT3-T3.5 NFAT GLuc MEL5 CD8αS53Nβ 
J.RT3-T3.5 NFAT GLuc MEL5 CD8αβM2 
J.RT3-T3.5 NFAT GLuc MEL5 CD8αβM3 
J.RT3-T3.5 NFAT GLuc MEL5 CD8αβM4 
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Table 2.4: Immortal T-cell lines 
generated in this thesis. 
J.RT3-T3.5 NFAT GLuc LC13 CD8- 
J.RT3-T3.5 NFAT GLuc LC13 CD8αβ 
J.RT3-T3.5 NFAT GLuc LC13 CD8αS53Nβ 
H9 ILA1 CD8- 
H9 ILA1 CD8αβ 
H9 ILA1 CD8αQ2K/S53Nβ 
H9 ILA1 CD8αS53Nβ 
H9 ILA1 CD8αβM2 
H9 ILA1 CD8αβM3 
H9 ILA1 CD8αβM4 
H9 MEL5 CD8- 
H9 MEL5 CD8αβ 
H9 MEL5 CD8αQ2K/S53Nβ 
H9 MEL5 CD8αS53Nβ 
H9 MEL5 CD8αβM2 
H9 MEL5 CD8αβM3 
H9 MEL5 CD8αβM4 
95 
Psi Broth: Tryptone 20 g/l, Yeast extracts 5 g/l and MgSO4 5 g/l. pH adjusted to 
7.6 with KOH. 
SOC Broth: Tryptone 20 g/L, Yeast extracts 5 g/l, NaCl 0.5 g/l, Potassium Chloride 
- 0.186 g/l, Magnesium Chloride Hexahydrate – 2.03 g/l, Magnesium Sulphate – 1.2
g/l and D-Glucose – 3.604 g/l. 
All media were autoclaved (liquid cycle at 121 °C for 60 minutes) and cooled to 
<55 °C before addition of selection agent, carbenicillin or kanamycin, at 100 
µg/ml. 
2.2.2 Buffers 
Tris-Acetate-EDTA (TAE) Buffer: 40 mM Tris, pH 7.6, 20 mM Acetic Acid and 1 mM 
EDTA. 
Tris-EDTA (TE) Buffer: 10 mM Tris-HCl, pH 8.0 and 1 mM EDTA 
Buffers were made with milliQ (double-distilled) H2O and filtered to 0.45 µm.
2.2.3 Making chemically competent bacteria (Hanahan Method) 
Buffers were made as follows: - 
TbfI: Potassium acetate 30 mM, Rubidium chloride 100 mM, Calcium chloride 10 
mM, Manganese chloride 50 mM, Glycerol 15%. Adjusted to pH 5.8 and filtered (0.2 
µM).  
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TbfII: MOPS 10 mM, Calcium chloride 75 mM, Rubidium chloride 10 mM, Glycerol 
15%. Adjusted to pH 6.5 and filtered (0.2 µM). 
50 ml of Psi broth supplemented with tetracycline at 50 µg/ml, was inoculated 
with 50 µl bacteria (Table 2.5), and incubated at room temperature overnight. A 
further 100 ml of Psi broth was inoculated with 1 ml of the starter culture, and 
incubated at 37 °C, with gentle aeration (shaker set to 110 rpm) to A 550 = 0.45. 
Alternatively, in order to achieve greater competency, the starter culture was 
maintained on ice during the day, and 100 ml of Psi broth inoculated with 1 ml 
started culture was incubated at room temperature overnight, similarly to A 550 = 
0.45.  
The culture was chilled on ice for 15 minutes before pelleting the cells at 6000 
rpm (7245 g) for 10 minutes in a pre-chilled Sorvall™ flask. Supernatant was 
discarded and replaced with 40% starting volume (40 ml) TbfI, and incubated on 
ice for 15 minutes. The cells were pelleted as previously, supernatant discarded, 
and resuspended in 5% starting volume (4 ml) TbfII. Cells were incubated on ice for 
15 minutes before aliquotting (50 µl), snap freezing on dry ice, and storage at -80 
°C (Hanahan, 1983). 
2.2.4 Transformation of Chemically competent bacteria 
Bacterial aliquots, stored at -80 °C, were thawed slowly on ice. ~50 ng of plasmid 
DNA was added to 50 µl of thawed competent bacteria, gently mixed with the 
pipette tip, and kept at 4 °C for 5 minutes. The bacteria were then heat-shocked 
for 90 s at 42 °C, then return to ice for a further 2 minutes. 100 µl of SOC media 
was then added to the bacteria, which were incubated at 37 °C, with shaker set to
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E. coli strain Application 
TOP10 Plasmid amplification for transformation, sequencing or 
transfection. 
XL10 gold Plasmid amplification for transformation, sequencing or 
transfection. Suitable for large, lentiviral plasmids. 
BL21 (DE3) 
pLysS 
DE3 lysogen expresses T7 upon IPTG induction. The pLysS 
plasmid produces T7, thus reduces basal expression of the 
gene of interest. 
Table 2.5:  Chemically Competent 
Bacterial Strains. 
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220 rpm, for 30 minutes, before streaking onto agar plates impregnated with the 
appropriate antibiotic for the transformed plasmid. Plates were incubated 
overnight at 37 °C, alongside a negative control plate (containing bacteria only, no 
DNA) for every transformation. 
2.2.5 Induced Target Gene Expression in Bacterial Culture 
A single colony was picked from a plate of recently transformed BL21 (DE3) E. 
coli, and used to inoculate 30 ml of TYP media, supplemented with 100 µg/ml 
carbenicillin, and incubated overnight at 37 °C, agitated at 220 rpm. 1 l of 
carbenicillin-supplemented TYP media was inoculated with 5 ml of starter culture 
and agitated again at 37 °C, until OD600 reaches between 0.5 and 0.6, as measure 
by spectrophotometer (Biochrom, Cambridge, UK). A 1ml pre-induction sample 
was retained, and protein expression was induced by addition of 1 ml 0.5 mM 
dioxin free isopropyl-1-thio-β-D-galactopyranoside (IPTG; Melford Laboratories). 
Shaker speed was reduced to 110 rpm, and flasks were agitated for a further 3 
hours post induction. A further (post-induction) sample was retained, before the 
culture was centrifuged at 4000 rpm (2772 g) for 20 minutes at 4 °C. The 
supernatant was discarded, and the bacterial pellet re-suspended in lysis buffer 
for immediate processing into inclusion bodies.  
2.2.6  Glycerol Stocks 
500 µl of bacterial starter culture was added to 500 µl 50% glycerol in a 1.5 ml 
lockable microcentrifuge tube (Eppendorf). Stocks were clearly labelled and stored 
at -80 °C, where they can be stored for several years, and used to reinitiate the 
bacterial culture without the need for re-transformation. 
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2.3 Molecular Biology 
2.3.1 DNA Preparation – Starter Culture 
The object DNA plasmid was transformed into either XL10 gold E. coli (large 
plasmids) or TOP10 E.coli (packaging plasmids) by heat shock treatment, expanded 
in SOC media and plated up on LB agar plates impregnated with an appropriate 
antibiotic for overnight incubation at 37 °C. A single bacterial colony was selected 
for inoculation into 5 ml LB broth, supplemented with selection antibiotics at 100 
µg/ml and shaken for 8 hours at 37 °C and 220 rpm. Starter culture was used to 
make a glycerol stock, and for DNA miniprep, or to inoculate a culture broth for 
DNA maxiprep. 
2.3.2 DNA plasmid Miniprep 
5 ml of bacterial culture broth was centrifuged at 4000 rpm (2772 g) for 10 
minutes, so pelleting the bacteria. The supernatant was discarded. Plasmid DNA 
was extracted using a commercially available DNA miniprep kit (Zyppy plasmid 
miniprep kit; Zymo Research, CA, USA), as per manufacturer’s instructions. These 
kits are based upon the alkaline lysis method. DNA was eluted into nuclease free 
water (Ambion®, LifeTechnologies, ThermoFisher Scientific), or Elution Buffer, and 
stored at -20 °C.  
2.3.3 DNA Plasmid Maxiprep 
1 ml of bacterial starter culture was used to inoculate 400 ml of LB broth 
supplemented with the appropriate selection antibiotic at 100 µg/ml. The culture 
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was agitated overnight at 37 °C and 220 rpm. Bacterial cells were pelleted by 
centrifugation at 4000 rpm (2772 g) for 20 minutes. The supernatant was 
discarded, and the plasmid DNA extracted from the bacterial cells by use of a 
commercially available maxiprep kit (PureLink®, Invitrogen, ThermoFisher 
Scientific), based upon the alkaline lysis method. Extracted DNA was eluted 
into nuclease free water (Ambion®, LifeTechnologies, ThermoFisher Scientific), 
or Elution Buffer, and stored at -20 °C.  
2.3.4 DNA Plasmid Maxiprep (Endotoxin-free) 
400 ml of bacterial culture was pelleted as previously. This was transferred to an 
aseptically prepared tissue culture hood, where the supernatant was discarded, 
and plasmid DNA was extracted with a commercially available endotoxin-free 
maxiprep kit (Endofree® Plasmid Maxi Kit, Qiagen), based upon the alkaline lysis 
method. Extracted DNA was eluted into endotoxin-free elution buffer, into a sterile 
vessel, and stored at -20 °C. 
2.3.5 DNA Quantification 
1 µl of DNA was measured using a Nano-drop (Thermo Scientific) set to record at 
260 nm wavelength. Nuclease free water (Ambion®, LifeTechnologies, 
ThermoFisher Scientific) was used as a blank reference. An absorbency of 1 at 260 
nm was assumed to indicate a DNA concentration of 50 ng/µl (after the extinction 
coefficient for DNA was taken into account). 
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2.3.6 DNA Sequencing 
Plasmid DNA was sent for sequencing by Eurofins Genomics. Samples were sent pre-
mixed with primer, as per sample submission guide 
(https://www.eurofinsgenomics.eu/media/892645/samplesubmissionguide_valuere
adtubes_update_296x105_4c.pdf). 
15 µl of DNA plasmid, at a concentration of 50 – 100 ng/µl, was placed in a clean 
1.5 ml lock-safe tube (Eppendorf), together with 2 µl primer at 10 pmol/µl (total 
volume 17 µl). For each construct, both forward and reverse sequencing primers 
were sent, and sequencing was checked at each stage of the cloning process. 
Sequencing data were analysed using CLC Genomics workbench. 
2.3.7 Restriction Digest 
Restrictions enzymes (FastDigest®, ThermoFisher™) were used to target specific 
regions of DNA plasmids and to liberate DNA facilitating cloning. Restriction 
enzymes were selected using plasmid maps, and as indicated in the text. DNA was 
subjected to restriction digestion by these specific enzymes as per manufacturers 
instruction.  
2.3.8 Agarose Gel Electrophoresis Separation and DNA Extraction 
Agarose gels were composed of 1 % Ultrapure agarose (Invitrogen) dissolved with 
heat into TAE buffer. Once fully dissolved, the agarose was allowed to cool a little 
before the addition of x 10,000 SYBR® Safe DNA gel stain (5 µl in 50 ml) or Midori 
Green Advanced DNA Stain (2 µl in 50 ml), which was gently mixed before casting 
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the gel. Once the gel had set the running tank was topped up with TAE buffer. 
Samples were mixed with x 6 DNA loading dye (ThermoScientific™), and loaded 
onto the gel, and run alongside an appropriate volume of 1 kb DNA ladder 
(GeneRuler™, ThermoFisher™) 75 V, 200 mA for 30 minutes. Gels were examined 
using an ultraviolet (UV) transilluminator. DNA bands were excised and so liberated 
from the gel, and the DNA extracted from the gel using a commercial kit (Wizard® 
DNA Clean-Up kit, Promega, UK, or ZymoClean™ Gel DNA Recovery Kit, Zymo 
Research) according to the manufacturer’s instructions. 
2.3.9 Ligation of DNA Products 
Vectors and inserts were ligated by mixing insert and vector at different ratios with 
1U DNA ligase (T4 DNA ligase Promega) and 3 µl DNA ligase buffer (Promega) and 
made up to a final volume of 30 µl with nuclease-free water (Ambion®, 
LifeTechnologies, ThermoFisher Scientific). Ligation reactions were set up on ice, 
and incubated for 16 hours at 16 °C. The end product was stored at 4 °C 
throughout the day, before transformation into XL10 Gold E. coli. 
2.3.10 Polymerase Chain Reaction (PCR) 
PCR reactions were set up using high-fidelity DNA polymerase (Phusion®, NEB), in 
combination with high fidelity (HF) Phusion buffer (NEB), MgCl2, and DMSO. dNTP 
aliquots, combining equal molar amounts of all four nucleotides, were stored at -20 
°C, and discarded following a single use. Primers were diluted to 100 pmol/µl in TE 
buffer. Primers are listed in Appendix A. PCR conditions are indicated below (Table 
2.6 & 2.7), with the annealing temperatures having been determined for each 
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primer pair used using the NEB website (http://tmcalculator.neb.com) A 
Mastercycler® Gradient (Eppendorf) was used. 
2.3.11 Site Directed Mutagenesis (SDM) 
Site Directed Mutagenesis (SDM) was used to introduce point mutations into the α-
chain of CD8. The GeneArt® cloning vector CD8β.IRES.CD8α.pMK was used as the 
template for this, with sense and antisense primers being designed to amplify each 
point mutation (Q2>K, F48>Q, and S53>N). 
Multiple reaction conditions were trialled for each mutation, with PCR cycling 
conditions as detailed below (Table 2.8). Subsequently, 1 µl of DpnI (FastDigest™, 
ThermoScientific™) and 5 µl 10 x FD Buffer (FastDigest™, ThermoScientific™), were 
added and incubated for 1 hour at 37 °C. The DNA was purified using a commercial 
kit (Wizard®, Promega), as per manufacturer’s instructions. The cleaned product 
was transformed into TOP10 E. coli. Bacteria were cultured on Kanamycin 
impregnated agar plates overnight at 37 °C. 
2.3.12 CD8 cloning strategy 
The cloning cassette, CD8β.IRES.CD8α.pMK, the design and concept of which is 
discussed below (2.3.15), was obtained from GeneArt®. The CD8β.IRES.α construct 
was liberated from the pMK cloning plasmid by restriction digestion, and re-ligated 
into the pELN lentiviral plasmid. Multiple restriction sites throughout the cloning 
cassette facilitated manipulation of both the α- and β-chains, enabling substitution 
of mutated CD8 into the lentiviral vector. The pMK cloning plasmid contains the
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Component Volume / 50 µl Final concentration 
DNA, 10 - 50 ng Varies 0.2 - 1 ng/ml 
Primer 1 (forward)/ 10 
pmol/µl 
1.25 µl 0.25 µM 
Primer 2 (reverse)/ 10 
pmol/µl 
1.25 µl 0.25 µM 
50 mM MgCl2 0.5 µl 0.5 mM 
 2.5 mM dNTP 5 µl 250 µM 
DMSO 0.5 µl 0.5% 
5 x HF Buffer 10 µl 1 x 
Phusion polymerase 0.25 µl 0.01 U/µl 
Nuclease-free H2O Up to 50 µl - 
Table 2.6: PCR Reaction Conditions 
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Stage Name Temperature Time 
1 Initial denaturing 94 °C 30 s 
2 
(Cycle x 30) 
Denaturing 
Annealing 
Extension 
94 °C 
54 – 72 °C 
74 °C 
10 s 
30 s 
40 s 
3 Final extension 74 °C 7 minutes 
- Hold 4 °C ∞ 
Table 2.7:  PCR Cycling Conditions 
!
Stage Name Temperature Time 
1 Initial denaturing 98 °C 30 s 
2 
(Cycle x 25) 
Denaturing 
Annealing 
Extension 
98 °C 
72 °C 
72 °C 
10 s 
30 s 
5 minutes 
3 Final extension 68 °C 10 minutes 
- Hold 4 °C ∞ 
Table 2.8:  PCR Cycling Conditions for SDM 
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gene for resistance to kanamycin, and the smaller plasmid was suitable for 
transformation into TOP10 E. coli, thus bacteria transformed with this plasmid, 
were cultured in media supplemented with kanamycin at 100 µg/ml. The pELN 
lentiviral plasmid contains the gene for resistance to carbenicillin, and was suitable 
for transformation into XL10 gold E. coli, thus bacteria transformed with this 
plasmid were cultured in media supplemented with carbenicillin at 100 µg/ml. 
Products were screened at each stage of cloning, initially by restriction digestion 
of DNA product, or by colony PCR. Where these results were favourable, the 
product was sent for DNA sequencing (Eurofins). 
2.3.13 Linearisation of DNA 
Plasmid DNA for stable transfection of C1R B-cells must first be linearised in order 
for it to successfully integrate with host cell DNA. It is essential that this DNA be 
produced in an endotoxin-free manner. 50 µg of plasmid DNA was digested with 10 
µl BglII (New England Biolabs), 20 µl of 10 x NEB buffer and 145 µl nuclease free 
water (Ambion®, LifeTechnologies, ThermoFisher Scientific). Plasmid DNA was 
subjected to restriction digestion by BglIII for 18 hours at 37 °C. Linearised DNA 
was run on a 1% agarose gel in order to measure digestion efficiency. 
2.3.14 Ethanol Precipitation 
400 µl of 100% ethanol (Sigma-Aldrich) was added to the linearised product, and 
incubated together at room temperature for 10 minutes. The reaction was then 
centrifuged for 10 minutes at 13,500 rpm (12,225 g), and the supernatant 
discarded. The DNA pellet was resuspended in 500 µl of 70% ethanol. 
Centrifugation was repeated, 
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supernatant once more discarded, and the final DNA pellet was resuspended in 50 
µl of endotoxin-free water. 
2.3.15 Designing of CD8β.IRES.CD8α construct (Figure 2.1) 
Previous work had utilised a CD8α.2A.CD8β construct, however this has resulted in 
failure of heterodimer expression. For this thesis, a new construct was designed. 
The expression cassette was as follows: - CD8β.IRES.CD8α (Figure 2.1B). It was 
hoped that this new design would overcome the preferential homodimer formation 
observed with the CD8α.2A.CD8β construct, as it was anticipated that in this 
cassette, CD8β would be synthesised in considerably larger (~10x greater) 
quantities than CD8α (Attal et al., 1999, Bouabe et al., 2008), estimated from the 
length of construct and the anticipated ribosomal drop-off rate. This rationale is 
further supported by the layout of the CD8α and CD8β genes in man, with the 
CD8β1 locus being located upstream to CD8α (DiSanto et al., 1993). The new 
CD8β.IRES.CD8α expression cassette contained CD8β and CD8α separated by an 
internal ribosome entry site (IRES), which directs ribosomes to initiate translation 
downstream of the stop codon in the first transgene, ensuring bicistronic 
expression of the two transgenes from the same transcript (Morgan et al., 1992, 
Szymczak et al., 2004). In addition, the 2A self-cleaving peptide was changed for 
an IRES promoter to avoid potential ribosomal skipping of peptides and associated 
mutations and other translation errors resulting from inefficient cleavage that 
have been reported with the 2A self-cleaving peptide (Szymczak et al., 2004). 
Another difference was the insertion of a STOP codon at the end of the CD8β 
gene, thus the two proteins are produced separately. The new expression cassette 
was codon
108 
A 
B 
Figure 2.1: The pELN lentiviral plasmid,  
showing major restriction sites and inserted 
CD8β.IRES.CD8α construct (A). Expanded 
schematic of the CD8 construct, CD8β.IRES.α (B), 
shows the restriction enzymes used whilst working 
with this plasmid. 
Once the whole plasmid had been cloned into the 
pELN lentiviral plasmid, mutations and variations 
were inserted into the construct, working with the 
packaging smaller pUC57 packaging plasmid. The 
mutated regions were then cut and cloned into the 
pELN. CD8 plasmid using the five main restriction 
enzymes utilised in this study; Xba1, AscI, Xho1, 
Nsi1, and Sal1. 
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optimised for mammalian expression by GeneArt, and cloned into the 
lentiviral packaging plasmid pELN, where its expression is controlled by the 
EF-1α promoter. 
2.3.16 Cloning of the CD8αβ expression cassette into the pELN lentiviral 
vector 
The CD8β.IRES.CD8α. construct was designed to contain a 5’ XbaI and a 3’ SalI 
restriction site flanking the expression cassette encoding CD8 (Figure 2.1). The 
CD8β.IRES.CD8α. pMK cloning plasmid and the pELN lentiviral transfer plasmid 
were subjected to restriction digest with XbaI and SalI enzymes (Figure 2.2). 
The samples were separated on a 1% agarose gel. The liberated insert and 
backbone were excised, then purified and ligated using DNAligase. The resultant 
DNA plasmid was transformed into competent XL10 gold E. coli bacteria and 
cultured on carbenicillin plates. Colonies were picked and assessed for successful 
plasmid transduction by colony polymerase chain reaction (PCR), and by culture 
and miniprep, and DNA sequencing. 
2.3.17 Site Directed Mutagenesis of CD8β.IRES.CD8α.pMK to generate α-
chain mutants and cloning into the pELN lentiviral plasmid 
Site directed mutagenesis was used to introduce mutations into the existing 
DNA maxiprep of the CD8β.IRES.CD8α.pMK cloning plasmid. The small size of 
this cloning plasmid facilitated mutation by this means. The resultant DNA was 
transformed into competent XL10 gold E. coli bacteria, which were cultured on 
kanamycin plates. Colonies were picked for culture in kanamycin selection 
media, and minipreps were performed on the resultant cell pellet to generate 
DNA for 
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Figure 2.2: The cloning plasmid (pMK) and 
the lentiviral vector (pELN) were 
subjected to restriction digest by the 
enzymes XbaI and SalI. 
The insert (a) and the lentiviral backbone (b) were 
liberated for ligation, before transformation of the 
resultant DNA product into chemically competent 
XL10 gold E. coli, for replication of the DNA 
plasmid. The successfully transformed bacteria can 
then be expanded in selection media (1% 
carbenicillin).
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sequencing. Sequencing was performed at Eurofins MWG Operon, and confirmed 
the presence of each mutation, with DNA product being aligned to the wild 
type sequence (Figure 2.3 & Appendix C). DNA aliquots that contained the 
desired mutation were retained for cloning into the pELN lentiviral transfer 
plasmid. 
2.3.18 Cloning of CD8α mutant variants into the pELN lentiviral plasmid 
The CD8β.IRES.CD8α. insert was designed to contain a 5’ NsiI and a 3’ SalI 
restriction site flanking the CD8α transgene, meaning that the CD8α part of the 
construct could be substituted easily for each of the SDM mutants, liberating this 
piece only from the packaging plasmid and re-inserting it into the lentiviral 
backbone, ligating it into the region where the wild type CD8α had been removed 
using the same restriction sites. The CD8β.IRES.CD8α.pMK cloning plasmid for 
each α-chain mutant variant, and the CD8β.IRES.CD8α.pELN lentiviral transfer 
plasmid were subjected to restriction digest by the enzymes NsiI and SalI. The 
samples were separated on a 1% agarose gel. The liberated CD8α inserts and pELN 
backbone were excised and purified and subjected to ligation by DNAligase. The 
resultant DNA plasmid was transformed into competent XL10 gold E. coli bacteria 
and cultured on carbenicillin plates. Colonies were picked for expansion, and 
checked for successful transformation by colony polymerase chain reaction (PCR), 
and by miniprep and DNA sequencing. 
2.3.19 Cloning of CD8β splice variants into the pELN lentiviral plasmid 
The CD8β.IRES.CD8α. insert was designed to contain a 5’ AscI restriction site in the 
trans-membrane region of the CD8β protein, and a flanking 3’ XhoI restriction site 
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Figure 2.3: DNA Sequence of CD8β.IRES.α 
and each of its α-chain mutants; S53N, 
F48Q, and Q2K. 
 DNA preps obtained from lysed bacterial cultures 
were subjected to digestion as described in Figure 
2.2. DNA preps, which could be digested in the 
correct manner, were selected for sequencing with 
the IRESfor primer (described in appendix C). The 
sequencing data was aligned with and compared to 
the sequences detailed for each mutant. Excerpts 
containing the mutations are depicted above, with 
the complete data set available in the appendices. 
The mutations Q2K (a), F48Q (B) and S53N (C) are 
highlighted at positions 1315, 1543, and 1468, 
respectively. (These positions are relative only to 
the start of the cassette sequence). 
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(Figure 2.1), thus the DNA encoding the CY-2 part of the cytoplasmic tail of the 
CD8β protein could be isolated. The pMK cloning plasmid, containing each of the 
splice variants, codon optimized for mammalian expression, was obtained from 
Genewiz (Figure 2.4). The restriction sites were located outside of the CY-2 
variant sequence, and thus were present in all variants. The cloning plasmid 
containing all variants, and the pELN lentiviral plasmid, were subjected to 
restriction digest by AscI and XhoI. The samples were separated on a 1% agarose 
gel. The liberated CD8β CY-2 inserts and pELN backbone were excised and 
purified, then subjected to ligation by DNAligase. The resultant DNA plasmid was 
transformed into competent XL10 gold E. coli bacteria and cultured on 
carbenicillin plates. Colonies were picked preparation of miniprep DNA for 
sequencing. The M-2 and M-4 variants could not be separated on a gel, owing to 
their similar sizes (only 13 base pairs difference), thus could not be truly 
identified prior to the sequencing stage (Figure 2.4), thus the one band was 
used for cloning, and successful clones were identified by sequencing of the 
ligation products.   
2.4 Protein Biochemistry 
2.4.1  Buffers 
The following buffers were used in this thesis: 
Lysis Buffer: 10 mM Tris, 10 mM MgCl2, 150 mM NaCl and 10% Glycerol, 
Triton Wash Buffer: 0.5% Triton 100, 50 mM Tris, 100 mM NaCl and 10 mM EDTA. 
Resuspension Buffer: 50 mM Tris, 100 mM NaCl and 10 mM EDTA.
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Figure 2.4: The CD8β cloning plasmid was 
subjected to digestion by AcsI and XhoI. 
The packaging plasmid was designed to contain an 
AscI restriction site near the junction of the trans-
membrane and cytoplasmic domains and flanked 3’ 
by an XhoI site. The plasmid also contained the CY-
2 domain of each of the β-chain splice variants; 
M2, M3 and M4, each also flanked by a 5’ AscI and 
a 3’ XhoI. The fractions were separated on a 2% 
agarose gel, allowing for liberation of the wild 
type M1 (a), the M2 and M4 CY-2 variants (b) and 
the M3 CY-2 variant (c). The M2 and M4 variants 
were treated as a single product prior to 
sequencing, owing to a size difference of only 13 
base pairs. 
(Data provided by Tomas Watkins) 
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Guanidine Buffer: 6 M Guanidine, 50 mM Tris, 2 mM EDTA and 100 mM NaCl. 
Urea (Denaturing) Buffer: 8 M Urea, 50 mM Tris pH, 100 mM NaCl, 10 mM EDTA 
and10 mM Di-thio-3-etinol (DTT)(added immediately before use). 
Refolding (REDOX) Buffer: 100 mM Tris, 400 mM L-Arginine, 2 mM EDTA, 
6.5 mM cysteamine (added immediately before use) and 3.7 mM cystamine (added 
immediately before use). 
Guanidine Denaturing Buffer: 6 M Guanidine, 50 mM Tris, 100 mM NaCl, 10 mM 
EDTA and 10 mM DTT (added immediately before use). 
Refolding (REDOX) Buffer for CD8: 200 mM Tris, 500 mM L-Arginine, 10 mM EDTA, 
6.5 mM cysteamine (added immediately before use) and 3.7 mM cystamine (added 
immediately before use). 
SDS Non-reducing sample running buffer: 125 mM Tris pH 6.8, 4% Sodium dodecyl 
sulphate (SDS), 20% Glycerol and 20 µg/ml bromothenol blue. 
SDS Reducing sample running buffer: 125 mM Tris pH 6.8, 4% Sodium dodecyl 
sulphate (SDS), 20% Glycerol, 20 µg/ml bromothenol blue and 10% DTT. 
HBS-EP Biacore Buffer: 10 mM HEPES pH 7.4, 150 nM NaCl, 3.4 mM EDTA and 
0.005% Surfactant P20. 
2.4.2 Preparation of Protein Inclusion Bodies 
Synthetic proteins used in this thesis (MHCI heavy (α-) chains (biotin tagged), β2m, 
CD8α, TCRα and TCRβ) were manufactured in D21 (DE3) pLys E. coli. The DNA 
sequence for the soluble (extracellular) part of these proteins is codon optimised 
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for prokaryotic expression, and cloned into the pGMT7 plasmid, where it is 
expressed under the control of the T7 promoter. 
The bacterial pellet produced as described above was resuspended in 40 ml lysis 
buffer. The suspension was transferred to a 50 ml Falcon tube and lysed by 
sonication. 200 µl of 20 µg/ml DNase was added to the tube, which was then 
rocked for 30 minutes at room temperature. The inclusion bodies were then 
transferred to a clean Sorvall™ plastic flask, to which 100 ml of Triton wash buffer 
was added. The inclusion bodies centrifuged at 10,000 rpm (11952 g) for 20 
minutes at 4 °C and the supernatant discarded. The pellet was the resuspended 
in 100 ml of resuspension buffer and centrifuged once again at 10,000 rpm (11952 
g) for 20 minutes at 4 °C and a 500 µl sample taken for purity assessment before 
discarding the supernatant. The inclusion bodies were then dissolved in 15 ml of 
guanidine buffer, the concentration assessed by spectrophotometry, and stored at 
-80 °C.
2.4.3 Refolding of Soluble Biotinylated pMHCI monomers 
30 mg of inclusion bodies for each MHCI heavy chain (wild type or each of its 
mutants) and β2m were denatured by incubating separately in 10 ml of urea buffer 
at 37 °C for 30 minutes. 1 l of refolding buffer was pre-chilled to 4 °C, and stirred 
vigorously. To this was added first 1 ml of peptide (4 mg/ml in DMSO), followed by 
30 mg of denatured β2m, and then lastly 30 mg of denatured MHCI heavy chain. 
Gentle stirring was continued for 3 hours at 4 °C before transferring the refold to 
12 kD cut-off dialysis tubing (Sigma-Aldrich) and dialysing against 12 l chilled dH2O 
overnight, followed by dialysing against 12 l chilled 10 mM Tris pH 8.1 for 48 hours, 
changing the dialysis bucket for fresh 10 mM Tris once during this time. 
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The refold was filtered (0.45 µM) and loaded onto a 5 ml anion exchange column 
(Hi Trap Q HP; GE healthcare), which had previously been equilibrated with 10 mM 
Tris pH 8.1. The protein was then eluted over a salt gradient (0 - 500 mM NaCl in 
10 minutes/10 mM Tris pH8.1). Protease inhibitors (1:100) (500 µM AEBSF, 1 µg/ml 
Aprotinin, 1 µM E-64, 500 µM EDTA and 1 µM Leupeptin; Calbiochem, UK) were 
added to eluted fractions, which were then stored at 4 °C whilst analysis by SDS-
PAGE gel was performed. Correctly folded fractions, those showing a heavy chain 
band at ~35 kD and a β2m band at ~12 kD, were retained, pooled, and 
concentrated to ~800 µl using a centrifugal filter device (Vivaspin® 20, Sartorius). 
The protein was then biotinylated overnight by addition of 100 µl BioMix A, 100 µl 
BioMix B and 1 µl (2.5 µg), Bir A enzyme (Avidity, Denver, USA), mixing well, and 
incubating at room temperature overnight. Excess Biotin was removed and the 
sample further purified by gel filtration into PBS using a Superdex HR 200 column 
(Amersham Pharmacia), which had previously been equilibrated into PBS. Fractions 
were again collected and pooled, and protease inhibitor added, before 
concentration was assessed by spectrophotometry. The monomer was then 
aliquotted and stored at -80 °C. 
2.4.4 Refolding of Soluble αβTCR monomers 
30 mg TCRα chain and 30 mg TCRβ inclusion bodies were denatured by incubating 
separately with 10 ml of guanidine buffer at 37 °C for 30 minutes. 1 l of refolding 
buffer was pre-chilled to 4 °C, and stirred vigorously, and refolding initiated by the 
addition of the denatured TCRα and TCRβ chains simultaneously. Stirring was 
continued for 3 hours at 4 °C before transferring the refold to 12 kD cut-off dialysis 
tubing (Sigma-Aldrich) and dialysing against 12 l chilled dH2O overnight, followed 
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by dialysing against 12 l chilled 10 mM Tris pH 8.1 for 48 hours, changing the 
dialysis bucket for fresh 10 mM Tris once during this time. 
The refold was filtered (0.45 µM) and loaded onto a 5 ml anion exchange column 
(Hi Trap Q HP; GE healthcare), which had previously been equilibrated with 10 mM 
Tris pH 8.1. The protein was then eluted over a salt gradient (0 - 500 mM NaCl in 
10 minutes/10 mM Tris pH8.1).  
Protease inhibitors (1:100) (500 µM AEBSF, 1 µg/ml Aprotinin, 1 µM E-64, 500 µM 
EDTA and 1 µM Leupeptin; Calbiochem, UK) were added to eluted fractions, which 
were then stored at 4 °C whilst analysis by SDS-PAGE gel was performed. Correctly 
folded fractions, those showing a α-chain band at ~28 kD and a β-chain band at ~30 
kD (reduced) and the whole monomer at ~58 kD (non-reduced), were retained, 
pooled and concentrated down to 1 ml using a centrifugal filter device (Vivaspin® 
20, Sartorius). The sample further purified by gel filtration into PBS using a 
Superdex HR 200 column (Amersham Pharmacia), which had previously been 
equilibrated into PBS. Fractions were again collected and pooled, and protease 
inhibitor added, before concentration was assessed by spectrophotometry. The 
monomer was then aliquotted and stored at -80 °C. 
2.4.5 Manufacture of Soluble CD8αα 
3 x 60 mg aliquots of CD8α inclusion bodies were denatured separately at 10 
minute intervals in 20 ml of guanidine buffer at 37 °C for 30 minutes each. The 
denatured CD8α inclusion bodies were added at 10 minutes intervals to 4 l of 
vigorously stirring, pre-chilled CD8 refold buffer. Stirring was continued for 1¾ 
hours at 4 °C. The refold was then concentrated to 150 ml using a MasterFlex L/
S (Cole/Palmer) concentrator using a VivaFlow® 200 filter (Sartorius) using a 10 
kD 
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cut off filter. Both the tubing and refold were maintained on ice throughout. The 
concentrated refold was then transferred to 12 kD cut-off dialysis tubing (Sigma-
Aldrich) and dialysing against 8 l dH2O overnight, followed by dialysing against 8 l 
chilled 10 mM 2-N-Morpholinoethanesulfonic acid (MES) pH 6.0 for 8 hours, then 
again overnight against fresh 10 mM MES.  
The refold was diluted in 500 ml MES pH 6.0, filtered (0.45 µm), and loaded onto a 
5 ml Hi Trap SP cation exchange column (GE healthcare) pre-equilibrated in 10 mM 
MES pH6 (Sigma-Aldrich). Protein was eluted from the column with a salt gradient 
(0 - 500 mM NaCl in 10 minutes/10 mM MES pH6.0). Fractions were analysed by 
SDS-PAGE gel (CD8α bands at ~13 kD (reduced) and CD8αα bands at ~26 kD (non-
reduced)), and correct fractions were pooled and concentrated down to 1 ml using 
a low molecular weight cut off (MWCO) centrifugal filter device (Amicon® Ultra 
Ultracell-3, Merck Millipore). The sample further purified by gel filtration into PBS 
using a Superdex HR 200 column (Amersham Pharmacia), which had previously 
been equilibrated into PBS. Fractions were again collected and pooled, and 
protease inhibitor added, before concentration was assessed by 
spectrophotometry. The monomer was then aliquotted and stored at -80 °C. 
2.4.6 Fast Protein Liquid Chromatography (FPLC) Trace 
FPLC was utilised to elute and purify refolded protein fractions, and for buffer 
exchange. Examples of the traces obtained for ion exchange (IE) and gel filtration 
(GF) of refolded monomers: MHCI, αβTCR and CD8αα, are detailed in Appendix B. 
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2.4.7 SDS PolyAcrylamide Gel Electrophoresis (PAGE) 
Proteins were separated and analysed using SDS-PAGE using the NOVEX NuPAGE® 
SDS-PAGE system (ThermoFisher™). Pre-cast gels, NuPAGE Novex 4–12% Bis-Tris Midi 
Gel w/ MOPS, were rinsed in dH2O prior to use. The gel was docked into the XCell 
SureLock™ Mini-cell Electrophoresis System, and the chamber filled with Nupage® 
MES running buffer. Samples were prepared by diluting 1:4 with running buffer, 
each sample being analysed with both reducing and non-reducing buffer. Samples 
were incubated at 95 °C for 5 minutes, prior to loading onto separate lanes of the 
gel, alongside the molecular weight ladder (PageRuler™ Plus pre-stained protein 
ladder, ThermoFisher™). Gels were run at 180 V for 40 minutes. The gel was 
removed from its casing, rinsed twice with dH2O before staining with Coomassie 
Blue Colloidal Stain Kit (ThermoFisher) by gentle agitation for 30 - 60 minutes, 
then de-staining for 1 – 2 hours with milliQ dH2O to allow visualisation. 
2.4.8 Spectrophotometry 
A Biomate spectrophotometer (ThermoScientific) was used to estimate protein 
concentration. Proteins were mixed well and samples for analysis were further 
diluted 1 in 100 in the buffer in which they were stored (guanidine buffer for 
inclusion bodies, PBS for monomers, or HBS-EP Biacore buffer for samples being 
prepared for SPR experiments). Furthermore the machine was made to blank 
reference with this same buffer prior to sample analysis. Readings were taken and 
recorded at 280 nm λ, and the protein concentration calculated using the dilution 
factor and the specific extinction coefficient the protein (calculated from the 
amino acid sequence). 
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2.4.9 Surface Plasmon Resonance (SPR) 
Before SPR experiments, proteins must first be gel filtrated into HBS-EP Buffer to 
ensure purity / remove any aggregates, and to exchange into the Biacore buffer. 
This was done using a Superdex 200 HR column (Amersham Pharmacia) as 
previously described. CD8αα and αβTCR were concentrated to 100 µM and 150 µM, 
respectively, using a low MWCO centrifugal filter device (Amicon® Ultra Ultracell-
3, Merck Millipore). SPR was performed using a BIAcore T100 machine (BIAcore AB). 
All reagents and proteins were kept at 4 °C, whilst experiments were carried out 
at 25 °C. A research grade CM5 sensor BIAcore chip was used.  
The flow cell was activated using a mix of sulfo-N-hydroxysuccinimide (NHS) and 1-
ethyl-3-(3-dimethylaminpropyl)-carbodimide hydrochloride (EDC) (O'Shannessy et 
al., 1992). The 1: 1 mix of 100 mM NHS and 400 mM EDC was flowed over the cell, 
followed by streptavidin solution (streptavidin 100µg/ml diluted in 10 mM Sodium 
Acetate, 0.1 mM EDTA, 1 mM NaCl, 1 mM DTT, pH 4.6), and finally 1 M 
ethanolamine-HCl pH 8.5. Each were injected for 600 s at a flow rate of 10 µl/min 
(O'Shannessy et al., 1992). Biotinylated pMHCI monomers diluted in HBS-EP BIAcore 
buffer were immobilized onto the chip surface at approximately 1000 response 
units (RU). Serial dilutions of analyte were prepared and flowed over the chip at a 
rate of 30 µl/min. The data generated were analysed using BIAevaluation 3.1, 
Microsoft Excel and Origin 6.1 software. The KD values were calculated using a 
nonlinear curve fit (y = [P1x]/[P2 + x]). 
2.4.10 Manufacture of pMHCI Tetramers 
Streptavidin has four binding sites for biotin, thus needs to be combined with 
soluble pMHCI monomers in a 1:4 molar ratio for the construction of tetramers 
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(Wooldridge et al., 2005). Tetramers were conjugated to either R-phycoerythrin 
(PE) or Allophycocyanin (APC). The concentration of the pMHCI monomers was 
measured as described above. The volume of conjugated streptavidin required for 
each tetramer reaction in order to complete the saturation of streptavidin 
molecules, was calculated and added to the monomer in 5 equal aliquots at 20-
minute intervals, mixing thoroughly each time. The reaction was carried out on ice 
and maintained in the dark. The tetramer was stored at 4 °C, protected against 
light degradation, for up to four weeks. During usage, it was monitored for signs of 
protein degradation. 
2.5  Flow Cytometry 
A list of antibodies used is detailed in Table 2.9. 
2.5.1 Tetramer Staining of CD8+ T-cell Clones 
5 × 104 cells were resuspended in 40 µl of PBS and stained with fixable violet 
fluorescin amine dye (ViViD, Life Technologies) at a 1 in 800 dilution. Cells were 
washed and resuspended in 40 µl of FACS buffer and stained with either A2 
DT227/8KA, A2 A245V, A2, A2 Q115E, A2/Kb A245V, or A2/Kb tetramers folded 
around the ELAGIGILTV peptide at 25 µg/ml for 20 min at 37 °C. Cells were washed 
twice and resuspended in 100 µl FACS buffer. Data were acquired using a 
FACSCanto flow cytometer, and analysed using FlowJo software.
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Manufacturer Species 
Specific 
clone 
Target Fluorochrome 
Dose per 
40 µl test 
Biolegend Mouse HCD14 CD14 Pacific Blue 0.5 µl 
BD Bioscience Mouse rmC5-3 CD14 QD V500 2 µl 
Biolegend Mouse HIB19 CD19 Pacific Blue 0.5 µl 
BD Bioscience Mouse SJ25C1 CD19 QD V500 2 µl 
Biolegend Mouse UCHT1 CD3 PerCP 0.5 µl 
Biolegend Rat 17A2 CD3 PE-Cy7 1 µl 
Biolegend Mouse UCHT1 CD3 H7 APC 0.5 µl 
Miltenyi 
Biotec 
Mouse M-T466 CD4 APC 2 µl 
Miltenyi 
Biotec 
Mouse VIT4 CD4 PE-Cy7 2 µl 
Miltenyi 
Biotec 
Mouse BW135/80 CD8 FITC 2 µl 
Miltenyi 
Biotec 
Mouse RPA-T8 CD8 APC 2 µl 
BD Bioscience Mouse RPA-T8 CD8 PE-Cy7 3 µl 
BD Bioscience Mouse RPA-T8 CD8 QD V705 3 µl 
Beckman 
Coulter 
Mouse IM2217U CD8β PE 2 µl 
Biolegend Mouse BB7.2 HLA-A2 FITC 1 µl 
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Biolegend Mouse FN50 CD69 APC-Cy7 1 µl 
Biolegend Mouse OX34 rat CD2 FITC 1 µl 
Biolegend Mouse OX34 rat CD2 PE 0.5 µl 
Biolegend Mouse IP26 αβTCR FITC 1 µl 
BD Bioscience Mouse D21-1351 MIP1β PE 1 µl 
BD Bioscience Mouse B27 IFNγ V450 3 µl 
BD Bioscience Rat MQ1-17H12 IL-2 APC 4 µl 
BD Bioscience Mouse MAb11 TNFα PE-Cy7 3 µl 
BD Bioscience Mouse H4A3 CD107a BV785 (pre-titred) 
Table 2.9:  Antibodies used for flow cytometry in this 
thesis  
(All targets are human unless otherwise stated) 
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2.5.2 A2 Staining of PBMC 
Following isolation of fresh PBMC from healthy donors, 105 PBMC were counted and 
resuspended in 40 µl of PBS and stained with fixable violet fluorescin amine dye 
(ViViD, Life Technologies) at a 1 in 800 dilution. PBMC were washed and 
resuspended in 40 µl of FACS buffer then stained with 1 µl of αHLA-A2-FITC. Cells 
were incubated at 4 °C in the dark for 20 minutes, before washing in PBS and 
resuspending in FACS buffer. Cells were analysed using a FACSCanto flow 
cytometer. Data were analysed, and the HLA-A2 restriction of healthy PBMC donors 
recorded for later experiments. 
2.5.3 Tetramer Staining of directly ex vivo PBMC 
Following isolation of fresh PBMC from healthy donors, 105 PBMC were counted and 
resuspended in 40 µl of PBS and stained with fixable violet fluorescin amine dye 
(ViViD, Life Technologies) at a 1 in 800 dilution. PBMC were washed and 
resuspended in 40 µl of FACS buffer then stained with either A2 DT227/8KA, A2 
A245V, A2, A2 Q115E, A2/Kb A245V, or A2/Kb tetramers folded around ELAGIGILTV 
at 0.5, 50, or 50 µg/ml for 20 min at 37 °C. PBMC were washed and resuspended in 
40 µl of PBS, resuspended in FACS buffer, and stained with αCD14-PB, αCD19-PB, 
αCD3-PE-Cy7, αCD4-APC, and αCD8-FITC for 20 minutes at 4 °C. Cells were washed 
twice in PBS and fixed in 100 µl 1% paraformaldehyde (PFA). Data were acquired 
using a FACSCanto flow cytometer, and analysed using FlowJo software.  
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2.5.4 HLA-A2 Staining of C1R B-cells 
C1R B-cells in culture were counted and 5 wells each containing 5 x 104 of each cell 
line were resuspended in 40 µl FACS buffer, and stained with fixable violet 
fluorescin amine dye (ViViD, Life Technologies) at a 1 in 800 dilution. A serial 
dilution of αHLA-A2-FITC in FACS buffer was prepared giving rise to a dilution of 1 
in 1000, 1 in 2000, 1 in 4000, and 1 in 8000. Cells were washed and resuspended in 
40 µl of either FACS buffer (unstained control) or each of the antibody dilutions. 
The cells were incubated for 15 minutes at 4 °C in the dark, before washing twice 
in PBS and resuspending in 100 µl of 1% PFA. Data were acquired using a FACSCanto 
flow cytometer, and analysed using FlowJo software.  
2.5.5 Staining of Transduced Immortal Cell lines for Sorting 
Lentivirally cells lines (J.RT3-T3.5 or H9) were counted and resuspended in FACS 
buffer at 106 /ml. 5 x 106 cells were re-suspended in 500 µl PBS and stained with 
fixable violet fluorescin amine dye (ViViD)(Life Technologies) at a 1 in 800 dilution 
for 5 minutes in the dark at room temperature, gently agitating throughout. Cells 
were then washed, re-suspended in 500 µl PBS, and stained with 2 µl αCD2-FITC, 5 
µl αCD8β-PE and 5 µl αCD8α-APC for 15 minutes at 4 °C in the dark, gently 
agitating throughout. Cells were then washed twice before re-suspending in FACS 
buffer. Cells were analysed and sorted using a modified FACSAriaIITM flow 
cytometer. Sorting was continued until 5 x 105 cells were obtained, or as many as 
possible. 
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2.5.6 Staining Immortal Cell Lines for Maintenance of Phenotype 
following expansion post-sorting 
105 cells were counted and re-suspended in 40 µl PBS and stained with fixable 
violet fluorescin amine dye (ViViD)(Life Technologies) at a 1 in 800 dilution for 5 
minutes in the dark at room temperature. Cells were then washed and re-
suspended in 40 µl PBS and stained with appropriate antibodies (αCD8β-PE, αCD8α-
APC, and αrCD2-FITC, occasionally αTCRαβ-FITC αCD3PerCP, αrCD2-PE, and αCD8α-
PE-Cy7 were also used) for 20 minutes at 4 °C. Cells were washed twice in PBS and 
fixed in 100 µl 1% PFA. Data were acquired using a FACSCanto flow cytometer, and 
analysed using FlowJo software. 
2.5.7 Tetramer Staining of J.RT3-T3.5 T-cell lines 
5 x 104 cells of each of J.RT3-3.5 ILA1 TCR+ CD8αβ-, J.RT3-3.5 ILA1 TCR+ CD8αβ+, 
and J.RT3-3.5 ILA1 TCR+ CD8αS53Nβ+ were counted and re-suspended in 40 µl PBS, 
before staining with fixable violet fluorescin amine dye (ViViD)(Life Technologies) 
at a 1 in 800 dilution for 5 minutes in the dark, at room temperature. Cells were 
washed in PBS, re-suspended in 40 µl PBS and stained with either A2 wild type (A) 
or A2 277/8 (B) tetramers folded around ILAKFLHWL at 25 µg/ml for 20 min at 37 
°C in the dark. Cells were washed twice and fixed in 100 µl 1% PFA. Data were 
acquired using a FACSCanto flow cytometer, and analysed using FlowJo software. 2 
x 104 events were captured, and dead and dying cells were excluded from analysis. 
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2.5.8 Activation of JR.T3-T3.5 lines 
6 x 105 C1R A2 target cells were incubated in 50 µL of R2 media with peptide, 
added at the desired final concentration (10-4 – 10-10, and 0 M). The target cells 
were pulsed with peptide for one hour before washing twice with R2 media. 3 x 105
of each J.RT3-3.5 T-cell line, suspended in 50 µL of R2 media, were applied to the 
peptide pulsed targets and incubated at 37 °C overnight. Cells were washed and 
re-suspended in 40 µl FACS buffer, before staining with fixable violet fluorescin 
amine dye (ViViD)(Life Technologies) at a 1 in 800 dilution for 5 minutes in the 
dark, at room temperature. Cells were washed in PBS, re-suspended in 40 µl FACS 
buffer and stained with αCD19-PB and αCD69-APC for 20 minutes at 4 °C, in the 
dark. Cells were washed twice with PBS and fixed in 100 µl 1% PFA. Data were 
acquired using a FACSCanto flow cytometer, and analysed using FlowJo software. 5 
x 104 events were captured, and both CD19+ and dead and dying cells (Pacific 
Blue+) were excluded from analysis.  
2.5.9 Intracellular Staining (ICS) 
CD8+ T-cell clones were rested overnight in R2 media. C1R B-cell targets were 
counted, plated at 5 x 105 / ml (2 x 104 / 50 µl / well) in R2 media, and pulsed with 
peptide at a final concentration of (10-2 – 10-8 M, and 0 M) for 1 hour. The serum-
starved CD8+ T-cells were counted, and resuspended at 106 / ml (5 x 104 / 50 µl) in 
R2, supplemented with 2 µl/ml brefeldin A (GolgiPlug; Sigma-Aldrich), 14 µl/ml 
monensin (GolgiStop; BD Biosciences), and 10 µl/ml αCD107a-FITC. CD8+ T-cells 
were plated together with the peptide-pulsed targets (50 µl of T-cell suspension 
added per well of B-cell targets), thus giving a final concentration / well of 1 µl/ml 
brefeldin A, 7 µl/ml monensin, and 5 µl/ml αCD107a-FITC.  
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The cells were incubated together for 4 hours and 18 hours at 37 °C and in a 5% 
CO2 atmosphere. Following incubation, cells were washed with PBS, and stained 
with LIVE/DEAD fixable Aqua dead cell stain (Invitrogen™, ThermoFisher) at a 1 in 
1000 dilution for 10 minutes at room temperature, protected from light. Cells were 
washed and subsequently stained with αCD19-BV500, αCD3-H7 APC, and αCD8-QD 
V705 at 4 °C, in the dark, for 20 minutes. Cells were washed twice with PBS and 
subsequently resuspended in 200 µl BD Cytofix/Cytoperm then incubated at 4 °C 
for 20 minutes in the dark. Cells were washed thrice in 1 x Perm/Wash (BD 
Biosciences), before staining with αIFNγ-V450, αTNFα-PE-Cy7, αMIP1β-PE and αIL-
2-APC at 4 °C for 20 minutes. Cells were washed three times before resuspending
in 200 µl Perm/Wash. Data was acquired using a modified FACSAria II flow 
cytometer (BD Biosciences) and analysed with FlowJo software (Tree Star). 
2.6 T-Cell Activation Assays
2.6.1 Non-specific Activation by C1R B-cell targets 
CD8+ T-cell clones were rested overnight in R2 media. The serum-starved CD8+ T-
cells were counted and resuspended at 6 x 105 /ml (i.e. 3 x 104 / 50 µl). C1R B-cell 
targets were counted, and resuspended at 6 x 105 /ml, 1.2 x 106 /ml, 3 x 106 /ml, 
and 6 x 106 /ml (3 x 104, 6 x 104, 1.5 x 105, and 3 x 105 / 50 µl, respectively). 
Subsequently, 3 x 104 CD8+ T-cells were plated, and incubated together with C1R B-
cells stably transfected with similar levels of A2 or each of its mutants, at different 
E: T ratios for 4 or 18 hours at 37 °C. The supernatant was harvested and assayed 
by ELISA for IFNγ (R & D Systems), as per manufacturers instructions.  
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2.6.2 Chromium Release Killing Assay 
106 C1R B-cell targets stably transfected with similar levels of HLA A2 or each of its 
mutants, were counted, and resuspended in 1 ml of R2 media. Each C1R cell line 
was labelled with 30 µCi of 51Cr (PerkinElmer, Cambridge, UK), and incubated for 1 
hour. Cells were washed twice, re-counted, and resuspended at a concentration of 
5 x 103 per 100 µl R2 media. Each target was incubated together with rested and 
counted CD8+ T-cell clones at different effector: target ratios. The cells were 
incubated together for 4 hours at 37 °C in a 5 % CO2 atmosphere. Each species of 
target was also cultured alone (target spontaneous release) and with TritonX-100 
(Sigma-Aldrich) at a final concentration of 5% (target total release). 15 µl 
supernatant was harvested from each and mixed with 150 µl OptiPhase Supermix 
Scintillation Cocktail (PerkinElmer). Plates were analysed using a liquid scintillator 
and luminescence counter (MicroBeta TriLux; PerkinElmer) with Microbeta Windows 
Workstation software (PerkinElmer). Specific lysis was calculated according to the 
following formula:  
 x 100% 
2.6.2 Peptide Activation of CD8+ T-cell clones 
CD8+ T-cell clones were rested overnight in R2 media. The serum-starved CD8+ T-
cells were counted and resuspended at 6 x 105 /ml (i.e. 3 x 104 / 50 µl). 6 x 104 C1R 
A2 target cells were incubated in 50 µL of R2 media with peptide at a final 
concentration of 10-5 – 10-11, and 0 M at 37 °C for 1 hour, before washing twice in 
R2 media. The peptide pulsed targets were then incubated together with 3 x 104 
experimental release - target spontaneous release 
target total release - target spontaneous release 
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CD8+ T-cells at 37 °C for 4 or 18 hours. The supernatant was harvested, and 
assayed for IFNγ or MIP1β by ELISA (R & D Systems), as per manufacturer’s 
instructions. 
2.6.3 Peptide Activation of H9 ILA1TCR+ CD8αvarβ T-cell lines. 
H9 ILA1 TCR+ CD8αvarβ lines were rested in R2 for 48 hours. 6 x 104 C1R A2 target 
cells were incubated in 50 µL of R2 media with peptide, as described in later 
chapters for the ILA system, added at a final concentration of 10-2 – 10-8 and 0 M.
The target cells were pulsed with peptide for two hours before washing twice and 
resuspending in 50 µl of R2 media. 3 x 104 of each H9 ILA1 TCR+ CD8αvarβ line, 
suspended in 50 µL of R2 media, were applied to the peptide pulsed targets and 
incubated at 37 °C overnight. The supernatant was harvested and assayed for IL-2 
or IL-10 by ELISA as per manufacturer’s instructions.  
2.6.4 Peptide Activation of J.RT3-T3.5 NFAT gluc lines. 
The J.RT3-T3.5 NFAT gluc cell lines were rested in R2 media for 24 hours prior to 
activation experiments. 6 x 105 C1R A2 target cells were incubated in 50 µL of R2
media with peptide, added at a final concentration of 10-4 – 10-10, and 0 M. The 
target cells were pulsed with peptide for two hours before washing twice with R2
media. 6 x 105 J.RT3-3.5 NFAT GLuc transTCR+ CD8αvarβ T-cells were suspended in 
50 µL of R2 media, and incubated together with the peptide-pulsed B-cell targets 
at 37 °C for 24 hours. Subsequently, the supernatant was harvested, and assayed 
for luciferase protein by bioluminescence as per manufacturer’s instructions.  
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2.6.5 ELISA (R & D Systems) 
ELISA kits for IFNγ and MIP1β were supplied by R & D Systems, and were performed 
according to the manufacturer’s instruction, using reagents as advised 
(DuoStop®)(Wash Buffer, Coating buffer, Diluent, Streptavidin HRP, Colour 
reagents A & B (Chromogen), Peroxide and STOP solution). Half-area 96 well plates 
were coated with 50 µl of capture antibody, diluted as per manufacturer’s 
protocol. Plates were sealed and incubated overnight at room temperature, or for 
one hour at 37 °C. Plates were washed twice using an Atlantis 2 line microplate 
washer (Biochrom Asys Atlantis, Biochrom, UK). Plates were blocked for one hour 
with 150 µl blocking antibody, diluted as per manufacturer’s instructions. Plates 
were washed, and 50 µl cell supernatant added, alongside 50 µl of a serially diluted 
standard solution. Plates were incubated at room temperature for 75 minutes, and 
subsequently washed, before adding 50 µl of detection antibody, diluted as per 
manufacturer’s instructions added. Plates were incubated for a further 20 minutes, 
washed and 50 µl of streptavidin horseradish peroxidase (StrepHRP), diluted as per 
manufacturer’s instructions, was added to wells. Plates were again washed, and 25 
µl of each of colour reagent A and B (chromogen and peroxide) were added to 
wells, before incubating for up to 20 minutes, protected from light, until colour 
change was appropriately developed (using standards). 25 µl of STOP solution 
(sulphuric acid) was added to wells, and the plates were read immediately at 450 
nm wavelength, using a reference of 570 nm (BioRad iMark microplate reader, 
BioRad). 
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2.6.6 Gaussia Luciferase Bioluminescence Assay 
Gaussia luciferase (GLuc) is a reporter luciferase, expressed in mammalian cells 
that have been transduced with reporter plasmids (commercially available, NEB). 
The J.RT3-T3.5 NFAT GLuc line is transduced to express GLuc upon activation of 
through the NFAT (Nuclear factor of Activated T-cells) cascade. Upon activation, 
cells have high levels of reporter luciferase GLuc in their cytoplasm, and it is 
secreted into the surrounding media. Whilst these cells can be lysed for assay, the 
test was found to be sensitive enough for assay of supernatant alone. 
Luciferase production, indicative of NFAT activation, was measured using a 
BioLux® Gaussia Luciferase assay kit (NEB), as per manufacturer’s instructions. 
Briefly, the substrate was diluted in BioLux assay buffer 100:1. An opaque (white-
walled) half-area 96-well plate (Corning) was used for the assay. 25 µl of the 
diluted substrate was added to each well, followed by 5 µl of the culture 
supernatant sample immediately prior to reading. A FLUOStar Optima spectrometer 
(BMG Labtech) was used to read the assay, set to read bioluminescence.  
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Chapter 3 
CD8+ T-cell specificity is compromised at a defined major 
histocompatibility complex class I/CD8 affinity threshold 
3.1 Introduction 
The CD8 co-receptor is capable of binding all MHCI complexes. It binds to the largely 
invariant region of the MHCI (Wooldridge et al., 2007, Gao et al., 1997b), thus its 
binding is unaffected by the presented peptide, and in doing so, enhances T-cell 
antigen sensitivity. The TCR has the potential to engage MHCI presenting both self 
and foreign peptides (Yachi et al., 2005, Colf et al., 2007). In addition, it has been 
suggested that the pMHCI/CD8 interaction may enable T-cell recognition at low copy 
numbers of specific pMHCI or low avidity ligands (Hampl et al., 1997). The 
pMHCI/CD8 interaction is characterized by very weak affinities (up to 100x weaker 
than the TCR/pMHCI interaction) and extremely rapid kinetics (Koff in the order of 
18s-1) (Wyer et al., 1999, Huang et al., 2007, Hutchinson et al., 2003). These 
biophysical properties do, however, differ somewhat between species; for example 
murine CD8 binds the murine H-2Kb MHCI with a KD of ~ 30 µM, whereas human CD8 
binds the comparable human HLA A*0201 (A2 hereafter) MHCI with a KD of ~ 120 µM 
(Purbhoo et al., 2001). The significance of these species differences remains 
uncertain, however it has been suggested this may be due to differences in the size 
of the T-cell repertoire; the mouse having less TCRs in comparison to man (Arstila et 
al., 1999, Casrouge et al., 2000).  
Previous studies have shown that as the pMHCI/CD8 interaction strength increases, so 
too does the sensitivity of the antigen specific T-cell response (Sun et al., 1995, 
Wooldridge et al., 2007, Sanders et al., 1991). The relationship is neither simple nor 
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direct: initially, the increase is disproportionate, with a x 1.5 fold increase in the 
strength of the pMHCI/CD8 interaction resulting in antigen sensitivity being increased 
by up to two orders of magnitude. Above a certain strength of pMHCI/CD8 
interaction, this response becomes non-specific, leading to T-cell activation 
irrelevant of the specificity of the TCR or the nature of the presented ligand 
(Wooldridge et al., 2010a). Other studies have examined the effects of reducing the 
strength of the pMHCI/CD8 interaction (~ KD = 500 µM) or abrogating its binding 
altogether (Xu et al., 2001, Gao et al., 2000) on CD8+ T-cell activation. I intend to 
classify the effects of manipulating the strength of the pMHCI/CD8 interaction in 
more detail by examining the point at which CD8+ T-cell activation becomes non-
specific i.e. how far the strength of this interaction may be increased before the 
observed loss of specificity is seen. Defining this threshold has importance in the 
development of novel therapeutic approaches for patient benefit, where enhanced 
target killing may be desirable. In this instance, it is vital that the specificity of the 
TCR be maintained.  
3.1.1 The Tripartite complex: CD8 as a co-receptor to the TCR/pMHCI 
interaction 
Individual TCRs are capable of recognizing large numbers of pMHCI ligands (up to 106) 
(Wooldridge et al., 2012), and indeed this feature is quintessential to maintaining a 
T-cell repertoire that is poised to recognize all potential pMHCIs that could be
encountered. Many of these ‘possible’ pMHCI ligands are not ‘real’ i.e. they do not 
occur in nature and will never be presented at the cell surface in the context of 
MHCI, nonetheless the promiscuity of the TCR remains an essential feature of an 
effective immune system. Whilst a plethora of pMHCI ligands may be recognized by a 
single TCR, the affinity of the TCR/pMHCI interaction can vary considerably, with the 
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recognition of pathogen derived pMHCI agonists being characterized by high affinity 
TCR/pMHCI interactions (mean KD of ~ 8 µM) (Bridgeman et al., 2012) and TCR 
interactions with self-peptide MHCI (auto-antigens) being typified by much weaker 
TCR/pMHCI interactions (mean KD of ~ 90 µM) (Bridgeman et al., 2012). Indeed, 
thymic selection of the T-cell repertoire relies on these very features; TCRs are 
selected which recognise self-antigen weakly. They do not encounter foreign 
antigens until presented with such a challenge, however the promiscuity of the TCR 
facilitates the likelihood that suitable T-cells may recognise and respond to the 
challenge. It is also believed that weak and on-going stimulation by self-antigens 
allows the naïve population and memory pool to persist in the periphery in the 
absence of a specific challenge (Goldrath and Bevan, 1999, Boyman et al., 2009, 
Anderton and Wraith, 2002). Antigens which can be found on neoplastic cells, whilst 
still self-antigens, are often subtly different from those expressed on healthy cells 
(Schumacher and Schreiber, 2015, Wang and Wang, 2017). TCRs which recognise 
cancer antigens very often do so at an affinity which falls between these two 
extremes, as one may expect with a peptide which is not completely foreign, and 
this may be one of the factors explaining how neoplasia may evade the immune 
system.  
TCR engagement with specific pMHCI is necessary for CD8+ T-cell activation, but is in 
most cases inadequate for a complete response (Holler and Kranz, 2003, Laugel et 
al., 2007a). Co-ligation of MHCI by CD8 is often necessary in order to elicit a 
complete response, particularly in the case of weaker affinity pMHCI ligands (Daniels 
and Jameson, 2000, Laugel et al., 2007b). CD8 interaction with the invariant region 
of the MHCI draws the two molecules together at the T-cell: target cell interface, co-
localizing CD8-associated lck and intracellular CD3 (Rybakin et al., 2011). 
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3.1.2 CD8+ T-cells and cancer 
As has already been discussed, TCRs exist which recognise cancer-specific antigens. 
TCRs recognise self-MHC with an affinity typically weaker than foreign antigens, 
(mean KD of ~ 90 µM) (Bridgeman et al., 2012), however significant overlap exists, 
and the highest TCR/pMHCI interactions documented to date (> 1 µM) are directed 
against foreign antigen ligands (Davis et al., 1998). Whilst we know these TCRs exist, 
this TCR/pMHCI interaction strength may in some instances be inadequate to clear 
the host’s cancer, as is evidenced by the existence of this disease (Bridgeman et al., 
2010b). Of the TCRs examined by Bridgeman et al, several cancer epitopes are 
recognised with an affinity not dissimilar to foreign. Indeed, the mean of the cancer 
interactions examined in this study is 41 µM, falling only a little lower than that of 
the foreign TCR/pMHCI interactions (32 µM). The persistence of these cancers in the 
host leads us to deduce that there must be further reasons for this apparent failure 
of the immune system to recognise and eliminate this challenge. 
Cancer epitopes may be further sub-grouped on the basis of their encoding genes. 
Some arise de novo and are unique to certain cancers, one example being the A24-
restricted peptide SYLDSGIHF, which is derived from a mutated β-catenin gene found 
in melanomata (Robbins et al., 1996). Tumour antigens may also be non-mutated and 
cell-line specific, such as epitopes derived from the MART-1 melanoma-specific 
protein which include the A2-restricted 9-mer, AAGIGILTV, and the similar A2-
restricted 10-mer, EAAGIGILTV (Kawakami et al., 1994, Ekeruche-Makinde et al., 
2012, Kessler et al., 2011). Onco-foetal antigens are epitopes, which are normally, 
only found during foetal development, thus their existence in the mature host cell is 
indicative of pathology. An example of such is NY-ESO-1, which is normally, only 
found in the developing foetus and the human testis, but may also be expressed in 
melanoma (Chen et al., 2000, Jager et al., 1998). However, the existence of tumour-
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reactive CD8+ T-cells is often insufficient for tumour clearance, but is suggestive of a 
possible therapeutic approach, as enhancing this response may elicit improved 
patient survival.  
Efforts to create vaccinations using these epitopes has failed to demonstrate 
effective responses in all but a very few cases, with T-cells being raised in 
inadequate numbers to result in a reduction in tumour burden (Brinkman et al., 
2004, Parmiani et al., 2002). Benign lesions resulting from Human Papilloma Viridae 
(HPV) have shown some response to autologous vaccines, although such 
papillomatous ‘warts’ often auto-regress in time suggesting self clearance, as have 
equine sarcoids, in which bovine papilloma virus has also been implicated (Kinnunen 
et al., 1999, Otten et al., 1993). Cancers associated with this type of virus may be 
prevented or their instance reduced by this type of approach, an example being the 
HPV-associated cervical cancer vaccine, which prevents aggressive lesions (Schwarz 
et al., 2009). This vaccine is considered to significantly reduce HPV associated 
cancers, and is estimated to prevent approximately 70% of cervical cancers. It is now 
routinely used, at least in girls, in 71 countries (as of 2017) (World Health 
Organization. Electronic address, 2017). 
In addition to this sub-optimal TCR/pMHCI interaction, tumours also utilise many 
other strategies to evade the host immune system, including down-regulation of 
pMHCI resulting in a low copy number being expressed at the cell surface, and the 
creation of an immunosuppressive tumour environment. 
Whilst the existence of naturally occurring T-cells which recognise cancer epitopes, 
has been known for some time, it is only in the last decade that this clinical direction 
has been pursued in earnest. CD8+ T-cells that recognise tumour antigens were 
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identified and cultured in the late 80s and early 90s (Jerome et al., 1991, Ioannides 
et al., 1991, Boon and van der Bruggen, 1996). The earliest work in this field went on 
to demonstrate that CD8+ T-cells found within the tumour infiltrate were enriched 
for this type of TCR, and the term Tumour Infiltrating Lymphocyte (TIL) was first 
utilized. Early research went on to demonstrate that CD8+ T-cells, when cultured and 
expanded in vitro are capable of reducing tumour burden and in some cases elicit 
tumour clearance (Rosenberg et al., 1986, Dudley and Rosenberg, 2003). This novel 
strategy in cancer immunotherapy, termed Adoptive Cell Transfer (ACT), utilized ex 
vivo expansion of TILs, and initial reports demonstrated improved patient survival. 
However, this therapy was still inadequate in some cases, and in recent years much 
work has been dedicated to improving tumour killing and thus patient survival. 
3.1.3 The potential for CD8 manipulation as a method for enhancing ACT 
therapies 
It has already been discussed that small increases in pMHCI/CD8 affinity can result in 
a disproportionately greater increase in CD8+ T-cell activation (Wooldridge et al., 
2007, Wooldridge et al., 2005). It has been demonstrated that super-enhancement of 
the CD8/pMHCI interaction results in a total loss of TCR antigen specificity resulting 
in blanket activation of all CD8+ T-cells (Wooldridge et al., 2010a). It is reasonable to 
hypothesise that there exists a threshold above which the TCR loses specificity, and 
that increasing the CD8/pMHCI interaction, whilst staying beneath this threshold, 
should result in maximal enhancement in T-cell activation without the loss of 
specificity 
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3.1.4 Super-enhanced CD8 binding leads to total loss of T-cell antigen 
specificity 
The pMHCI/CD8 interaction is characterized by very low solution binding affinities 
and extremely rapid kinetics. Although some variation exists between different MHCI 
alleles, due to polymorphisms that affect the CD8 binding site, the average 
pMHCI/CD8 interaction has a KD ~ 145µM (KD range of 100 - 220 µM). There are a 
small number of exceptions with even weaker pMHCI/CD8 solution binding affinities 
(KD ~500 µM), such as HLA A*6801 and HLA A* 4801. The HLA-A*0201 (A2 hereafter) 
MHCI was chosen for use in this study. It’s pMHCI/CD8 affinity falls in the middle of 
this range, close to the average (KD ~130-145 µM). Introducing a glutamine (Q) > 
glutamic acid (E) mutation at position 115 of the MHCI alpha 2 domain has been 
shown to increase the pMHCI/CD8 solution binding affinity by ~ 1.5 fold (KD ~ 87 µM) 
without any affect on TCR/pMHCI binding affinity (Wooldridge et al., 2007). This 
incremental increase in the strength of the pMHCI/CD8 interaction afforded a 
significant increase in the sensitivity of pMHCI antigen recognition (up to 100 fold) 
without any significant loss of T-cell specificity. In a subsequent study it was 
demonstrated that increasing the strength of the pMHCI/CD8 interaction by ~ 15 fold 
(KD~ 10 µM) resulted in a complete loss of pMHCI recognition specificity (Wooldridge 
et al., 2010a). However the strength of the pMHCI/CD8 interaction at which CD8+ T-
cell activation specificity is lost has not been defined. This is the specific research 
question that I intend to answer in this thesis chapter. 
3.1.5 Summary & Aims 
CD8+ T-cells are capable of recognizing and eliminating cancerous cells in vivo. This 
has sparked great interest in the use of cellular therapy against cancer. Owing to the 
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non-polymorphic nature of CD8, such a molecule used as a gene vaccine or 
transfectant would be globally applicable to enhance ACT systems, and thus a 
potentially invaluable tool for future potential immunotherapies. Barriers to the 
widespread use of this approach still exist. One of the most common problems is that 
‘natural’ anti-cancer T-cells are not very antigen sensitive and as a result, not very 
effective at killing tumour cells. This is because cancer-specific TCRs are often 
characterized by affinities that are not sufficiently strong to elicit a robust response. 
One approach that can be used to circumvent this issue is to develop strategies that 
enhance the cancer-specific T-cell response by increasing the strength of the 
pMHCI/CD8 interaction. Due to the non-polymorphic nature of CD8, strategies to 
enhance the antigen specific T-cell response by increasing the strength of the 
pMHCI/CD8 interaction would be globally applicable to any system in which enhanced 
T-cell immunity is desirable such as the design of ACT.
Although there is significant scope to increase the strength of the pMHCI/CD8 
interaction for therapeutic benefit, it has also been demonstrated that increasing the 
strength of the pMHCI/CD8 interaction by 10-fold results in complete loss of pMHCI 
antigen specificity. Before such therapies can be developed it is essential that this 
loss of TCR specificity is fully characterized. In this chapter, I aim to better 
characterise the strength of the pMHCI/CD8 interaction, and how it affects the T-cell 
response. To this end I will use a panel of MHCI variants with different pMHCI/CD8 
affinities to determine the pMHCI/CD8 affinity threshold at which loss of pMHCI 
specificity occurs. Any effort to utilise CD8 manipulation to enhance ACT must ensure 
that the strength of the pMHCI/CD8 interaction falls short of this threshold to avoid 
catastrophic consequences for the patient. 
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3.2 Results 
3.2 1 Generating a panel of MHCI mutants with a spectrum of CD8 binding 
affinities 
To determine the pMHCI/CD8 affinity at which loss of pMHCI recognition specificity 
occurs, it was necessary to design a novel MHCI mutant with a pMHCI/CD8 interaction 
dissociation constant (KD) of between 87 µM and 10 µM. In order to achieve this, I 
introduced an alanine (A) > valine (V) substitution at position 245 of A2/Kb (a fusion 
molecule comprising the α1/α2 peptide binding platform of HLA A2 and the α3 
domain of H2-Kb) to give A2/Kb A245V. Surface plasmon resonance (SPR) confirmed 
that A2/Kb A245V interacts with CD8 with a KD of 27.8 µM (Figure 3.1B) and 
importantly, does not affect the TCR/pMHCI interaction (Figure 3.1D). Construction 
of this novel MHCI mutant extends the panel of MHCI mutants that are available for 
performing comprehensive studies on the affect of varying the strength of the 
pMHCI/CD8 interaction. The complete panel consists of MHCI variants that exhibit 
abrogated (A2 DT227/8KA), weak (A2 A245V), wild type (A2), slightly enhanced (A2 
Q115E), enhanced (A2/Kb A245V) and super-enhanced (A2/Kb) interaction with CD8 
(Table 3.1). SPR measurements confirm that none of these MHCI mutations have any 
effect on the strength of the TCR/pMHCI interaction. This extended panel of MHCI 
mutations, which is represented as a schematic in Figure 3.2, were either 
introduced into soluble MHCI for the subsequent construction of pMHCI tetramers or 
expressed at the cell surface of C1R B-cells (Figure 3.3). 
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Figure 3.1: A2/KbA245V exhibits enhanced 
affinity for CD8 without impacting the 
TCR/pMHCI interaction.  
Biotinylated A2 (A&C) or A2/Kb A245V (B&D) pMHCI 
monomers folded around the heteroclitic 
ELAGIGILTV epitope were immobilized on a 
streptavidin-coated BIAcore chip. Serial dilutions 
of soluble human CD8αα (A&B) or MEL5 TCR (C&D) 
were flowed over the chip to measure equilibrium 
binding by surface plasmon resonance. Data were 
analysed using BIAevaluation 3.1, Microsoft Excel 
and Origin 6.1. 
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Location of 
Mutation 
Description of 
Mutation 
pMHCI/CD8 KD 
(µM) 
MHCI α3 domain A2 DT227/8KA > 10,000 (NTB) *
MHCI α3 domain A2 A245V 498 * 
wild type no mutation 137 ± 9.7 * 
MHCI α2 domain A2 Q115E 98 ± 14.5 * 
MHCI α3 domain A2/Kb A245V 27.8 ± 0.7 
MHCI α3 domain A2/Kb 10.9 * 
Measurements taken from Wooldridge et al, 2005, Wooldridge et al, 
2007, and Wooldridge et al, 2010. 
NTB: No detectable binding 
Table 3.1: Summary of mutations examined in this 
chapter. 
Table of HLA A2 mutations, and their respective affinity for CD8αα 
as measured by SPR. These point mutations in the MHCI molecule 
influence CD8 binding, without affecting TCR binding affinity (Wyer 
et al., 1999, Purbhoo et al., 2001, Xu et al., 2001, Wooldridge et 
al., 2007, Ekeruche-Makinde et al., 2012, Wooldridge et al., 2010, 
Clement et al., 2011, Huang et al., 2010). 
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Figure 3.2: Schematic representation of 
the mutations used in this chapter  
pMHCI/CD8 binding affinity of HLA A2 mutants 
demonstrating abrogated, decreased, normal, 
slightly enhanced (x1.5), enhanced (x5) and 
superenhanced (x10) affinity. The TCR binding 
platform and thus the interaction of the TCR with 
pMHCI remain unaffected by each of these 
mutations. 
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Figure 3.3: Mutations used in this study  
Mutations were inserted into either synthetic 
monomers, which were used for SPR studies or to 
measure staining using multimer technology, or 
into stably transfected C1R targets for cell 
function assays. 
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3.2.2 Increasing the strength of the pMHCI/CD8 interaction results in 
enhanced recognition of pMHCI by the TCR 
pMHCI monomers for each of the MHCI mutants described in Table 3.1, were created 
by refolding the heavy chain bearing each mutation around the peptide ELAGIGILTV, 
with human β2m, and used to create pMHCI tetramers (Figure 3.3). ELAGIGILTV is a 
heteroclitic variant of the A2 restricted Melan-A/MART-126-35 epitope, EAAGIGILTV. 
Monomeric pMHCI complexes bind cell surface TCRs with an extremely short half-life, 
and for this reason are unsuitable tools for examining cell-surface interactions. The 
use of multimers such as tetramers and dextramers is a well-documented means of 
overcoming this limitation, and examining cell surface interactions enabling us to 
characterize CD8+ T-cells (Altman et al., 1996). Tetramers increase the valency to 
four by means of conjugation with streptavidin, which is in turn conjugated to a 
fluorochrome to facilitate examination of antigen specific T-cells by flow cytometry 
(Wooldridge et al., 2009). These tetramers were used to stain 3 different A2-
restricted, ELAGIGILTV-specific CD8+ T-cell clones: MEL2, MELc5 and MEL5 (Figure 
3.4A-C). 
In all cases, pMHCI tetramer staining where CD8 binding was abrogated (A2 
DT227/8KA) was minimal, or indistinguishable from the unstained control. As the 
strength of the pMHCI/CD8 interaction increased, an increase in the level of pMHCI 
tetramer staining was observed, with maximal staining being seen with the A2/Kb
tetramer. The results clearly show enhanced recognition of specific pMHCI at the cell 
surface as the strength of the pMHCI/CD8 interaction is increased (Figure 3.4A-C). In 
addition, the data obtained appears to show a plateau effect such that increases in 
the strength of the pMHCI/CD8 interaction above a certain threshold (KD < 30 µM) 
result in a minimal increase in pMHCI recognition as measured by tetramer staining 
(Figure 3.4C).
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Figure 3.4: Tetramer staining vs. 
pMHCI/CD8 affinity of HLA A2-restricted 
ELAGIGILTV-specific clones 
The effect of altering the strength of the 
pMHCI/CD8 interaction on tetramer staining of 
three HLA A*0201 ELAGIGILTV-specific CD8+ T-cell 
clones was examined Cells were stained with 
either A2 DT227/8KA, A2 A245V, A2, A2 Q115E, 
A2/Kb A245V or A2/Kb tetramers folded around the 
ELAGIGILTV peptide. Data were acquired using a 
FACScanto flow cytometer, and analysed using 
FloJo software. Viable events are shown in 
histogram plots for the MEL2 clone (A) and the 
MELc5 clone (B). C depicts a summary of events 
recorded for all clones examined, as compared to 
the pMHCI/CD8 binding affinity of the mutants. 
These data are representative of multiple (>8) 
experiments.
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3.2.3 Specificity of pMHCI recognition is compromised at a defined 
pMHCI/CD8 affinity threshold  
An essential feature of the TCR is its unique and exquisite specificity, and it is well 
documented that tetramers replicate this in their staining (Burrows et al., 2000). 
Blood was obtained from healthy donors of known A2 restriction. Fresh PBMC were 
isolated from these donors and stained with the A2 mutant tetramer panel at 0.5, 5, 
and 50 µg/ml, then subsequently stained for CD14, CD19, CD3, CD4, and CD8. Live, 
CD14-, CD19-, CD3+ cells were gated upon, as shown in Figure 3.5, to allow for 
examination of tetramer staining of CD8+ T-cells (Figures 3.6 & 3.7). 
No background staining was observed with wild type A2 tetramers in A2pos or A2neg
(Figures 3.6 & 3.7). This is to be expected; in the absence of alloreactivity (which 
was not observed in any of the A2neg restricted donors examined), one would not 
expect A2neg restricted individuals to harbour TCRs specific for A2-restricted 
epitopes. A total loss of tetramer staining specificity was seen when donor PBMC 
were stained with the A2/Kb tetramer, with over 85% of CD8+ T-cells staining 
tetramer positive (Figures 3.6 & 3.7). This has previously been observed and 
published with A2pos donors (Wooldridge et al., 2010a), and here, the same pattern 
was observed with both A2pos and A2neg donors (Figures 3.6 & 3.7). These 
experiments were repeated multiple times (n>10) at a single tetramer 
concentration (25 µg/ml) and the same pattern was observed, although in earlier 
experiments the A2 specificity of the donor was not known. This supports my 
hypothesis that once pMHCI/CD8 affinity is enhanced above a certain level, this 
interaction becomes dominant over the TCR/pMHCI interaction. Here we see that 
irrelevant of the peptide ligand, or even the presenting MHCI, the interaction with 
CD8 becomes the driving force, with the kinetics being stabilised to such an extent 
as to facilitate tetramer staining even with little or no recognition of the pMHCI by 
the TCR itself.
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Figure 3.5: Gating Strategy employed for 
Figures 3.6 & 3.7:  
Data were acquired using a FACScanto 
flow cytometer, and analysed using FloJo 
software. Data were plotted displaying forward 
scatter/side scatter area, and this plot was used 
to gate on a live lymphocyte population (A). 
Data within this gate only were then plotted on 
a forward scatter area/height plot to enable 
doublets or dividing cells to be eliminated (B). 
Live CD3+ events were gated upon (C). The 
resultant populations were taken forward for 
analysis. A quadrant gate was applied using the 
A2 tetramer applied at 50 µg/ml was used to set 
the gates for each figure. These gates were then 
applied to all samples analysed. 
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A2 D227K/T228A, A2 A245V, A2 and A2 Q115E tetramers up to a
concentration of 50 μg ml− 1 (Figure 4). Similarly, no background
staining was detected with the A2/Kb A245V tetramer at 0.5 and
5 μg ml− 1. However, at high concentrations, background staining was
detected with this reagent (50 μg ml− 1), and exceeded the levels of
nonspeciﬁc binding observed in experiments with A2– PBMCs. The
A2/Kb tetramer was again largely nonspeciﬁc, although this effect was
not obvious at 0.5 μg ml− 1.
To consolidate these ﬁndings, we performed analogous experiments
across a broader range of tetramer concentrations using PBMCs from
a different A2+ donor (Figure 5a). Again, no loss of speciﬁcity was
detected with the A2 D227K/T228A, A2 A245V, A2 or A2 Q115E
tetramers up to a concentration of 25 μg ml− 1. Similarly, no back-
ground staining was detected with the A2/Kb A245V tetramer at
concentrations ⩽ 5 μg ml− 1. At concentrations45 μg ml− 1, however,
some loss of staining speciﬁcity started to emerge. Substantial
nonspeciﬁc staining was observed with the A2/Kb tetramer at
concentrations 45 μg ml− 1. To clarify these data, we plotted
nonspeciﬁc staining as a function of tetramer concentration versus
pMHCI/CD8 afﬁnity (Figure 5b) and used non-parametric tests to
examine the impact of these variables on tetramer binding at the cell
surface (Figure 6). Our analyses revealed that loss of tetramer
Figure 4 pMHCI-binding speciﬁcity is compromised at a deﬁned pMHCI/CD8 afﬁnity threshold in A2+ donors. In all, 1×106 A2+ PBMCs were stained and
analyzed as described in the legend for Figure 3. Values shown in the upper right quadrant indicate % tetramer+ CD8+ T cells.
The pMHCI/CD8 interaction controls T-cell speciﬁcity
T Dockree et al
5
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Figure 3.6: The effect of altering the 
strength of the pMHCI/CD8 interaction on 
tetramer staining of PBMC from an A2pos
donor, directly ex vivo. 
PBMC were obtained from a known A2pos donor. 
Following isolation, directly ex vivo PBMC were 
stained to exclude dead/dying cells, before 
staining with A2 DT227/8KA, A2 A245V, A2, A2 
Q115E, A2/Kb A245V or A2/Kb tetramers folded 
around the ELAGIGILTV peptide at different 
concentrations. PBMC were then stained with 
antibodies (αCD14, αCD19, αCD3, αCD4, and 
αCD8before fixing in PFA for analysis by flow 
cytometry. Data were acquired using a FACScanto 
flow cytometer, and analysed using FloJo 
software. The data plotted represent the live, 
CD3+ populations.  
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presence of a superenhanced pMHCI/CD8 interaction (KD~11 μM).28
To deﬁne the pMHCI/CD8 afﬁnity threshold at which pMHCI-
binding speciﬁcity is compromised, we stained healthy donor periph-
eral blood mononuclear cells (PBMCs) with ﬂuorescent tetrameric
complexes of A2 D227K/T228A, A2 A245V, A2, A2 Q115E, A2/Kb
A245V and A2/Kb refolded with wild-type β2m and ELAGIGILTV.
First, we stained A2– PBMCs. In the absence of alloreactivity, we
would not expect these samples to harbour TCRs that recognize
peptides in the context of A2. Any observable tetramer staining
under these circumstances can therefore be attributed to peptide-
independent recognition of pMHCI. No background staining was
detected when A2– PBMCs were stained with the A2 D227K/T228A,
A2 A245V, A2 or A2 Q115E tetramers up to a concentration of
50 μg ml− 1 (Figure 3). A similar pattern was observed with the A2/Kb
A245V tetramer at 0.5 and 5 μg ml− 1. In line with a concentration-
dependent effect, however, the same reagent displayed moderate
background staining at 50 μg ml− 1. The A2/Kb tetramer was almost
entirely nonspeciﬁc, as described in a previous report.28
Next, we repeated this analysis using A2+ PBMCs, which frequently
harbour TCRs speciﬁc for ELAGIGILTV. The clonotypic repertoire in
these samples is also shaped by positive selection to ensure an intrinsic
level of reactivity with A2. Staining speciﬁcity was maintained with the
Figure 3 pMHCI-binding speciﬁcity is compromised at a deﬁned pMHCI/CD8 afﬁnity threshold in A2–ve donors. In all, 1×106 A2–ve PBMCs were stained
with ViViD and the indicated ELAGIGILTV tetramer (A2 D227K/T228A, A2 A245V, A2, A2 Q115E, A2/Kb A245V or A2/Kb) at 0.5, 5 or 50 μg ml−1,
followed by a panel of lineage-speciﬁc monoclonal antibodies as described in the Methods section. Plots are gated on live, CD3+ populations. Data were
acquired using a FACSCantoII ﬂow cytometer and analyzed with FlowJo software version 10.6 (TreeStar Inc.). Values shown in the upper right quadrant
indicate % tetramer+ CD8+ T cells.
The pMHCI/CD8 interaction controls T-cell speciﬁcity
T Dockree et al
4
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Figure 3.7: The effect of altering the 
strength of the pMHCI/CD8 interaction on 
tetramer staining of PBMC from an A2neg
donor.  
Following isolation, A2neg PBMCs were prepared and 
analysed in the same manner as those from A2pos
donors (see Figure legend 3.6). 
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No loss of tetramer staining specificity was observed when staining with A2 Q115E 
tetramers, i.e. when pMHCI/CD8 was only slightly enhanced by ~ 1.5 fold. In both 
A2pos and A2neg donors, loss of specificity of the TCR was first observed in staining 
with A2/Kb A245V tetramers, and only at a staining concentration of 50 µg/ml 
(Figures 3.8). A more detailed study with tetramer staining at a broader range of 
concentrations in an A2pos donor was performed, the results of which are summarized 
in Figure 3.9. No loss of specificity was observed with the A2 DT227/8KA, A2 A245V, 
A2, or A2 Q115E tetramers. The A2/Kb A245V tetramer was also highly specific at ≤5 
µg/ml, although some reactivity was observed with the same reagent at >5 µg/ml. 
Considerable background staining was apparent with the A2/Kb tetramer (Figure 
3.9A). To clarify these data, we plotted non-specific staining as a function of 
tetramer concentration versus pMHCI/CD8 affinity (Figure 3.9B). In addition, two 
non-parametric tests (Friedman and Jonckheere-Terpstra) were conducted to 
examine the dependence of non-specific CD8+ T-cell staining intensity on tetramer 
concentration and the KD of the pMHC/CD8 interaction (Figure 3.10). These data 
clearly demonstrate that the loss of TCR specificity observed at the cell surface is 
not a gradual phenomenon, but that a rapid loss occurs once the apparent threshold 
of around KD ~ 27-30 µM is exceeded.  
3.2.4 T-cell activation specificity is compromised if the strength of the
pMHCI/CD8 interaction is increased above a defined threshold 
C1R B-cells (EBV transformed B-cells expressing little or no natural MHCI) were stably 
transfected with each of the A2 mutants, and the resulting lines were cloned to 
allow for selection of clones expressing similar levels of A2 (Figure 3.11). These 
clonal populations were then used to examine non-specific activation, in the absence
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Figure 3.8: Similar staining patterns are 
seen in both A2+ and A2- donors.  
The data obtained for figures 3.6 & 3.7 may be 
summarized as above. The figure clearly shows 
that the first loss of TCR specificity, as measured 
by tetramer staining of fresh ex vivo PBMC is when 
the strength of the pMHCI/CD8 interaction is ≤ KD 
of 30 μM. This is demonstrably true in both A2pos
(A) and A2neg (B) donors, with all data being
displayed on figure C.
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Figure 3.9: Detailed analysis of pMHCI 
tetramer binding specificity across a range 
of pMHCI/CD8 affinities in an A2pos donor: 
(A)  
A2pos donor PBMCs were stained and analysed as 
described in the legend to Figure 5, with the 
exception that each tetramer was used at 2, 3, 4, 
5, 10, 15, 20 or 25 μg/ml. (B) The same data is 
shown as % tetramer+ CD8+ T-cells versus 
pMHCI/CD8 affinity. 
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Figure 3.10: Statistical analysis of the data 
depicted in Figure 3.9 supported the 
significance of these finding:  
The fraction of CD8 tetramer-positive cells varies 
with tetramer concentration (P = 4.4×10–3; 
Friedman test for tetramer effect); modest to 
strong evidence was found for the individual MHC 
variants (Jonckheere-Terpstra test for increasing 
dependence on tetramer concentration P-values: 
A2 227/8: 1.6×10–2; A2 245V: 1.4×10–1; A2: 1.4×10–
1; A2 QE: 1.0×10–2; A2/KbA245V: 5.4×10–2; A2/Kb: 
8.8×10–4).The tetramer stain was strongly 
dependent on the dissociation constant of the 
pMHC/CD8 interaction (P < 10–7; Jonckheere-
Terpstra test for increasing dependence on KD). 
The virtual absence of staining below KD = 30 µM 
suggests that a value of this order of magnitude 
behaves a threshold value; whereas there was 
strong evidence for an effect of KD on staining 
(P = 3×10–7; Friedman test), this effect was not 
detectable when data for the two lowest KD-values 
were left out (P = 1.7×10–1; Friedman test, whereas 
P = 6.2×10–4 when only the lowest KD-value was 
omitted). 
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A          B 
Figure 3.11: A2 staining of C1r targets 
C1R B-cells of each species were stained with αA2 
antibody. 2x104 events were captured, and dead 
and dying cells were excluded from analysis. 
Viable events are shown in concatenated histogram 
plots for each of the C1R target lines (A), and 
these data are then summarized (B). The data 
shows that all cells lines express similar surface 
levels of HLA A2. The cell lines were regularly 
stained whilst maintained in culture to ensure 
phenotype was maintained, and these data are 
representative of multiple (>4) experiments.  
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of cognate peptide, of CD8+ T-cell clones. CD8+ T cells may achieve full activation 
in response to low pMHCI copy numbers; it has been shown that as few as 10 triple 
complexes may be required to elicit full calcium release, leading to synapse 
formation (Purbhoo et al., 2004). Therefore, it is possible that whilst the threshold 
for loss of TCR specificity as measured by tetramer staining appears to be in to 
region of KD ~ 27-30 µM, owing to the low levels of cell surface pMHCI required to 
elicit a response, that this threshold may differ in the context of T-cell activation.  
MEL5 was incubated overnight with C1R targets expressing each of the mutant 
MHCI shown in Figure 3.2, in the absence of cognate antigen. Following 
incubation, the resultant supernatant was harvested and assayed by ELISA for IFNg 
(Figure 3.12). After overnight incubation, non-specific IFNγ release was only 
observed in the presence of A2/Kb C1R B cells. A similar pattern was observed 
when the supernatant was assayed for MIP1β, however there was some non-
specific activation in the presence of the C1R A2/kbA245V targets, however it was 
realised that the targets themselves release MIP1β, making the data unreliable and 
flawed, thus this data is not shown.  
Incubation of C1R A2 (or each of its mutants) targets together with CD8+ T-cell 
clones resulted in increased non-specific target of targets as pMHCI/CD8 affinity 
and E:T ratio increased, however a marked increase was observed with the C1R 
A2/kb target compared to those bearing mutants with weaker affinity for CD8 
(Figure 3.12).  
These data indicate that CD8+ T-cell activation specificity is maintained below a 
defined pMHCI/CD8 affinity threshold (KD~27 µM). 
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Figure 3.12: Surface expressed MHCI with 
superenhanced pMHCI/CD8 interaction 
affinity can activate CD8+ T-cells in the 
absence of cognate peptide.  
Loss of TCR specificity is evident above a given 
threshold. MEL5 CD8+ clones were incubated with 
C1R A2 (wild type or each of its mutants) B-cells, 
at different E:T ratios for 18 hours at 37 °C. The 
supernatant was harvested and assayed by ELISA 
for IFNγ as per manufacturers instructions. The 
mean of two replicate assays, and their standard 
deviation, is plotted. The B-cell targets 
demonstrated no IFNγ release, and the background 
(IFNγ released by T-cells only) was subtracted in 
order to obtain the values plotted. This 
experimental protocol was repeated on four 
separate occasions, and these data are 
representative of the results obtained. 
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Figure 3.13: Surface expressed MHCI with 
superenhanced pMHCI/CD8 interaction 
affinity can cause non-specific lysis of 
target cells by CD8+ T-cells in the absence 
of cognate antigen. 
Targets, which had been previously labelled with 
51Cr, were counted and cultured together with 
counted Mel2 clones, alone (target spontaneous 
release), or with TritonX-100 (target total 
release). Cells were incubated at 37 °C for 4 
hours, before harvesting supernatant for analysis 
using a liquid scintillator and luminescence counter 
in order to calculate specific lysis of targets. The 
mean of two replicate assays and their standard 
deviation is plotted. These assays were performed 
3 times, and these data are representative.  
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3.3 Discussion 
CD8+ T-cells are capable of recognizing and killing cancerous cells in vitro. 
However, this interaction is very often sub-optimal, with the TCR/pMHCI 
interaction in the context of cancer epitopes being typified by a moderate to weak 
interaction affinity (KD of ~ 90 µM) (Bridgeman et al., 2012). Non-self epitopes, for 
example those generated in response to viral challenge are characterized by a 
much stronger TCR/pMHCI interaction (KD ~8 µM) (Bridgeman et al., 2012), and as a 
result of this, virally infected cells may be more readily recognized and eliminated 
by CD8+ T-cells (Laugel et al., 2007b). Tumour Infiltrating Lymphocytes (TILs) have 
been effectively used to target cancer cells in a number of trials (June, 2007, 
Rosenberg and Dudley, 2009, Dudley et al., 2002). These T-cells are expanded ex 
vivo before being re-infused into the patient (June, 2007, Dudley et al., 2002). 
Whilst success rates vary between trials, it does appear that the effectiveness of 
this approach is compromised by the low affinity of naturally occurring anti-cancer 
TCRs which do not recognize these epitopes strongly enough to reliably eliminate 
established cancers (Morgan et al., 2006, Hinrichs and Rosenberg, 2014).  
As has been discussed, in addition to sub-optimal ligand strength, tumours employ 
multiple strategies in order to evade the immune system. 
Not only are cancer antigens very often of sub-optimal affinity, but they may also 
be of low avidity, with the tumour cells expressing low copy numbers of MHCI at 
the cell surface (La Rocca et al., 2014, Hicklin et al., 1999). Some tumours have 
been shown to down-regulate specific antigen, resulting in a reduction in cell 
surface MHCI in general and specific target pMHCI. Down-regulation of cell surface 
pMHCI has been shown to be linked to an unfavourable outcome in some cancer 
patients, suggesting that immune evasion by this means is an important mechanism 
in mortality and morbidity (Hanagiri et al., 2013).  
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Thus it becomes essential that if a TCR encounters its cognate ligand, adequate 
triggering should result. Not only can the tumour down-regulate these specific 
antigens, but it may also become resistant to immune-mediated destruction 
(Costello et al., 1999, Seliger, 2005, Bubenik, 2004, Topfer et al., 2011). Tumour 
cells may lose their ability to recognise signals for apoptosis and thus persist (Igney 
and Krammer, 2002, Topfer et al., 2011). They can also become more resistant to 
induced lysis by CD8+ T-cells (Marincola et al., 2000, Igney and Krammer, 2002), 
thus if tumour clearance is to be achieved the T-cell response must be fully robust. 
One strategy that has been employed in order to enhance tumour killing is the 
creation of ‘high affinity TCRs’. Naturally occurring TCRs are isolated and 
clonotyped. These may be reintroduced into the host (Morgan et al., 2006), 
however success rates may be further enhanced by the introduction of mutations 
to enhance the TCR recognition of pMHCI (Hebeisen et al., 2013). It has been 
demonstrated that enhancement of the TCR beyond a certain point results in loss 
of specificity of the TCR, likely to be due to the TCR recognising the MHCI part of 
the pMHCI binding platform with such strength that the nature of the peptide 
becomes irrelevant (Holler et al., 2003). 
In addition, one issue with this approach is that a new TCR must be designed for 
each epitope. The co-receptor CD8 is non-polymorphic in nature, and binds the 
invariant region of the MHCI molecule (Wooldridge et al., 2007). This makes this 
molecule an excellent candidate for the development of a more universal 
approach. Manipulation of the CD8 co-receptor itself in order to enhance the TCR 
response may generate a molecule that may be added to existing systems.  
Potential target cells express a vast array of pMHCI on their cell surface, and the 
unique αβTCR of the CD8+ T-cell must be able to distinguish between them. In this 
manner it may recognize self, dysregulated-self, or foreign peptide in order to 
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target cells for deletion. Whilst some TCR/pMHCI interactions are sufficiently 
strong to initiate TCR triggering in the absence of the co-receptor, for the most 
part its presence is absolutely required (Laugel et al., 2011, Knall et al., 1995). If 
this were not so, constant TCR recognition would occur. It has been postulated that 
this is the reason for the rapid kinetics and low affinities of the co-receptor; to 
prevent this from happening, thus allowing the TCR its unique specificity (Wyer et 
al., 1999). Complete loss of specificity of the TCR has been previously 
demonstrated when the pMHCI/CD8 is increased substantially above its natural 
limits to a similar affinity to that of foreign peptide TCR/pMHCI (Wooldridge et al., 
2010a). It is evident therefore, that in order to maintain the unique specificity of 
the TCR, the pMHCI/CD8 interaction must be maintained within a defined window. 
I have created the mutated chimeric A/Kb A245V MHCI molecules in order to test 
this hypothesis. These molecules interact with CD8 with a KD of a similar order to 
that of the murine pMHCI/CD8 interaction (Purbhoo et al., 2001). 
In this chapter, I demonstrated a loss of TCR specificity, as measured by tetramer 
staining and cytokine production, where the pMHCI/CD8 interaction has a KD that is 
less than 30 µM. Therefore, when the KD of the pMHCI/CD8 interaction is < 30 µM, 
T-cell activation becomes CD8 driven and TCR-independent. In addition, the flow 
cytometry data collected would suggest that this effect is greatest where higher 
levels of cell surface CD8 are expressed; cells expressing highest levels of CD8 
exhibit the greatest shift in tetramer staining (Figures 3.6 & 3.7).  
I have also shown that above this threshold, increases in the strength of the pMHCI/
CD8 interaction result in minimal increases in the specific recognition of pMHCI. 
However below this threshold, small increases in pMHCI/CD8 result in relatively 
large increases in the recognition of cognate pMHCI as measured by 
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tetramer staining (Figure 3.4C). This phenomenon has large and direct 
implications for any future efforts to engineer CD8 for patient benefit. 
Clement et al suggested that the A2/Kb chimeric molecules elicit activation in an 
‘antibody-like’ manner (Wooldridge et al., 2010a). The cytoplasmic tail of CD8α 
brings with it to the TCR/pMHCI complex the early signalling kinase, lck, which 
acts to facilitate TCR signalling. I would hypothesise and argue that this effect, 
rather than inducing conformational changes in an antibody-like manner, is due to 
the dramatic changes in kinetics. My interpretation of the mathematical model 
put forward by Szomolay et al (Szomolay et al., 2013), is that either the TCR or 
the CD8 co-receptor may engage the pMHCI first. Under normal circumstances the 
very fast kinetics of CD8 would mean that it would engage and disengage far too 
rapidly for TCR engagement to occur concurrently, meaning that the TCR would 
need to engage first to allow the tripartite structure to form. However, if the 
kinetics are altered such that the off rate of CD8 is markedly decreased, this 
would allow this state to exist for longer, enabling fleeting TCR/pMHCI 
interactions, such as those potentially generated by an irrelevant peptide to allow 
TCR triggering to occur. It is reasonable to assume that the TCR samples the 
myriad of pMHCI presented at the target cell surface, thus very fleeting 
interactions must exist. If CD8 is already bound at this stage, and thus lck 
localized, this would facilitate non-specific triggering. If one considers this 
alongside the kinetic segregation model for T-cell activation as put forward by 
Davis and Van der Merwe (Davis and van der Merwe, 2006, van der Merwe and 
Davis, 2003), it becomes likely that if CD8 engages first, and remains in situ, lck 
will remain localised close to the CD3 ITAMs causing on going phosphorylation, 
however CD45 will be constantly acting to bring about de-phosphorylation, thus 
preventing triggering. As soon as a fleeting TCR engagement occurs, CD45 is 
excluded, facilitating rapid triggering as lck is already localised to the ITAMs. 
Moreover, it has been suggested that, rather than TCR triggering being 
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essential for T-cell activation, it is the formation of close-contacts which the TCR-
pMHCI interaction creates which is important. Super-enhancement of the 
pMHCI/CD8 interaction will enable close contact formation in the absence of strong 
TCR recognition of the presented pMHCI (Chang et al., 2016). If this hypothesis is 
correct, it would also follow that those effector functions requiring greater TCR 
occupancy, such as IFNγ and target lysis, are likely to occur above a threshold, 
rather than in a stepwise manner, and that this threshold may appear to be higher 
than for example MIP1β, which requires very low levels of TCR occupancy to 
stimulate release (Valitutti et al., 1996a, van den Berg et al., 2013).  
In summary, I have demonstrated that a pMHCI/CD8 interaction KD of ≤ 30 µM will 
lead to loss of the unique specificity of the TCR. In conclusion, CD8 must bind 
pMHCI with an affinity lower than this threshold in order to preserve the unique 
specificity of the TCR. Indeed, increases in pMHCI/CD8 above the wild type and 
below this threshold have been demonstrated to elicit the greatest increase in 
cognate pMHCI recognition. To properly utilize this knowledge for patient benefit, 
it would be useful to further characterize the effects of pMHCI/CD8 binding 
affinities which fall in between those examined (range KD = 30 - 90 µM).  
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Chapter 4 
CD8αβ With Increased Affinity for pMHCI Enhances T-cell 
Activation 
4.1 Introduction 
CD8αβ is constitutively expressed on cytotoxic CD8+ T-cells, where it binds to the 
invariant region of MHCI, without interfering with the TCR binding platform 
(Wooldridge et al., 2007, Jiang et al., 2011, Gao et al., 1997a). The CD8 co-receptor 
acts extracellularly to stabilise the TCR/pMHCI interaction (Artyomov et al., 2010, 
Wooldridge et al., 2005). In addition, similarly to the CD4 co-receptor, it acts at an 
intracellular level to recruit lck (Gascoigne et al., 2011, Artyomov et al., 2010) to 
the CD3 complex (Beddoe et al., 2009), where it can bring about phosphorylation of 
ITAMs, the first step in downstream signalling from the TCR. As a result, CD8 can 
enhance T-cell antigen sensitivity by up to one million fold (Holler and Kranz, 2003). 
It has been demonstrated that CD8 co-receptor activity is not absolutely required for 
T-cell activation in the case of high affinity agonists (Laugel et al., 2011), and that
dependence on CD8 is inversely proportional to TCR/pMHCI interaction affinity 
(Clement et al., 2016). However some studies have shown that CD8+ T-cell function is 
incomplete in the absence of CD8 engagement, and only partial function such as 
target lysis is observed (Knall et al., 1995). 
The pMHCI/CD8 interaction is characterised by weak affinities (100x weaker than 
most viral TCR/pMHCI interactions) and very rapid kinetics (18 s-1) (Wyer et al., 1999, 
Wooldridge et al., 2003, Huang et al., 2007). It has previously been demonstrated 
that increasing the strength of the pMHCI/CD8 interaction above that which is 
physiologically normal, through manipulation of the MHCI molecule, results in an 
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enhanced CD8+ T-cell response (Wooldridge et al., 2007), and that greatly enhancing 
the strength of the pMHCI/CD8 interaction results in loss of T-cell specificity, and 
activation irrespective of cognate ligand (Wooldridge et al., 2010a). In the previous 
chapter, I demonstrated that rather than being a gradual phenomenon, this loss of 
CD8+ T-cell specificity occurs at a specific threshold (KD ≤ 30 µM). These studies have 
all involved manipulation of the pMHCI/CD8 interaction via mutation of the MHCI 
invariant region, at the binding site of CD8, however, it follows that manipulation of 
the pMHCI/CD8 interaction via mutation of the CD8 molecule itself could have similar 
affects. 
4.1.1. CD8αα and CD8αβ 
CD8 exists as a dimeric molecule, found in two forms at the cell surface; the 
heterodimeric CD8αβ which is constitutively expressed by cytotoxic CD8+ T-cells, and 
the homodimeric CD8αα, which is found on more diverse populations including γδ T-
cells, IELs and others, and seems to have a regulatory role (Norment and Littman, 
1988, Das et al., 2003, Konno et al., 2002). The homodimeric isoform CD8ββ has 
been shown to theoretically exist under laboratory conditions in humans. However, it 
is unstable, rapidly degrades, has not been found to date in nature, and is of 
uncertain significance (Devine et al., 2000). Whilst in vitro studies have suggested 
that extracellular interactions between CD8αα or CD8αβ, and classical MHCI are 
comparable (Sun and Kavathas, 1997, Gangadharan and Cheroutre, 2004), the same 
is not true of the intracellular regions of these molecules. CD8α possesses in its 
cytoplasmic tail, two vicinal cysteine residues which, with a free Zn2+ ion, bind lck, 
thus as CD8 binds the pMHCI extracellularly, lck is localised in the TCR-CD3 complex, 
where it can act to phosphorylate the ITAMs (Artyomov et al., 2010).  
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One might suppose that CD8αα is capable of better co-receptor function than CD8αβ 
as it is capable of recruiting two rather than one lck molecule, however the reverse 
appears to be true. It has been suggested that if two lck molecules are present in the 
tail of CD8αα, they sterically hinder the molecular interactions required for 
triggering (McNicol et al., 2007). This has been seen to dampen T-cell function, and 
the transient up-regulation of CD8αα in some cells where signalling suppression is 
required and has led to the hypothesis of a regulatory or inhibitory role for CD8αα 
(Cheroutre and Lambolez, 2008). CD8αα is capable of performing co-receptor 
function to the TCR/pMHCI interaction in the absence of CD8αβ, albeit in a limited 
manner, although it inhibits T-cell function where CD8αβ is present (Cawthon et al., 
2001). CD8αα does not effectively support the activation of lower affinity pMHCI 
ligands, i.e. those that absolutely require CD8 (Renard et al., 1996). CD8αβ performs 
far better as a co-receptor, both in terms of level of response and the ensuing 
degeneracy of the TCR. When one examines the breadth of the T-cell repertoire 
generated in its presence, it is evident that CD8αβ is essential for full function and 
for thymic generation of a complete and robust T-cell repertoire (Zamoyska, 1994, 
Van Laethem et al., 2012).  
4.1.2 Studies with Soluble CD8 
The refolding of soluble human CD8αβ is extremely challenging, largely due to the 
preference of CD8α to homodimerise, but also compounded by the difficulty of 
purification and separation, the instability of the small CD8 dimer (both CD8αα and 
CD8αβ), and the high yields required for biophysical analysis owing to the weak 
affinity of the pMHCI/CD8 interaction. The small CD8αα molecule (26 kD) can be 
prone to precipitation at the concentration required for SPR (10 mg/ml), thus 
achieving these concentrations in the laboratory can prove tricky for the researcher. 
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Indeed, this was one of the reasons for Cole et al’s mutant design: to obtain a higher 
affinity CD8 that could be utilised at lower concentrations for crystallography 
studies. Studies into the biophysical properties of CD8αα and CD8αβ in the murine 
system, and its interactions with pMHCI suggest that the interaction is similar 
between the two molecules, and that they both interact with comparable affinities 
(Willcox et al., 1999, Wyer et al., 1999, Kern et al., 1998). Studies utilising human 
CD8αα suggest that the same is true in man (Gao et al., 1997a, Leahy et al., 1992). 
4.1.3 High Affinity Soluble CD8αα 
Cole et al generated a soluble CD8αα molecule, conceived through computational 
modelling and design, which was predicted and later demonstrated via SPR and 
crystallography, to exhibit enhanced binding for MHCI (Cole et al., 2005, Cole et al., 
2007). Other mutants were briefly examined in this study, although none of these 
were demonstrated to have enhanced affinity for MHCI as measured by SPR (Cole et 
al., 2007). The α-chain mutation examined by Cole et al was a substitution of the 
serine residue at position 53, involved in contacts with the α2 domain of the MHCI 
heavy chain, for an asparginine (S53>N). Cole et al also substituted an alanine for the 
cysteine at position 33 (C33>A), however the purpose of this mutation was to 
eliminate the free cysteine from the α-chain, thus improving refolding efficiency and 
increasing the laboratory yield of synthetic CD8αα monomers. 
4.1.4 Adoptive Cell Transfer for Cancer (ACT) 
CD8+ T-cells exist which are capable of recognising, and in many instances killing, 
cancer cells (Rosenberg et al., 1986). However, possibly owing to the similarity of 
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cancer ligands to self-antigens, this response is very often sub-optimal, falling 
somewhere between recognition of ‘normal-self ligands’ and recognition of 
‘pathogen-derived ligands’. Cancer cells may be recognised, but the response 
triggered is often inadequate to clear them, therefore neoplasia is able to persist in 
the host. Whilst naturally occurring CD8+ T-cells can recognise cancer antigens in the 
context of MHCI, effective killing and clearance of the tumour by non-engineered T-
cells is rare (June, 2007). In addition, tumours may adopt a number of mechanisms in 
order to evade the immune system, such as down-regulation of MHCI and the 
creation of an unfavourable environment for T-cell migration, proliferation, and 
activation (Seliger, 2005, Topfer et al., 2011).  
ACT involves the in vitro expansion of the host’s cells, and re-infusion of large 
numbers into the patient (Dudley and Rosenberg, 2003). The earliest studies of this 
technique as a potential cancer therapy involved the expansion of immune cells 
found within the tumour tissue (Tumour Infiltrating Lymphocytes: TILs) (Rosenberg et 
al., 1986, Topalian et al., 1987). Whilst these trials demonstrated some degree of 
efficacy, other researchers have gone on to explore ways of improving this response. 
In addition to the amount of work involved in generating TILs for expansion; invasive 
tissue biopsy (therefore solid tumours only) and digestion to isolate cells prior to 
expansion, the expansion of this mixed population means that the exact targets of 
the expanded cells is unknown, and very likely involves expansion of both inhibitory 
cells in addition to those involved in killing. This provides one possible explanation 
for the mixed responses to this type of therapy.  
Therefore researchers have continued to explore other means of improving the T-
cells used in ACT. The utilisation of CD8+ T-cells obtained directly from separation of 
patient PBMC is considerably less invasive, involving only a blood sample. Engineering 
strategies to improve the response of these cells have thus far concentrated on the 
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TCR, either by manipulating the TCR itself (Hebeisen et al., 2013, Bridgeman et al., 
2012, Morgan et al., 2006), or by the creation of chimeric antigen receptors (CARs), 
utilising the intracellular signalling component of the TCR-CD3 complex, but 
substituting the head of the TCR for an alternative recognition molecule (Bridgeman 
et al., 2010a, Bridgeman et al., 2010b, Haji-Fatahaliha et al., 2015). To date, 
manipulation of the co-receptor molecule has not been attempted, as a strategy to 
enhance the antigen sensitivity of cancer specific T-cells. If such an approach proved 
to be successful in enhancing the CD8+ T-cell response then, owing to its non-
polymorphic nature, this could potentially be a global strategy, ready to be added to 
any existing TCR-based ACT system. 
4.1.5 Manipulating pMHCI/CD8 interaction affinity via cell surface CD8α 
Whilst a previous study using soluble CD8αα has enabled us to identify a high affinity 
variant of CD8, for all of the reasons discussed above, it is essential that 
manipulations in a cell model be made to the heterodimer, CD8αβ. To this end I first 
created a lentiviral construct enabling me to stably transduce cell lines with wild 
type CD8αβ, described in chapter 2. Once efficacy of this model had been proven, 
further α-chain mutations were also introduced and used to generate lentiviral 
particles. Whilst Cole et al had successfully refolded soluble CD8αS53N in 
homodimeric form, it remained to be seen how this would refold alongside CD8β, or 
traffic to the cell surface. The α-chain mutations trialled in this chapter are listed in 
Table 4.1.
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Location of mutation Description of 
mutation 
pMHCI/CD8 KD (µM) 
Wild type No mutation 137 ± 4.73 
CD8α, extracellular domain F48Q NDB 
CD8α, extracellular domain Q2K 363 + 5.3 
CD8α, extracellular domain Q2K/S53N Not measured 
CD8α, extracellular domain S53N/C33A* 30.8 + 1.5 
Table 4.1: CD8α-chain mutations, and the affinity of the 
homodimer CD8αα for the pMHCI, as measured by SPR. 
Measurements are taken from a study by Cole et al, 2007 
(Cole et al., 2007). 
*The C33A mutation was introduced by Cole et al in order to remove
the free cysteine residues, which can prove problematic to the
structural biologist. Cole et al demonstrated no difference in
binding when the wild type CD8αα was compared to the C33A
mutant, thus they concluded that the C33A mutation had no impact
on the pMHCI/CD8 interaction.
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4.1.6 Immortal T-cell lines 
In order to culture primary cells in the laboratory effectively, it is necessary to 
mimic in vivo growth conditions as closely as possible. In addition, these cells have a 
finite lifespan, and, owing to the re-stimulation process required in order to maintain 
them in culture, they can rapidly become exhausted. To circumvent these 
constraints, an immortal cell line model was selected in the first instance to allow 
optimisation of the transduction process. Immortal cell lines are cells that require no 
stimulation in order to keep growing and dividing. For this study, 3 immortal cell 
lines were utilised: the J.RT3-T3.5 line, the J.RT3-T3.5 NFAT GLuc line, and the 
HUT78 H9 derivative. 
The J.RT3-T3.5 line, originally designated JM, was isolated from a 14-year-old boy 
with acute T-cell leukaemia in the 1970s (Schneider et al., 1977). The cells are 
commercially available (ATCC, 2014b), and widely utilised in research. They are a 
derivative of the E6-1 clone from the original jurkat line (ATCC TIB 152) first derived 
from this patient by Schneider et al, which has subsequently been mutated to lack 
the β-chain of the TCR. Therefore, J.RT3-T3.5 cells do not naturally express either a 
TCR or CD3 at their cell surface, nor do they express any co-receptor. The 
endogenous α-chain remains functional if the β-chain is replaced, and doing so 
restores CD3 expression (Ohashi et al., 1985). There are very few markers of 
activation for this cell line as the activation cascade is largely incomplete, however 
they retain the ability to up-regulate CD69 in response to activation through a 
transduced TCR, a feature that was exploited in this chapter.
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The J.RT3-T3.5 NFAT GLuc line is derived from the J.RT3-T3.5 line, however, has 
been stably transduced to express luciferase in response to activation. Luciferase is a 
class of oxidative enzymes, which produce bioluminescence upon activation. This 
luminescence can be measured in intensity as a marker of cellular activation. The 
line was derived from a single clone following transduction, thus luciferase 
expression is the same for the same activation stimulus. Again, the endogenous β-
chain is lacking, thus there is no natural cell surface TCR or CD3 prior to transduction 
(Ohashi et al., 1985), although as previously, the theoretical potential for mis-pairing 
with the endogenous α-chain exists. 
The CD4+ HUT78 cell line was initially isolated from a 54-year-old lymphoma patient 
(Gootenberg et al., 1981, Chen, 1992, Mann et al., 1989). The HUT78 H9 derivative 
was further derived from this original line, and has since been shown to be near 
triploid in chromosome complement, with nearly 2/3 of its chromosomes being 
structurally altered (Chen, 1992). In addition, it has lost expression of the CD4 co-
receptor. It retains an endogenous αβTCR, and, although this line is suitable for 
transduction, the theoretical possibility of mis-pairing and/or recognition through the 
endogenous TCR remains. The parental cell line was highly susceptible to HIV 
infection, and has been widely utilised in research of this virus (Chen, 1992). The 
HUT78 H9 cell line is widely available commercially for research (ATCC, 2014a). It is 
capable of producing the cytokines IL-2 and IL-10 in response to activation through a 
transduced TCR, a feature that was exploited in production of this thesis (Brigino et 
al., 1997, Chen, 1992). 
Immortal cell lines have the benefits of continually dividing without the need for 
continued stimulus, thus they are easily transducible by lentiviral particles, and 
readily expand once stable transduction and enrichment has taken place. For these 
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reasons, they were an ideal starting point for initial exploration of my CD8 constructs 
and models, prior to any attempts to utilise this system in primary CD8+ T-cells. 
4.1.7 Aims 
It has already been demonstrated that increasing the strength of the pMHCI/CD8 
interaction acts to enhance T-cell activation (Wooldridge et al., 2010a, Wooldridge 
et al., 2007). However, in previous studies, increasing the strength of pMHCI/CD8 
interaction was achieved by mutating MHCI. In this chapter, I aim to revisit this 
phenomenon, but instead by introducing point mutations into cell surface expressed 
CD8. The first aim was therefore to stably transduce cell lines to co-express a known 
TCR (Table 4.2) and the CD8αβ co-receptor (or one of the α-chain mutants as 
summarised in Table 4.1), thus generating the tools required for this study. Secondly, 
I examined activation of these cell lines in response to the index peptide of the TCR, 
and then in response to known cross-reactive ligands (Table 4.3).
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TCR 
name 
Cognate ligand Residue 
numbers 
Origin TCR/pMHCI 
KD (µM) 
ILA1 HLA A2 
ILAKFLHWL 
540-548 hTERT 36.6 + 6.25 
MEL5 HLA A2 
ELAGIGILTV 
26-35 Melan-A 18 + 1 
LC13 HLA B*0801 
FLRGRAYGL 
339-347 EBV 
EBNA3A 
9 ± 0.4 
Table 4.2: Summary of the TCRs used in this chapter, 
their cognate ligands, and the relative affinity of the TCR 
for these ligands. 
(Laugel et al., 2007, Bridgeman et al., 2012, Burrows et al., 1994). 
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System 
Peptide ligand TCR/pMHCI KD (µM) 
ILA1 
HLA A2 
ILAKFLHWL 
36.6 + 6.251 
HLA A2 
ILAKFLHEL (8E) 
>5001
HLA A2 
ILAKYLHWL (5Y) 
242 + 201 
HLA A2 
ILAKFLHTL (8T) 
27.6 + 4.711 
HLA A2 
ILGKFLHWL (3G) 
3.7 + 0.281 
LC13 HLA B*0801 FLRGRAYGL 9 + 0.42 
HLA B*4402 EEYLQAFTY 49 + 0.22 
Table 4.3: Summary of the TCR systems used in this 
chapter, and the relative affinity of the TCR for cross-
reactive ligands examined.  
Measurements were taken from: - 
1- Laugel et al, 2007
2- MacDonald et al, 2009
3- Bridgeman et al, 2012
(Laugel et al., 2007, Clement et al., 2011, Ekeruche-Makinde et al.,
2012, Bridgeman et al., 2012, Macdonald et al., 2009).
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4.2 Results 
4.2.1 The generation of immortal J.RT3-T3.5 cell lines co-transduced 
with ILA1 TCR and CD8αvarβ 
The J.RT3-3.5 parental cell line was co-transduced with wild type CD8αβ and the 
ILA1 TCR, which is specific for the HLA A2 restricted hTERT telomerase derived 
epitope ILAKFLHWL (residues 540-548). Analysis of these cells demonstrated co-
expression of both the ILA1 TCR and wild type CD8αβ co-receptor (Figure 4.1A). 
Presence of the ILA1 TCR was confirmed by the detection of rat CD2 (rCD2, 
hereafter), the marker gene cloned into the lentiviral TCR construct which has 
been shown to correlate to TCR and CD3 expression (Figure 4.1A & B). Presence of 
the wild type CD8αβ co-receptor was confirmed by positive staining with anti-CD8α 
antibody, and anti-CD8β antibody. The two antibodies stained at similar levels, 
suggesting heterodimer expression 
(Figure 4.1C). 
In addition, the J.RT3-T3.5 parental cell line was transduced with the ILA1 TCR, and 
one of each of the CD8α-chain mutants; Q2>K, F48>Q, or S53>N (Table 4.1). Upon 
expansion, cells transduced with CD8αQ2Kβ and CD8αS53Nβ were demonstrated to 
express the heterodimeric co-receptor (Figure 4.1B & C). In contrast, J.RT3-T3.5 
ILATCR rCD2+ lines transduced with CD8β.IRESαF48Q failed to express any detectable 
CD8αβ at the cell surface (Figure 4.1B)
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Figure 4.1: J.RT3-3.5 ILA1 TCR+ CD8αvarβ+
lines were stained for enrichment by TCR+
CD8αβ+ sorting:  
Lentivirally transduced J.RT3-T3.5 lines, following 
expansion were stained with antibody (αrCD2, 
αCD8α, and αCD8β) to enable sorting by flow 
cytometry to enrich for TCR+ CD8αβ+ populations. 
Sorting was continued until 5 x 105 cells were 
obtained, or as many as possible, employing the 
gating strategy detailed (A). Cells were sorted into 
R20 media, and expanded, before re-staining to 
check for maintenance of phenotype. The first sort 
of cells lines (B) revealed failure to express 
CD8αF48Qβ at the cell surface, as measured by 
CD8β antibody staining. Following expansion, 
variant cell lines were found to express different 
levels of CD8αβ, thus were re-sorted (C). Despite 
repeated sorts, J.RT3-3.5 ILATCR+ CD8αQ2Kβ+ 
continued to stain highly for CD8β. 
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4.2.2 Establishing J.RT3-T3.5 ILA1 TCR+ CD8αβ+ and J.RT3-T3.5 ILA1 TCR+
CD8αS53Nβ+ cell lines with similar levels of TCR and CD8αβ 
expression  
J.RT3-T3.5 ILA1 TCR+ CD8αvarβ+ cell lines stained with anti-rCD2, anti-CD8α and anti-
CD8β antibodies were sorted using a modified FACSAria flow cytometer/cell sorter 
(Figure 4.1B & C). Following enrichment in this manner, the sorted cell populations 
were expanded and re-stained (Figure 4.2). J.RT3-T3.5 ILA1 TCR+ CD8αβ+ and J.RT3-
T3.5 ILA1 TCR+ CD8αS53Nβ+ were found to express similar levels of cell surface TCR 
and CD8αβ (Figure 4.2). Despite, repeated re-sorts, J.RT3-T3.5 ILATCR+ CD8αQ2Kβ+ 
line expressed higher levels of CD8αβ compared to wild type, and was therefore not 
used in subsequent experiments. 
4.2.3 Increasing the strength of the pMHCI/CD8 interaction results in 
enhanced recognition of pMHCI by the TCR 
J.RT3-T3.5 ILA1 TCR+ CD8αvarβ+ cell lines were stained with pMHCI tetramers loaded
with cognate peptide for the ILA TCR, ILAKFLHWL (ILA, hereafter) (Purbhoo et al., 
2007). Increased pMHCI tetramer staining of CD8+ T-cells in the presence of the CD8 
co-receptor, as compared to CD8- cells expressing the same TCR has previously been 
demonstrated (Campanelli et al., 2002), supporting the hypothesis that the CD8 co-
receptor acts to enhance pMHCI recognition by the TCR. Here, I observed that pMHCI 
tetramer staining was increased as the strength of the pMHCI/CD8 interaction was 
increased, in a similar manner to that seen in Chapter 3 (Figure 3.4) (Dockree et al., 
2017): The J.RT3-T3.5 ILA1 TCR+ CD8αS53Nβ+ line stained with greater intensity than 
J.RT3-T3.5 ILA1 TCR+ CD8αβ+, which in turn stained more than J.RT3-T3.5 ILA1 TCR+
CD8αβ- (Figure 4.3A). The same pattern, albeit with a lesser degree of staining, was 
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MFI CD8β, PE (A) CD3, PerCP (B) 
CD8αβ- 342 36392 
CD8αβ+ 9927 39952 
CD8αS53Nβ+ 9823 35353 
Figure 4.2: Staining of the J.RT3-3.5 ILA1 
TCR+ CD8αvarβ lines.  
Sorted J.RT3-T3.5 ILA1 TCR+ CD8αvarβ lines were 
stained with antibodies (αCD8β PE and αCD3 
PerCP) post-expansion in order to check expression 
of the transgenes. Data were acquired using a 
FACSCanto flow cytometer, and analysed using 
FlowJo software. Data were concatenated into 
histogram plots, and an MFI obtained for CD8β (PE, 
A) and CD3 (PerCP, B). The data plotted represent
the live, singlet populations. This experiment was
repeated whilst the cell lines remained in culture
to ensure that this phenotype was maintained.
CD8β, PE! CD3, PerCP! 
--- CD8- 
--- CD8+ 
--- S53N+ 
A B 
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MFI tetramer, APC A2 ILA β2m (A) A2 227/8 ILA 
β2m (B) 
CD8αβ- 271 756 
CD8αβ+ 6346 1738 
CD8αS53Nβ+ 98624 3468 
Figure 4.3: Tetramer staining of the 
J.RT3-3.5 ILA1 TCR+ CD8αvarβ lines:
The J.RT3-T3.5 ILA1 TCR+ CD8αvarβ T-cell lines
were stained with either A2 wild type (A) or A2
277/8 (B) tetramers folded around ILA. Viable
events are shown in concatenated histogram plots
for each line. These figures show data
representative of >6 repetitions (A), or 2
repetitions (B).
--- CD8- 
--- CD8+ 
--- S53N+ 
Tetramer, APC ! 
A B B 
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seen upon staining with a CD8 null pMHCI tetramer folded around ILA; A2 227/8 ILA, 
with minimal staining of J.RT3-T3.5 ILA1 TCR+ CD8αβ-, marginally more staining of 
J.RT3-T3.5 ILA1 TCR+ CD8αβ+, and increased staining of J.RT3-T3.5 ILA1 TCR+
CD8αS53Nβ+ (Figure 4.3B). 
4.2.4 CD8αβ with increased affinity for pMHCI enhances T-cell antigen 
sensitivity 
J.RT3-T3.5 ILA1 TCR+ cell lines co-expressing either no CD8, wild type CD8αβ, or high
affinity CD8αβ (S53N) were incubated for 24 hours with C1R A2 B-cells, which had 
been previously pulsed with the cognate ILA peptide. Assayed cells were stained with 
anti-CD19 antibody, in order to gate out the B-cell populations from analysis, and 
anti-CD69 antibody (Figure 4.4A). Increased antigen sensitivity is demonstrated in the 
presence of the wild type CD8αβ co-receptor, indicating that the transduced co-
receptor is capable of acting to increase the TCR recognition of the pMHCI, as it does 
when endogenously expressed in primary CD8+ T-cells (Campanelli et al., 2002, Holler 
and Kranz, 2003). T-cell activation as measured by CD69 up-regulation is further 
enhanced in cells that express the mutant CD8αS53Nβ co-receptor (Figure 4.4A). 
Data from four replicate experiments were subjected to statistical analysis and the 
differences shown to be significant (Figure 4.5). 
CD8+ T-cells are highly cross-reactive, with the degeneracy of the TCR being an 
essential feature for the maintenance of an effective T-cell response (Wooldridge et 
al., 2012, Laugel et al., 2011, Wooldridge et al., 2010b). The CD8 co-receptor has 
been shown to control cross-reactivity (Wooldridge et al., 2010b). The ILA1 TCR and 
its cross-reactive ligands have been well characterised in the literature (Purbhoo et 
al., 2007, Laugel et al., 2007b, Wooldridge et al., 2010b, Cole et al., 2008). Ligands
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Figure 4.4: Enhanced recognition of every 
ligand via the ILA TCR when co-receptor 
affinity for MHCI is increased:  
J.RT3-T3.5 ILA1 TCR+ CD8αvarβ lines were incubated 
together with C1R B-cells, which had been pre-
pulsed with peptide selected for the ILA system as 
described in Table 4.3. Following overnight 
incubation, cells were stained with Live/Dead stain, 
and with αCD19 PB and αCD69 APC-Cy7, so that 
dead/dying cells, and B-cells could be excluded 
from analysis, and activation of T-cells by CD69 up-
regulation could be quantified. Viable effector T-
cell (CD19-) events were concatenated into 
histogram plots in order to obtain the MFI, and the 
data plotted is the mean of two replicate samples, 
and their standard deviation. Data were plotted 
comparing the activation of the different cell lines 
by the same ligand (A). Activation by ligands at 10-5 
M peptide concentration was compared for 
J.RT3-3.5 ILATCR+ CD8αβ+ and
J.RT3-3.5 ILATCR+ CD8αS53Nβ (wild type vs. high 
affinity CD8)(B). These data are representative of 
multiple identical experiments (n>4). Data plotted 
at the origin of the x-axis are obtained in the 
absence of exogenous peptide.
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Figure 4.5: Cells transduced with 
enhanced affinity CD8 coreceptor are 
capable of significantly greater activation 
as measured by CD69 up-regulation when 
compared to the wild type. 
Data obtained from the activation of J.RT3-3.5 
ILATCR+ CD8αβ-, J.RT3-3.5 ILATCR+ CD8αβ+ and 
J.RT3-3.5 ILATCR+ CD8αS53Nβ+ cells in response to 
C1R A2 targets pulsed with the cognate peptide ILA 
(as described in Figure 4.4) from four replicate 
experiments were used to calculate pEC50s (see 
appendix E). A representative example of curve 
fitting for the purpose of calculating pEC50s is 
shown in this figure (see appendix E for all other 
curve fits). The pEC50 data from each of these 
four replicate experiments were subjected to 
statistical analysis by Mann–Whitney U test in order 
to compare both the CD8- and the high affinity 
CD8αS53Nβ+ cell lines to the wild type. Both lines 
were found to activate with pEC50s that were 
significantly different to the wild type, with a p 
value of 0.0210706 (S53N) and 0.00894157 (CD8-), 
where n=4. 
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were selected from previous studies across a broad range of TCR/pMHCI interaction 
affinities; very low (ILAKFLHEL, 8E hereafter), low (ILAKYLHWL, 5Y hereafter), index 
(ILA), high (ILAKFLHTL, 8T hereafter), and very high, or CD8-independent 
(ILGKFLHWL, 3G hereafter) (Table 4.3) (Wooldridge et al., 2010b), and the same 
assay as described above was performed. There was increased CD69 staining with cell 
lines expressing CD8αS53Nβ as compared to wild type CD8 for every ligand examined 
(Figure 4.4A & B). These data demonstrate that enhancing the strength of the 
pMHCI/CD8 interaction by manipulating cell surface CD8 results in enhanced T-cell 
antigen sensitivity. 
4.2.5 The HUT78 derivative H9 was successfully co-transduced with ILA1 
TCR and one of the CD8αβ variants  
The HUT78 derivative H9 cell line is capable of producing both IL-2 and IL-10 in 
response to activation (Brigino et al., 1997, Chen, 1992). Lentiviral particles were 
used to co-transduce this cell line with the ILA1 TCR, and one of the CD8αβvariants 
(either no CD8, wild type CD8αβ, or high affinity CD8αS53Nβ). The resultant cell 
lines were stained with anti-rCD2, anti-CD8α and anti-CD8β antibodies. Cells 
expressing similar levels of TCR (as indicated by rCD2+) and CD8 (as indicated by 
CD8α+ CD8β+) were gated upon and sorted in order to enrich for TCR+ CD8+ 
populations (Figure 4.6). The resultant sorted cells were expanded and re-stained. 
The data clearly demonstrate sustained expression of similar levels of TCR and CD8 
on all cell lines (Figure 4.7).
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Figure 4.6: Generation of H9 ILA1 TCR+ 
CD8αvarβ cell lines:  
HUT78 derivative H9 cells were transduced with 
lentiviral particles for the ILA1 TCR alone, or the 
ILA TCR and either wild type CD8αβ or the high 
affinity mutant CD8αS53Nβ. Following expansion, 
cell lines were counted and stained for sorting as 
follows: A H9 ILA1TCR+ CD8-, αrCD2 PE, or B & C H9 
ILA1TCR+ CD8αβ+ (wild type or S53N), αrCD2 FITC, 
αCD8α APC, and αCD8β PE. Sorting was continued 
until 5 x 105 cells were obtained, or as many as 
possible. Viable, rCD2+ events were gated upon, 
either for selection (A), or for gating further to 
enrich for a CD8α+β+ population (B & C). Cells were 
sorted into R20 media, and expanded, before re-
staining to check for maintenance of phenotype. 
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Figure 4.7: Expanded post-sort H9 ILATCR+
CD8αvarβ cell lines express similar levels of 
TCR at their cell surface, and, where 
expected, similar levels of CD8αβ. 
H9 ILA1TCR+ CD8αvarβ T-cell lines were expanded 
post sorting and stained with antibodies (αrCD2 
FITC, αCD3 PerCP, αCD8α PE-Cy7 and αCD8β PE) 
post-expansion in order to check expression of the 
transgenes. Data were acquired using a FACSCanto 
flow cytometer, and analysed using FlowJo 
software. The data plotted represent the live, 
singlet populations, concatenated into histogram 
plots. This experiment was repeated whilst the cell 
lines remained in culture to ensure that this 
phenotype was maintained. 
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4.2.6 CD8αβ with increased affinity for pMHCI enhances the recognition 
of pMHCI by the ILA1 TCR, as measured by IL-2 release 
Once expanded and expression levels of TCR and CD8αβ had been confirmed, the 
resultant H9 cells lines were rested for 48 hours in order to reduce background. Cells 
were counted and incubated overnight with C1R A2 B-cells that had been previously 
pulsed with ILA, the index peptide for the transduced TCR. The supernatant was 
harvested after 18 hours, and subjected to analysis by ELISA for IL-2, as per 
manufacturers instructions. The data obtained demonstrates increased activation 
where the high affinity mutant co-receptor, CD8αS53Nβ, is present, as evidenced by 
increased levels of IL-2 in the resultant supernatant (Figure 4.8). Data from three 
replicate experiments were subjected to statistical analysis and the differences 
shown to be significant (Figure 4.9) 
4.2.7 CD8αβ with increased affinity for pMHCI enhances the recognition 
of pMHCI by the ILA1 TCR, as measured by IL-10 release 
A peptide activation of the H9 lines was performed, as for Figure 4.4, and the 
resultant supernatant subjected to analysis by ELISA for IL-10, as per manufacturers 
instructions. The five agonists used previously; 3G, 8T, ILA, 5Y and 8E, were used for 
peptide titrations. The data had at all but the highest peptide concentration a high 
background. Examination of the data generated at the maximum peptide 
concentration demonstrates that increasing the affinity of the CD8 co-receptor for 
the pMHCI results in enhanced T-cell activation to cognate and high affinity peptide 
variants, as measured by IL-10 cytokine production (Figure 4.10), however has little 
effect on lower affinity ligand.
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Figure 4.8: Enhanced recognition of index 
peptide (ILAKFLHWL) via the ILA TCR when 
co-receptor affinity is increased, as 
measured by IL-2 release. 
Peptide–pulsed C1R A2 targets were incubated 
together with each of the H9 ILATCR+ CD8αvarβ lines 
at 37 °C overnight. The supernatant was harvested 
and assayed for IL-2 ELISA as per manufacturer’s 
instructions. Data plotted represent the mean of 
two replicate assays and their standard deviation, 
however the standard deviation is so small as to 
not be visible on this chart. This assay was 
repeated four times, and these data are 
representative. Data plotted at the origin of the x-
axis are obtained in the absence of exogenous 
peptide. 
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Figure 4.9: Cells transduced with 
enhanced affinity CD8 coreceptor are 
capable of significantly greater activation 
as measured by IL-2 release, when 
compared to the wild type. 
Data obtained from the activation of H9 ILATCR+
CD8αβ-, H9 ILATCR+ CD8αSβ+ and H9 ILATCR+
CD8αS53Nβ+ in response to C1R A2 targets pulsed 
with the cognate peptide ILA (as described in 
Figure 4.4) from three replicate experiments were 
used to calculate pEC50s (see appendix E). A 
representative example of curve fitting for the 
purpose of calculating pEC50s is shown in this 
figure (see appendix E for all other curve fits). The 
pEC50 data from each of these four replicate 
experiments were subjected to statistical analysis 
by Mann–Whitney U test in order to compare both 
the CD8- and the high affinity CD8αS53Nβ+ cell 
lines to the wild type. Both lines were found to 
activate with pEC50s that were significantly 
different to the wild type, with a p value of 
0.011225 (S53N) and 0.0319112 (CD8-), where n=3. 
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Figure 4.10: Enhanced recognition of 
every ligand via the ILA TCR when co-
receptor affinity is increased, as measured 
by IL-10 release:  
The activation experiment as described for Figure 
4.7 was performed, including all the cross-reactive 
peptides for the ILA1 system described in table 
4.3, and the resultant supernatant harvested and 
assayed for IL-10, as per manufacturer’s 
instructions. The mean of two replicate readings 
and their standard deviation, as obtained at the 
highest peptide concentrations for high affinity 
and wild type are plotted.  
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4.2.8 The J.RT3-3.5 NFAT GLuc monoclonal line was successfully co-
transduced with the ILA1, the MEL5, or the LC13 TCR, and one of 
the CD8αβ variants  
The MEL5 TCR was isolated and sequenced from the MEL5 clone, as described in 
Chapter 3. MEL5 was expanded in response to the peptide agonist, ELAGIGILTV, 
which is a heteroclitic variant of the A2 restricted Melan-A/MART-126-35 epitope, 
EAAGIGILTV. Both the MEL5 T-cell clone and the TCR have been well characterised 
(Clement et al., 2011, Laugel et al., 2007b, Ekeruche-Makinde et al., 2012). LC13 is a 
public TCR, which has been well studied by many authors. Its cognate ligand is the 
B*0801 (B8 hereafter) restricted Epstein-Barr Virus (EBV) determinant FLRGRAYGL, 
derived from the latent Epstein-Barr Nuclear Antigen (EBNA) 3A (Burrows et al., 
1990). Alloreactivity has also been documented against B*3501 (B35 hereafter) and 
allotopes restricted by B*4402 and B*4405 (Burrows et al., 1994, Burrows et al., 1995, 
Archbold et al., 2006). This TCR is interesting owing to its marked cross-reactivity 
extending into other MHCI-presented ligands (alloreactivity).  
The J.RT3-3.5 NFAT GLuc line was co-transduced with the ILA1 TCR, MEL5 TCR or 
LC13 TCR, alongside either no CD8αβ, wild type CD8αβ or high affinity CD8αS53Nβ. 
Following expansion, the transduced lines were stained as previously described, with 
anti-rCD2, anti-CD8α and anti-CD8β, and sorted in order to enrich for rCD2+CD8αβ+
cells. The sorted populations were expanded, and re-stained to examine expression 
levels of rCD2, CD8α and CD8β. The data obtained demonstrated maintained 
expression of cell surface TCR and CD8α at similar levels (Figure 4.11A). 
Interestingly, and in contrast to previous cell lines, the CD8β expression was more 
variable (Figure 4.11B), however the cells were double positive (CD8α+ CD8β+) . As 
TCR and CD8α levels were similar on ILA1 TCR+, MEL5 TCR+ and LC13 TCR+ J.RT3-3.5 
NFAT GLuc lines, I decided to use them in subsequent activation assays.
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Figure 4.11: Expanded post-sort J.RT3-3.5 
NFAT GLuc TCR var+ CD8αvarβ cell lines 
express similar levels of TCR and, where 
expected, similar levels of CD8α. 
Transduced cell lines had been sorted and enriched 
as previously, and following expansion, were 
stained with αrCD2 FITC, αCD8α APC, and αCD8β 
PE. Data were acquired using a FACSCanto flow 
cytometer, and analysed using FlowJo software. 
The data plotted represent the live, singlet 
populations, concatenated into histogram plots 
(A), or dot plots (B).  
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CD8α staining of the Mel line was observed to be higher than that seen in other 
lines. This was in the CD8- line, which have never encountered a CD8 LV and so 
cannot be express CD8α as they have no endogenous CD8. No explanation could be 
offered for this, however, given that the CD8αβ and CD8αS53Nβ lines expressed 
higher levels when compared to this, I took this to be the normal negative staining 
for this line, and so proceeded with subsequent assays. 
4.2.9 High affinity CD8 results in enhanced recognition of pMHCI by TCR, 
as measured by a bioluminescence assay  
The J.RT3-3.5 NFAT GLuc line has been stably transduced as a reporter line of NFAT 
activation. This means that upon activation via the NFAT cascade, these cells will up-
regulate and produce luciferase protein, which is released into the supernatant. 
Overnight peptide activation assays were performed as described, using serum-
starved ILA1 TCR+ or MEL5 TCR+ J.RT3-3.5 NFAT GLuc cell lines and cognate peptide-
pulsed C1R A2 B-cell targets. The harvested supernatant was then assayed for 
luciferase protein as per the manufacturers instructions (NEB BioLux® Gaussia 
Luciferase Assay Kit BioLux® Gaussia Luciferase Assay). The equipment available for 
reading of luminescence meant that only a single ligand could be analysed at any one 
time. The data shows increased luminescence, indicating increased luciferase protein 
into supernatant, following activation through NFAT by the cognate ligand with cell 
lines expressing the high affinity CD8αS53Nβ co-receptor as compared to wild type 
(Figure 4.12).
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Figure 4.12: Cell lines transfected with 
high affinity CD8αS53Nβ exhibit enhanced 
recognition of cognate ligand via the TCR 
compared to the wild type CD8αβ co-
receptor, as measured by NFAT-linked 
luciferase protein release. 
C1R A2 target cells which had been pulsed with 
either the ELA or the ILA peptide, were incubated 
together with either the J.RT3-3.5 NFAT GLuc ILA1 
TCR+ CD8αvarβ line or the J.RT3-3.5 NFAT GLuc 
MEL5 TCR+ CD8αvarβ line, at 37 °C for 24 hours. The 
supernatant was subsequently harvested, and 
assayed for luciferase protein by bioluminescence 
as per manufacturer’s instructions. The data 
plotted represent the mean of two replicate assays 
and their standard deviation, and are 
representative of multiple experiments (n = 4). 
Data plotted at the origin of the x-axis are 
obtained in the absence of exogenous peptide. 
These data demonstrate increased activation of 
NFAT through the TCR by cognate ligand as the 
pMHCI/CD8 affinity of the expressed co-receptor is 
increased, as measured by luciferase protein 
release into the supernatant. 
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4.2.10 High affinity cell surface CD8 affords increased activation via the 
LC13 TCR by both cognate and alloreactive ligands 
The cognate ligand of the LC13 TCR is the B8-restricted epitope, FLRGRAYGL (FLR 
hereafter) (Burrows et al., 1990). LC13 has been shown to be alloreactive against 
B*4402 and B*4405 (Burrows et al., 1994, Burrows et al., 1995, Macdonald et al., 
2009). Previously, the B*4405 restricted allotope has been identified as EEYLQAFTY 
(EEY hereafter), a proposed natural alloptope for the LC13 TCR (Macdonald et al., 
2009, Bridgeman et al., 2012). Overnight peptide activation assays were performed 
using serum-starved J.RT3-3.5 NFAT GLuc LC13 TCR+ CD8var lines and T2 B-cell 
targets, which had been previously pulsed with either FLR or EEY peptides. The 
harvested supernatant was subjected to luciferase luminescence assay as per 
manufacturer’s instructions. The data obtained from the assays shows increased 
activation where the CD8αβ co-receptor is expressed at the cell surface, and that 
this activation is further enhanced when this is replaced with the CD8αS53Nβ high 
affinity mutant co-receptor (Figure 4.13). 
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Figure 4.13: Cell lines transfected with 
high affinity CD8αS53Nβ exhibit enhanced 
recognition of both the cognate ligand, 
and the allotope, via the LC13 alloreactive 
TCR compared to the wild type CD8αβ co-
receptor, as measured by NFAT-linked 
luciferase protein release. 
T2 B*0801 target cells were pre-pulsed with the 
cognate ligand FLR, and T2 B*4405 alloreactive 
target cells were pre-pulsed with the mimotope 
EEY; each peptide being added at the desired final 
concentration (10-4 – 10-10, and 0 M). Serum-starved 
J.RT3-3.5 NFAT GLuc LC13 TCR+ CD8αvarβ cells
were applied to the peptide pulsed targets and
incubated at 37 °C for 24 hours. The supernatant
was harvested, and assayed for luciferase protein
by bioluminescence as per manufacturer’s
instructions. The data plotted represent the mean
of two replicate assays and their standard
deviation, and are representative of two
independent experiments. Data plotted at the
origin of the x-axis are obtained in the absence of
exogenous peptide.
Data demonstrate increased activation of NFAT
through the TCR by both ligands as co-receptor
affinity for the pMHCI is increased.
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4.3 Discussion 
CD8+ T-cells are capable of recognising MHCI-presented cancer epitopes. Indeed, 
cancer has been described by some as a failure of the immune system (Swann and 
Smyth, 2007, Finn, 2012). If we consider that an important role of the immune 
system is constant and on-going surveillance for dysregulated cells, then neoplastic 
cells should be recognised and eliminated before they are grossly evident in the 
host. Tumours that present as recognisable pathology have already evaded those 
CD8+ T-cells capable of recognising their unique onco-antigens. Therefore, CD8+ T-
cells are capable of recognising cancer epitopes, but their inadequate response can 
allow the tumour to persist, and grow, in the host. This chapter represents 
attempts to examine the enhancement of the antigen-specific T-cell response to 
onco-antigens by manipulation of the CD8αchain, specifically to enhance the 
affinity for MHCI. 
The data sets generated from activation of all transduced immortal cell lines 
examined in this chapter (TCR+ CD8αvarβ) by cognate ligand, presented in the 
context of MHCI expressed by B-cell targets all demonstrated the same trend, that 
increasing the affinity of CD8αβ for MHCI by manipulation of the α-chain results in 
increased antigen sensitivity. This was the case for all ligands examined, including 
low affinity ligands, where activation was detectable in these assays. Whilst this 
obviously has implications for enhanced recognition of cancer cells by CD8+ T-cells, 
it also needs to be considered that enhanced recognition of all other ligands 
recognised by the TCR was observed.  
It remains to be seen what effect the use of high affinity CD8 will have on cross-
reactivity with self, and the importance of a robust investigation into the effect of 
increasing the strength of the pMHCI/CD8 interaction on the promiscuity of the 
TCR, is recognised. TCR promiscuity is an essential feature of CD8+ T-cells, 
206 
rendering them capable of recognising the vast number of potentially harmful 
challenges that might exist (Mason, 1998, Sewell, 2012). The range of ligands, 
which may be recognised by a single TCR, is variable. Some may be highly 
promiscuous; a TCR recognising over 106 different peptide ligands was 
characterised by Wooldridge et al (Wooldridge et al., 2012). It is recognised that 
autoimmune TCRs, such as the one characterised in this publication, tend to be 
more cross-reactive, and that TCRs recognising foreign ligands recognise the fewest 
epitopes, in some cases as few as 102, however the average is of the order of 105 
(Wooldridge et al., 2012, Sewell, 2012). As has been mentioned already, there is a 
great need to fully characterise the effect that the use of high affinity CD8 has on 
TCR promiscuity. The data obtained for this chapter demonstrated that, in the case 
of CD69 up-regulation, an early and low-occupancy indicator of T-cell activation, 
the S53N mutation enhanced T-cell activation for all ligands examined, even with 
very low affinity for the TCR. Extrapolation of these data may suggest that such a 
mutation would greatly increase TCR promiscuity. It should also be noted, that in 
the case of CD69 expression, the basal level of CD69 expression is higher in 
CD8αS53Nβ lines as compared to the wild type. Interestingly, when one examines 
readouts such as IL-2 and IL-10, the weaker affinity ligands examined did not 
exhibit enhanced activation, giving hope to the possibility that increasing the 
affinity of the CD8 co-receptor may not dramatically increase the promiscuity of 
the TCR in a manner which could prove detrimental to the patient. 
It has already been noted in Chapter 3 that increasing the strength of the 
pMHCI/CD8 interaction above a defined threshold resulted in non-specific 
activation. For this reason, it is essential that the effect of enhancing pMHCI/CD8 
interaction on cross-reactivity be fully classified. To this end, I attempted to 
transduce primary T-cells with the lentiviral particles in order to examine this 
system in primary cells, however, at the time of writing, this had proved 
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problematic. Limits of the jurkat system utilised in this chapter include the 
inability to respond to combinatorial peptide library screens, owing to poor 
sensitivity of effector function read-outs. Thus, examination of the high affinity 
CD8αS53Nβ in primary cells remains an essential goal for the continuation of this 
work. 
The affinity of the pMHCI/CD8 interaction of the S53>N α-chain mutant homodimer 
for HLA A2-Tax and the HLA A24-EBV, was measured by Cole et al to be around 30 
µM (Cole et al., 2007). This is very close to the affinity at which we recognise loss 
of specificity of the TCR (Dockree et al., 2017), as discussed in Chapter 3. If we are 
to utilise such an enhancement in pMHCI/CD8 interaction for patient benefit, it is 
anticipated that a mutation with a lesser degree of enhancement above the wild 
type would be more likely to be useful. As was demonstrated in chapter 3, 
enhancement of the pMHCI/CD8 affinity above this threshold results in loss of TCR 
specificity, with potentially catastrophic consequences for the host. It is 
anticipated that an enhancement of pMHCI/CD8 affinity similar to that of the 
Q115>E mutation examined in chapter 3 would be of more use for future strategies 
(Wooldridge et al., 2007, Dockree et al., 2017). 
In conclusion, the jurkat model utilised in this chapter has provided valuable early 
insights into the ability of high affinity CD8 molecules to enhance CD8+ T-cell 
activation, and their potential for enabling CD8+ T-cells to elicit a more robust 
response to cancer ligands. The system requires further testing, and very likely the 
examination of further CD8 mutations. We have already approached a molecular 
modeller in order to identify further mutants for study. It has been suggested that 
CD8 has a key role in the control of T-cell cross-reactivity (Wooldridge et al., 
2010b, van den Berg et al., 2007, Szomolay et al., 2013), narrowing the focus of 
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the TCR within its potential cross-reactive ligands. This will be examined in more 
depth in the next chapter. 
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Chapter 5 
Manipulation of the pMHCI/CD8 interaction has the effect of ‘re-
focussing’ the TCR by re-arranging the relative potencies of its 
cross-reactive ligands 
5.1 Introduction 
CD8 has been shown to enhance and modulate the antigen-specific T-cell response 
(Garcia et al., 1996, Laugel et al., 2011, Miceli and Parnes, 1991), by reducing the 
TCR/pMHCI dissociation rate by over 50% and facilitating downstream triggering by 
recruitment of the TCR/CD3 complex to lipid rafts (Wooldridge et al., 2005, 
Gakamsky et al., 2005). Mathematical modelling has enabled us to consider the 
effect of altering the strength of the pMHCI/CD8 interaction on the relative 
potencies of TCR ligands and thus upon TCR degeneracy (Szomolay et al., 2013). van 
den Berg et al predicted that changes in the cell surface density of CD8 could alter 
T-cell functional avidity for agonists, and rearrange the relative potencies of each
potential agonist (van den Berg et al., 2007). The ability to re-arrange the relative 
potency hierarchy of TCR agonists could act to facilitate a robust response to 
antigenic challenge, whilst damping down the response to self-ligands and thus 
avoiding autoimmunity, and has been described as a ‘focussing effect’. 
Mathematical modelling has enabled us to predict that a similar ‘focussing effect’ 
will be seen if one examines activation data obtained over a range of different 
pMHCI/CD8 interaction affinities. This suggests that for any given pMHCI ligand, there 
would be an optimal pMHCI/CD8 affinity which would afford maximal functional 
sensitivity. A deeper understanding of this mechanism would allow us to exploit this 
phenomena for patient benefit; it could be possible to design a CD8 molecule with a 
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defined affinity for the target MHCI which would result in greatest antigen sensitivity 
to a given cancer pMHCI ligand. This would enable us to optimise existing ACT 
systems. 
5.1.1 TCR Degeneracy 
Whilst early authors considered that a TCR possessed only a single pMHCI ligand, with 
each individual T-cell targeting a specific challenge, it very quickly became evident 
that this could not possibly be the case. It has been suggested that there exists ~1015 
different pMHCI possibilities; how then could a T-cell repertoire of 2.5 x 107 
(Nikolich-Zugich et al., 2004) recognise all of these antigens if each TCR had only a 
single designated target ligand? Therefore TCRs must be highly degenerate, and this 
promiscuity is an essential feature of an effective immune response. The 
promiscuous nature of the TCR has been documented in the literature since the early 
1990s (Lopez et al., 1993, Wraith et al., 1992, Dedeoglu et al., 1992, Colombani, 
1990, Burrows et al., 1994), however attempts to further classify this have been 
limited, examining only a small number of peptide ligands as compared to the entire 
peptide universe of all possible pMHCI ligands. Wooldridge et al utilised a 
combinatorial peptide library (CPL) screen to classify TCR promiscuity, identifying a 
single autoimmune TCR, which is capable of recognising over 106 different pMHCI 
ligands (Wooldridge et al., 2012). Whilst this example is considered to be highly 
cross-reactive, even as compared to other TCRs, 105 ligands is considered to be the 
average scope of recognition, and this degeneracy of the TCR is taken to be an 
essential feature of T-cell biology (Mason, 1998, Wooldridge et al., 2010b, Sewell, 
2012).  
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5.1.2 CD8 can control T-cell cross-reactivity 
Wooldridge et al examined the cross-reactivity of the TCR over a range of different 
pMHCI/CD8 affinities (Wooldridge et al., 2010b). Their data demonstrated that only a 
small number of pMHCI ligands are recognized in the absence of pMHCI/CD8 binding 
(CD8-independent ligands). As the strength of the pMHCI/CD8 interaction is 
increased, the number of pMHCI ligands recognised was also increased. This led the 
authors to conclude that CD8 controls T-cell cross-reactivity, ensuring that the 
immune system is able to mount a robust response to infected or dysregulated cells, 
whilst remaining quiescent in the face of self-antigens, mounting only the minimal 
response required in order to maintain the naïve and memory pool.  
The study described above also observed that altering the strength of the pMHCI/CD8 
interaction changed the pattern of pMHCI recognition (Wooldridge et al., 2010b). 
Further mathematical modelling predicted that increasing the strength of the 
pMHCI/CD8 interaction could enhance the recognition of one pMHCI ligand, whilst 
reducing the response to others, thus adjusting the relative potency. It was 
predicted that adjusting the CD8 co-receptor density at the cell surface could be a 
means by which this might be achieved in vivo (van den Berg et al., 2007, Szomolay 
et al., 2013). Whilst the effect of altered CD8 levels at the cell surface are 
hypothesised in this model, the exact means by which the T-cell might achieve this 
are unclear, however I propose a possible explanation in section 7.1.2. 
5.1.3 Aims 
It has been suggested that manipulation of CD8 co-receptor density is the means by 
which the T-cell is able to re-arrange the relative potencies of its potential ligands. 
It has been further hypothesised that a similar "focussing effect" may be observed via 
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manipulation of the pMHCI/CD8 interaction affinity. In this chapter, I have probed 
this role of CD8 further by examining how altering the strength of the pMHCI/CD8 
interaction by manipulating cell surface CD8 affects recognition of a range of cross-
reactive ligands with different TCR/pMHCI affinities. In order to do this, I have 
utilised the following jurkat lines: J.RT3-3.5 ILA1 TCR+ CD8αβ-, J.RT3-3.5 ILA1 TCR+ 
CD8αβ+ and J.RT3-3.5 ILA1 TCR+ CD8αS53Nβ+, and H9 ILA1 TCR+ CD8αβ-, H9 ILA1 TCR+ 
CD8αβ+ and H9 ILA1 TCR+ CD8αS53Nβ+. In addition, I examined activation of the MEL5 
CD8+ T-cell clone in response to a range of cross-reactive ligands with different TCR/
pMHCI affinities presented in the context of the mutant A2 panel described in 
chapter 3 (Table 3.1). 
213 
System Peptide ligand TCR/pMHCI 
ILA1 A2 ILAKFLHWL 36.6 + 6.251
A2 ILAKFLHEL (8E) >5001
A2 ILAKYLHWL (5Y) 242 + 201
A2 ILAKFLHTL (8T) 27.6 + 4.711
A2 ILGKFLHWL (3G) 3.7 + 0.281
MEL5 A2 ELAGIGILTV 18 + 11
A2 ELTGIGILTV (3T) 82 + 42
A2 FATGIGIITV (FAT, 8I) 3 + 0.43
Table 5.1: Summary of the TCR systems used in this 
chapter, and the relative affinity of the TCR for cross-
reactive ligands examined.  
Measurements were taken from: - 
1- Laugel et al, 2007
2- Clement et al, 2011
3- Ekeruche-Makinde et al, 2012
The majority of these ligands were found using combinatorial
peptide library (CPL) screen technology.
(Ekeruche-Makinde et al., 2012, Clement et al., 2011, Laugel et al.,
2007).
214 
5.2 Results 
5.2.1 Increasing the strength of the pMHCI/CD8 interaction re-arranges 
the relative potencies of ILA1 TCR agonists  
The affinity of the ILA1 TCR for its cognate and cross-reactive pMHCI ligands has been 
well characterised in the literature (Purbhoo et al., 2007, Laugel et al., 2007b, 
Wooldridge et al., 2010b, Cole et al., 2008). pMHCI ligands spanning a broad range of 
TCR/pMHCI interaction affinities were selected: very low (ILAKFLHEL, 8E hereafter), 
low (ILAKYLHWL, 5Y hereafter), index (ILA), high (ILAKFLHTL, 8T hereafter), and 
very high, or CD8-independent (ILGKFLHWL, 3G hereafter) (Table 5.1) (Wooldridge et 
al., 2010b). 
To examine activation induced by different TCR agonists in the context of different 
pMHCI/CD8 affinities, J.RT3-3.5 ILA1 TCR+ cell lines co-expressing either no CD8, 
wild type CD8αβ, or high affinity CD8αS53Nβ were incubated for 24 hours with C1R 
A2 B-cells, which had been previously pulsed with the range of pMHCI ligands listed 
above (Figure 5.1). pEC50 values were obtained for all J.RT3-3.5 ILA1 TCR+ cell lines 
activated against all pMHCI ligands using simultaneous curve fitting (Table 5.2, Figure 
5.2 & Appendix D). In the absence of CD8, the CD8-independent agonist, 3G, was the 
best activator, and the following activation hierarchy was observed: 3G>8T>ILA>5Y 
(Figure 5.1 & 5.2, and Table 5.2). 8E is not shown because neither this nor 5Y 
elicited any CD69 up-regulation in the absence of CD8. This activation hierarchy is 
directly correlated with the strength of the TCR/pMHCI interaction (Cole et al., 
2008, Laugel et al., 2007b) (Figure 5.1 & 5.2, and Table 5.2). When the ILA1 TCR was 
co-expressed with wild type CD8αβ, the observed hierarchy of activation was: 
8T>3G>ILA>5Y>8E (Figure 5.1 & 5.2, and Table 5.2). Whereas, transduction with the 
high affinity CD8αβ co-receptor, CD8αS53Nβ, resulted in the following activation
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Figure 5.1: Altering the pMHCI/CD8 
interaction affinity has the effect of 
altering the relative potencies of different 
pMHCI ligands as seen by the TCR.  
Data obtained from the assays plotted in Figure 4.4 
were re-plotted in order to compare activation of 
each cell line in response to different pMHCI 
ligands. For the sake of simplicity, the 8E peptide 
was omitted from the CD8- plot as no activation as 
measured by CD69 up-regulation was observed, 
and the data overlaid that of the 5Y peptide. The 
data represent the mean and standard deviation of 
two replicate assays, and the data at the origin of 
the x-axis is obtained in the absence of exogenous 
peptide. 
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Ligand 
CD8 
variant 
5Y ILA 8T 3G 
CD8- -1952.15 -10.3357 -8.22473 -5.35621
CD8αβ+ -4.86265 -1.73276 -0.69812 -1.21762
CD8αS53Nβ+ 1.16908 3.71495 5.39886 2.82922 
Table 5.2: Scaled pEC50s for the J.RT3-T3.5 ILA1TCR 
system 
The data portrayed in Figure 5.1 were used to generate scaled dose 
response curves. These data were then used to generate pEC50s, 
scaled to the weakest ligand presented in the context of the 
weakest pMHCI/CD8 interaction. In order to do so, the data were 
treated as a single batch for analysis, the assumption being that all 
cell lines share the same maximum output level. Given that all cells 
were treated in an identical manner, that the target cells were the 
same, and that each J.RT3-T3.5 ILA1TCR+ CD8var line originated from 
the same parent cell line, this assumption is warranted. 
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Figure 5.2: Re-arrangement of the scaled 
relative potencies of ligands as pMHCI/CD8 
interaction affinity is increased. 
The data tabulated in Table 5.2 is presented in the 
Figure above. The pEC50s have been scaled 
relative to each other. The pEC50 value for 
activation of the J.RT3-T3.5 ILA1 TCR+ CD8- line by 
5Y is null and as such is plotted as 0. 
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hierarchy: 8T>ILA>3G>5Y>8E (Figure 5.1 & 5.2, and Table 5.2). These data suggest 
that enhancing the affinity of cell surface CD8 for pMHCI has the effect of re-
arranging the relative potencies of agonists for the ILA1 TCR.  
5.2.2 High affinity CD8 results in a reduced response to high affinity 
ligands  
Once expanded and expression levels of ILA1 TCR and CD8 had been confirmed, the 
resultant H9 cells lines were rested for 48 hours in order to reduce background. Cells 
were counted and incubated overnight with C1R A2 B-cells that had been previously 
pulsed with the range of pMHCI ligands listed above. The supernatant was harvested 
after 18 hours, and subjected to analysis by IL-2 ELISA. The weaker affinity ligands, 
5Y and 8E elicited no detectable response. For the index peptide ILA, activation was 
enhanced by the expression of wild type CD8αβ and further enhanced by the 
expression of high affinity CD8αβ (S53>N) (Figure 5.3A), consistent with results in 
chapter 5. For the higher affinity ligands (8T and 3G), activation was also enhanced 
by the expression of wild type CD8αβ but interestingly, this was not further enhanced 
by the expression of high affinity CD8αβ (S53>N). In fact, for both 8T and 3G, 
activation with high affinity CD8αβ (S53>N) was lower in magnitude than that 
observed with wild type CD8αβ (Figure 5.3A).  
Interestingly, when I examined the effect of increasing the strength of the 
pMHCI/CD8 interaction on the relative potencies of ILA, 8T and 3G, a shift in the 
hierarchy of specific responses via the TCR was observed (Figure 5.3B & 5. 4, and 
Table 5.3). For H9 ILA1 TCR+ lines with no CD8αβ or expressing the wild type CD8αβ 
co-receptor, the order of ligand potency observed was: 3G=8T>ILA>5Y (Figure 5.3B & 
5.4, and Table 5.3). However, for H9 ILA1 TCR+ lines expressing the high affinity co-
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Figure 5.3: Increasing the pMHCI/CD8 
affinity reduces activation through the 
TCR as measured by IL-2 release for higher 
affinity agonists. 
Peptide-pulsed targets (peptides as described in 
Table 5.3 for the ILA system) added at the 
indicated concentrations, were incubated together 
with each of the H9 ILA1 TCR+ CD8αvarβ lines, at 37 
°C overnight. The supernatant was subsequently 
harvested and assayed for IL-2 by ELISA. Data 
plotted represent the mean and standard deviation 
of two replicate assays, and are representative of 
3 replicate experiments. The data sets closes to 
the origin of the x-axis represent data obtained in 
the absence of any exogenous peptide. Data sets 
are plotted to compare activation of different cell 
lines by the same ligand (A), and activation of the 
same cell line by different ligands (B).  
220 
Ligand 
CD8 
variant 
5Y ILA 8T 3G 
CD8- -4.74167 -1.71556 0.115127 0.235721 
CD8αβ+ -53.2726 -1.7405 1.00874 2.18829 
CD8αS53Nβ+ -3.88575 0.3525 1.49607 1.16599 
Table 5.3: Scaled pEC50s for the H9 ILA1TCR system. 
The data portrayed in Figure 5.2 were used to generate scaled dose 
response curves. These data were then used to generate pEC50s, 
scaled to the weakest ligand presented in the context of the 
weakest pMHCI/CD8 interaction. In order to do so, the data were 
treated as a single batch for analysis, the assumption being that all 
cell lines share the same maximum output level. Given that all cells 
were treated in an identical manner, that the target cells were the 
same, and that each H9 ILA1TCR+ CD8var line originated from the 
same parent cell line, this assumption is warranted. 
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Figure 5.4: Re-arrangement of the scaled 
relative potencies of ligands as pMHCI/CD8 
interaction affinity is increased.  
The data tabulated in Table 5.2 is presented in the 
Figure above. The pEC50s have been scaled 
relative to each other. The pEC50 value for 
activation of the H9 ILA1 TCR+ CD8- line by ILA is 
null and as such is plotted as 0.
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receptor, CD8αS53Nβ, the following hierarchy of ligand potency is seen: 
8T>3G>ILA>5Y (Figure 5.3B & 5.4, and Table 5.3). Therefore a shift in activation 
hierarchy as the strength of the pMHCI/CD8 interaction is increased was also 
observed in the H9 system (when effector function was measured by IL-2 release), 
albeit more subtle than the shift observed in the J.RT3-T3.5 system, as measured by 
CD69 up-regulation (Figure 5.1 & 5.2). The shift in hierarchy was not measurable by 
IL-10 release resulting from identical assays in the same H9 system (n=3). 
5.2.3 Altering the strength of the pMHCI/CD8 interaction by manipulation 
of MHCI facilitates ‘focussing’ 
C1R A2 targets utilised in Chapter 3 of this thesis in order to examine non-specific 
activation of CD8+ T-cells were used to further examine the ‘focussing effect’ 
observed above. A panel of cross-reactive ligands recognised by the MEL5 TCR with 
different TCR/pMHCI affinities were selected from previously published studies 
(Table 5.1). These ligands had been identified using CPL technology. The ligands 
selected were ELAGIGILTV (index peptide, ELA), the weak affinity agonist 
ELTGIGILTV (3T hereafter), and the high affinity agonist FATGIGIITV (FAT hereafter) 
MEL5 CD8+ T-cells clones were counted and rested overnight in R2 media in order to 
reduce the background readout. C1R A2 B-cells expressing either wild type or mutant 
MHCI were counted and pulsed for two hours with either index or a cross-reactive 
ligand as indicated (Figure 5.5). Targets were then washed and the MEL5 CD8+ T-cell 
clone added, then incubated overnight. The resultant supernatant was harvested and 
assayed for IFNγ by ELISA.
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Figure 5.5: Altering the strength of the 
pMHCI/CD8 interaction by manipulation of 
MHCI facilitates ‘focussing’ 
C1R A2 target cells were pulsed with peptide, as 
described in Table 3.1 for the MEL5 system, added 
at the concentration indicated, and subsequently 
incubated together with serum-starved MEL5 CD8+ 
T-cells at 37 °C overnight. The supernatant was
harvested and assayed by ELISA for IFNγ. The mean
and standard deviation of two replicate assays is
plotted. Experimental assays were repeated on six
occasions, and these data are representative. The
data sets at the origin of the x-axis are obtained in
the absence of exogenous peptide. Data is
displayed to depict activation using different
target cells, and thus differing pMHCI/CD8
interaction strength, by the same peptide.
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I observed that when the pMHCI/CD8 interaction is abrogated (A2 227/8 MHCI), the 
only robust response made by the MEL5 CD8+ T-cell clone is to the high affinity 
ligand, FAT (Figure 5.5), and no activation was seen in response to either the 
cognate (ELA) or reduced affinity (3T) agonists. Therefore, the activation hierarchy 
observed in the absence of pMHCI/CD8 engagement was: FAT>ELA=3T (Figure 5.5 & 
5.6, and Table 5.4). The activation hierarchy observed when cross-reactive ligands 
were presented in the context of wild type pMHCI was: FAT=ELA>3T (Figure 5.5 & 
5.6, and Table 5.4). As pMHCI/CD8 interaction affinity is increased, I observed a shift 
in this hierarchy, through FAT>ELA>3T (A2 QE) to ELA>FAT>3T (A2/KbA245V) to 
ELA>FAT>3T (A2/Kb) (Figure 5.5 & 5.6, and Table 5.4). Plotting the same data to 
show how activation of the same ligand in different B-cell targets, i.e. pMHCI/CD8 is 
varied, we can observe which pMHCI interaction elicits the greatest T-cell response 
to the same TCR agonist (Figure 5.7).  
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Ligand 
A2 
variant 
ELTGIGILTV ELAGIGILTV FATGIGIITV 
A2 227/8 -2.63907 -1243 5.8255 
A2 2.8892 5.5501 6.1982 
A2 Q115E 3.788 6.2565 6.6447 
A2 Kb 
A245V 
2.1098 4.5299 3.4376 
A2 Kb 1.5917 4.5109 3.2516 
Table 5.4: pEC50s obtained by single batch analysis for 
the Mel System. 
The data portrayed in Figure 5.3 were used to generate scaled dose 
response curves. These data were then used to generate pEC50s, 
scaled to the weakest ligand presented in the context of the 
weakest pMHCI/CD8 interaction. In order to do so, the data were 
treated as a single batch for analysis, the assumption being that all 
cell lines share the same maximum output level. Given that all cells 
were treated in an identical manner, and that all target cell lines 
originated from the same C1R parent line, with the same clone 
being applied to each, this assumption is warranted. 
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Figure 5.6: Altering the strength of the 
pMHCI/CD8 interaction by manipulation of 
MHCI facilitates ‘focussing’ 
A The relative potencies of the ligands examined 
for Figures 5.3 and 5.5 are compared at a peptide 
concentration of 10-5 M. B The data generated 
above was displayed as scaled dose response 
curves, which could then be used to calculate 
pEC50s, thus allowing comparison of the relative 
potencies of the TCR agonists when considered 
over the whole curve. pEC50s are scaled relative 
to the weakest agonist and the lowest CD8/pMHCI 
affinity. In order to generate pEC50s, these data 
were treated as a single batch analysis, the 
assumption being that all cell lines share the same 
maximum output level. Given that all cells were 
treated in an identical manner, and that all target 
cell lines originated from the same C1R parent 
line, with the same clone being applied to each, 
this assumption is warranted. Activation by 
ELAGIGILTV-A2 227/8 represented a null result, 
and as such is drawn as 0. pEC50s are summarised 
in Table 5.2. 
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Figure 5.7: Rearrangement of the relative 
potencies of different TCR agonists as 
pMHCI/CD8 is altered.  
The data generated for Figure 5.3 was re-plotted 
to compare activation of the MEL5 clone by 
different peptide ligands presented by different 
target cell lines. 
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5.3 Discussion 
The binding of both TCR and CD8 is usually necessary to trigger downstream 
signalling with the exception of very potent TCR agonists or a greatly enhanced 
pMHCI/CD8 interaction (the A2/Kb mutant) (Wooldridge et al., 2010a, Laugel et al., 
2007b, Cole et al., 2012). It has been recognised that dependence on CD8 is 
inversely related to TCR/pMHCI affinity; high affinity ligands may act as agonists in 
the absence of CD8, whilst poor agonists have an absolute requirement for co-
receptor function, and moderate agonists which have a partial requirement for CD8 
(Cole et al., 2012). Mathematical modelling has suggested that CD8 may exert a 
differential affect on the functional sensitivity of different ligands (van den Berg et 
al., 2007, Szomolay et al., 2013). It is predicted that in vivo this effect is likely to 
be achieved by alteration of the CD8 co-receptor density at the cell surface (van 
den Berg et al., 2007, Szomolay et al., 2013). It seems probable that manipulating 
the affinity of the pMHCI/CD8 interaction is likely to have a similar effect and thus 
may be a useful tool to manipulate the functional sensitivity of the TCR to differing 
affinity ligands (Szomolay et al., 2013, van den Berg et al., 2007). It would appear 
from experimental data that enhancing the strength of the pMHCI/CD8 interaction 
may increase the sensitivity of the TCR to a sub-optimal ligand, whilst the same 
enhancement may make an already favourable interaction less so, thus resulting in 
a ‘focussing’ effect.  
It is uncertain why this effect was not observed when examining IL-10 release by 
the H9 system, although the different TCR occupancies required may offer an 
explanation. In short, this discrepancy reiterates the need for more robust testing 
of multiple systems in order to more fully classify this effect. 
I have examined both the ILA1 and MEL5 system experimentally, altering the 
strength of the pMHCI/CD8 interaction both by manipulating the CD8 molecule 
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itself, and by manipulating the CD8 binding region of the MHCI molecule. Similar 
effects were observed in both systems and with different functional read-outs 
(Figures 5.1 – 5.7). For a given pMHCI ligand, enhancing the strength of the 
pMHCI/CD8 interaction initially results in enhancement of the T-cell response, 
however, further enhancement of this interaction resulted in the pMHCI ligand 
becoming sub-optimal, and if this is increased further the pMHCI ligand may 
become an increasingly poor agonist. The exception is very high affinity pMHCI 
ligands, which serve best as agonists to the TCR in the absence of CD8 or presence 
of wild type CD8. These observations are made most evident to see, if one 
rearranges the data in order to display the shift in ligand activation hierarchy as 
the pMHCI/CD8 interaction affinity is altered (Figure 5.1, 5.3 & 5.5).  
On the basis of the data generated in this chapter, I propose the model detailed 
in Figure 5.8. In order for a ligand to function as an optimal agonist, a complex 
balance exists between the TCR/pMHCI affinity and the pMHCI/CD8 affinity. The 
relationship appears to be an inverse one; i.e. where TCR/pMHCI is relatively high 
(a strong agonist) then optimal activation through the TCR is achieved with a 
relatively low (or even absent) pMHCI/CD8 affinity. The converse is also true; a 
weak agonist may function as an effective TCR agonist if pMHCI/CD8 affinity is 
artificially increased beyond what is physiological normal. The model predicts 
that increasing the pMHCI/CD8 affinity would act to alter the relative potencies of 
different ligands for the TCR, so that response to weaker agonists may be 
enhanced whilst the response to stronger agonists may be reduced. Indeed the 
experimental data generated in this chapter is consistent with this prediction, 
and mathematical modelling has yielded a similar prediction (Figure 5.9), 
although in
230 
Figure 5.8: A hypothetical model of how 
altering the strength of the pMHCI/CD8 
interaction influences the recognition of 
ligands with different affinities for the 
TCR. 
The absence of CD8 renders a normally optimal 
agonist (-black) sub-optimal, and possibly too 
weak to elicit a T-cell response. A CD8 
independent agonist (-red) can be weakened by 
the presence of CD8, and if the pMHCI/CD8 
interaction is enhanced, it may cease to act as an 
agonist. Conversely a weak TCR agonist (-blue) can 
be stabilised by an enhanced affinity pMHCI/CD8 
interaction, thus it may act as an effective agonist 
to the TCR.  
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Figure 5.9: Predicting the effect that 
increasing the pMHCI/CD8 interaction 
affinity has on the functional sensitivity of 
the TCR. 
Depicted is a mathematical model predicting the 
TCR response to different agonists as pMHCI/CD8 
interaction affinity is varied, provided by Barbara 
Szomolay and Hugo van den Berg, University of 
Warwick (Szomolay and van den Berg, 2014, 
Szomolay et al., 2013, van den Berg et al., 
2007). 
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this model it is predicted that both moderate and low affinity ligands will be co-
enhanced at similar pMHCI/CD8 interaction affinities. Whilst this is a model, and 
as such subject to multiple variables, if enhancement of pMHCI/CD8 results in 
enhanced response to all of these ligands at similar affinities, then the 
implications at this level of enhancement is huge, with enhancement of the 
pMHCI/CD8 interaction potentially resulting in a marked increase in TCR 
promiscuity. Further examination of this area of CD8 biology is indicated in order 
to characterise this in vivo. This may be an important feature if one is to consider 
utilising CD8 manipulations for therapeutic gain.  
I have previously discussed that as a non-polymorphic molecule necessary to 
perform a co-receptor function in CD8+ T-cells, CD8 could be ideal to enhance the 
activity of adoptively transferred CD8+ T-cells, as it could be globally applicable. 
The inherent cross-reactivity of the TCR has previously been discussed (Sewell, 
2012, Mason, 1998). If increasing the pMHCI/CD8 affinity were to increase the TCR 
response to every single one of its multiple agonists, then the ramifications for 
cross-reactivity are vast, however, the data as discussed in this chapter would 
suggest that this is not the case, rather that altering the strength of the 
pMHCI/CD8 interaction serves to redefine the TCR/pMHCI interaction affinity at 
which agonists are ‘optimal’. However, the effect of increasing the pMHCI/CD8 
interaction affinity on cross-reactivity requires robust testing.  
The reasons for this ‘focussing’ effect are likely to be linked to the kinetics of 
both the TCR/pMHCI and pMHCI/CD8 interactions. The pMHCI/CD8 interaction is 
characterised by very rapid kinetics (Koff > 18 s-1) (Wyer et al., 1999, Gao et al., 
2000), and a relatively weak affinity (average KD 145 µM), with notable outliers 
being far weaker (Bridgeman et al., 2012, Cole et al., 2012, Hutchinson et al., 
2003). TCR/pMHCI interactions have been recorded over a far broader range; < 10 
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µM (viral epitopes) -  > 250 µM (autoimmune).  The off-rates are also highly 
variable between epitopes, with the strongest interactions tending to have the 
longest off-rates. If we consider the kinetics of the tri-partite structure as this 
pertains to TCR triggering, we can see why both TCR and CD8 co-receptor kinetics 
are important to, and dependent upon, each other.  
In order for the TCR triggering to occur, both TCR and CD8 need to co-engage 
simultaneously. The triple structure must remain intact for long enough to allow 
phosphorylation of all ITAMs, facilitating downstream signalling. The structure then 
dissociates freeing the TCR; multiple single TCR events being required for full 
triggering.  When a ligand is optimal, both molecules rapidly co-engage, remain 
engaged and triggering rapidly ensues. A weak agonist has a faster off rate and a 
shorter dwell time, thus is more likely to dissociate before phosphorylation of all 
ITAMs has occurred, making triggering less likely. Enhancement of the pMHCI/CD8 
interaction has the effect of stabilising the TCR/pMHCI interaction, thus increasing 
the dwell time of the TCR. This enables weaker affinity ligands to initiate TCR 
triggering before the structure can dissociate. A strong TCR agonist, with a slow Koff 
will rapidly engage the TCR, and owing to its greater dwell time, will remain 
bound. CD8 independent agonists may form sufficiently stable interactions with the 
TCR to initiate TCR triggering without CD8 co-receptor help. In this instance, a high 
affinity co-receptor may still engage, facilitating ITAM phosphorylation and 
downstream signalling; however both interactions now have slower kinetics. The 
dwell time is directly related to both the TCR/pMHCI interaction affinity, and the 
pMHCI/CD8 interaction affinity, thus when both interactions are strong, the dwell 
time is greatly increased. The structure cannot dissociate, so further signalling 
cannot occur. The internalnalisation of the TCR, the recycling of pMHCI, and serial 
activation is thought to be essential for full and robust activation of the T-cell 
(Valitutti et al., 1995).  
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At one end of the spectrum are those interactions capable of initiating T-cell 
activation without co-engagement of the second receptor. CD8-independent 
ligands do not require CD8 in order to facilitate T-cell activation, and, as has been 
discussed, in some instances the agonist is so strong that the presence of the co-
receptor can actually damp down the T-cell response. These agonists are however 
still limited by the specificity of the TCR itself. CD8 is non-polymorphic and binds 
the invariant region of the MHCI, thus may bind any MHCI. When this interaction 
affinity is increased above a certain point, specific activation through the TCR is 
not required, as was discussed in Chapter 3, and the co-receptor is capable of 
bringing about T-cell activation in an antibody like manner (Wooldridge et al., 
2010a, Dockree et al., 2017).  
The data presented in this chapter suggest a possible means by which CD8 can 
modulate the CD8+ T-cell response. I have demonstrated that by manipulating the 
pMHCI/CD8 interaction affinity the relative potency of different pMHCI ligands 
presented in the context of the same MHCI is re-arranged. CD8 is uniform and 
mostly non-polymorphic in nature, thus it is evident that this is not the means by 
which CD8 modulates the specificity of the TCR in vivo, however it does provide 
some insights that it is possible to ‘re-focus’ the TCR, and give some clues as to 
possible means by which this can be achieved. It has been considered that the 
same effect might be achieved by manipulating the levels of CD8 expressed at the 
cell surface. Increased co-receptor density has been postulated as a possible 
functional analogue for increased interaction affinity (Park et al., 2007).  
In summary, this chapter has highlighted a further way in which the CD8 co-
receptor may be essential in CD8+ T-cell biology. The focussing effect described 
here may be essential to the host in terms of damping down cytotoxic responses to 
potent ligands thereby avoiding both catastrophic damage to host tissues and T-cell 
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exhaustion in the event of chronic infection. The exact mechanism by which this is 
achieved in vivo remains uncertain, but modulation of cell surface CD8 co-receptor 
levels has been postulated and will be probed in more depth in the next chapter. 
236 
Chapter 6 
The level of CD8αβ expressed at the cell surface can 
affect CD8+ T-cell activation 
6.1 Introduction 
The heterodimer CD8αβ is constitutively expressed at the surface of cytotoxic CD8+ T-
cells (Janeway, 1992). During TCR engagement, CD8αβ co-engages the target pMHCI 
simultaneously with the TCR, where it acts to stabilise, enhance and fine-tune the 
antigen-specific T-cell response, and is thus termed the ‘co-receptor’ (Wooldridge et 
al., 2005, Janeway, 1992, Miceli and Parnes, 1991, Garcia et al., 1996). In man, 
CD8αβ is largely non-polymorphic and binds the invariant region of the pMHCI, thus 
binds different MHCI alleles with similar affinities (although outliers do exist), 
meaning that it may perform co-receptor function to multiple pMHCI to which the 
highly promiscuous TCR is capable of recognising (Bridgeman et al., 2012, Wooldridge 
et al., 2012, Wooldridge et al., 2010b). In addition to stabilising the tri-partite 
structure extracellularly, CD8αβ acts to deliver lck to the CD3 ITAMs thus facilitating 
downstream signalling (Arcaro et al., 2001, Artyomov et al., 2010, Gascoigne et al., 
2011, Veillette et al., 1988, Bosselut et al., 1999). 
6.1.1 The level of CD8αβ expressed at the cell surface 
The levels of CD8αβ expressed at the cell surface of CD8+ T-cells can vary both 
between populations, and in the same T-cell over time. 
Different effector phenotypes have been described following activation, with 
different functions being attributed to CD8high versus CD8low populations (Kienzle 
et 
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al., 2004, Martinez, 2010). Some authors have described cell divisions giving rise to 
daughter cells expressing different levels of CD8, CD8high and CD8low, resulting in two 
distinct populations with different roles and phenotype (Chang et al., 2007, Gerlach 
et al., 2013, Feinerman et al., 2008).  
These differences in CD8 expression have been described by some as existing due to 
the asymmetrical division of transcription factors such as c-Myc (Do and Li, 2016, 
Feinerman et al., 2008). Indeed, manipulation of c-Myc has been suggested as a 
potential vehicle for the manipulation of CD8, and in doing so affecting the T-cell 
response. Do and Li suggest that this may be utilised for patient benefit in the 
development of novel cancer therapies (Do and Li, 2016). Feinerman et al describe 
an inverse relationship between levels of cell surface CD8 and the absolute number 
of ligands required for T-cell activation, whilst the percentage of the overall 
population that is capable of responding remains mostly unchanged (Feinerman et 
al., 2008). In addition, T-cell function is intrinsically linked to CD8 expression. In 
most instances, loss of cell surface CD8 leads to reduced tetramer staining (Demotte 
et al., 2002, Drake et al., 2005).  
6.1.2 The CD8high and CD8low Phenotypes 
T-cells (CD3+ cells) may be split into six subsets based upon their CD4 and CD8 
expression at the cell surface: CD4-CD8-, CD4+CD8- (CD4 T-cells), CD4+CD8low, 
CD4+CD8high, CD4-CD8low, and CD4-CD8high (Orru et al., 2013). Thus there are two 
distinct subsets for each of the CD8-expressors (DP and CD8+ T-cells); CD8low and 
CD8high (also occasionally termed CD8dim and CD8bright, respectively). Both CD8high and 
CD8low CD8+ T-cells may be CD28+ or CD28- (effector or memory), suggesting that 
CD8high and CD8low subsets represent a separate phenotype. An IL-2 rich environment 
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favours the differentiation of naïve CD8+ T-cells into only CD8high effector cells, 
whereas in the presence of IL-4 both CD8high and CD8low phenotypes result, with 
plasticity between these two latter subtypes being demonstrated in response to IL-4 
(Olver et al., 2013, Kienzle et al., 2004, Apte et al., 2008). T-cell clones produced in 
the absence of IL-4 are unable to produce IL-4, maintain a neutral environment, and 
remain CD8high effector T-cells. They produce perforin, granzymes and IFNγ and are 
cytolytic of targets (Kienzle et al., 2004, Kienzle et al., 2002). CD8high T-cells 
produced in the presence of IL-4 maintain the ability to produce IL-4, but otherwise 
have a cytotoxic phenotype. In contrast, CD8low  T-cells, are able to produce IL-4 but 
otherwise have limited cytolytic function.  
It is debated whether these two last subsets cycle between the two states under the 
influence of IL-4, where IL-4 and IFNγ reciprocally control CD8 expression, and thus 
effector phenotype (Apte et al., 2008, Kienzle et al., 2004, Olver et al., 2013, 
Kienzle et al., 2002). CD8low T-cells may exhibit long-term survival, and whilst they 
are only weakly cytotoxic, have been shown to demonstrate anti-tumour activity 
(Olver et al., 2013). Given the similarity of tumour antigens to self, it is possible that 
this down-regulation of CD8 and plasticity between the IL-4-derived subsets is an 
essential feature to avoid cross-reactivity with self. It should be noted that these 
CD8low subsets represent distinct and sustained populations, and are entirely 
different from the transient down-regulation of CD8 at the cell surface seen in CD8+ 
effector cells which is normal following stimulation and activation via the TCR (Kao 
et al., 2005, Xiao et al., 2007).  
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6.1.3 Evidence for tuning of T-cell function 
Following T-cell activation, there is a transient down-regulation of cell surface CD8 
and TCR, and a reduction in T-cell antigen sensitivity (Garcia et al., 1996, Xiao et 
al., 2007). Others have suggested that CD8 levels at the cell surface remain 
unchanged however binding of CD8 and TCR to the pMHCI is reduced thus affecting 
function (Kao et al., 2005, Drake et al., 2005). It has been suggested that up-
regulation of cell surface CD8 allows more efficient recognition of low affinity and 
low avidity ligands (Takada and Jameson, 2009b). Naïve T-cells expressing low levels 
of CD8 on their cell surface are therefore weakly stimulated by self-antigen 
encountered in the periphery (Sprent and Surh, 2011, Surh and Sprent, 2008, Takada 
and Jameson, 2009a). It is likely that this low level of weak stimulation allows them 
to continue to exist, since long-term survival of the T-cell is impaired in the absence 
TCR stimulation (Takada and Jameson, 2009b, Park et al., 2007).  
Whilst this low level recognition, and partial activation of T-cells by self pMHCI is 
necessary for the persistence of these cells, it is evident that complete activation 
and targeting of self-ligands can occur resulting in autoimmune disease. The very 
fact that activation may occur to the same ligands and result in these two different 
consequent activities would suggest that the T-cell is capable of modulating its 
response. Indeed, it is essential that if the T-cell requires autologous stimulation in 
order to maintain the naïve pool in the long term, that a regulatory mechanism exists 
in order to prevent complete activation and thus widespread autoimmunity. CD8 
levels at the cell surface are adjusted according to the specificity of the TCR (Park et 
al., 2007). This chapter will attempt to explore the possibility that altering the levels 
of cell surface CD8 is a mechanism by which the antigen sensitivity of the TCR can be 
modulated, and levels of T-cell cross-reactivity can be controlled.  
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6.1.4 Factors that control of CD8αβ expression 
Cell surface CD8αβ levels are altered in response to various cytokines. CD8 is up 
regulated in the presence of IFN-γ and down regulated in response to IL-4 (Apte et 
al., 2008). These cytokines reciprocally result in increased or decreased levels of 
CD8α mRNA, suggesting that they are responsible for, or involved in, the switching on 
(IFN-γ) or off (IL-4) of the CD8α gene (Apte et al., 2008). CD8β does not exist on its 
own in nature, nor in the form of the CD8ββ homodimer, thus control of the CD8α 
gene ultimately results in control of cell surface CD8αβ expression (Devine et al., 
2000, DiSanto et al., 1988, Gorman et al., 1988). 
6.1.5 TCRs are inherently cross-reactive 
An essential feature of the TCR is its promiscuity, enabling the T-cell to recognise 
and respond to a multitude of different peptide ligands (Wooldridge et al., 2012, 
Mason, 1998). Whilst it is recognised that a single TCR may be highly cross-reactive, 
potentially recognising an average of 105 different peptide ligands, not all of these 
are ‘real’, or encountered in nature. The TCR recognises a range of ligands with 
varying affinity, thus the T-cell response is similarly variable. The exact mechanism 
by which it differentiates between different ligands is uncertain. A role for CD8 in 
controlling T-cell cross-reactivity has been postulated (Wooldridge et al., 2010b, van 
den Berg et al., 2007).  
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6.1.6 Altering the pMHCI/CD8 interaction affinity alters the ‘focus’ of the 
TCR 
It has been demonstrated in previous chapters, that altering the strength of the 
pMHCI/CD8 interaction affects the resultant T-cell response. Different TCR/pMHCI 
interactions are differently affected by these manipulations, leading to preferential 
activation of different affinity ligands, or, more simply, an alteration of the 
activation hierarchy when different peptide ligands are considered and compared. As 
has been discussed, this is true whether the manipulation of pMHCI/CD8 is achieved 
by altering the MHCI/CD8 binding region, or by manipulation of the CD8 molecule 
itself. Whilst it is evident that the non-polymorphic CD8 molecule itself remains 
unchanged in vivo, there are differences in the pMHCI/CD8 binding affinity between 
different MHCI alleles owing to differences in the invariant MHCI binding region, and, 
although the exact role of these natural variants remains unclear, it is possible that 
they are of biological significance.  
A better understanding of this possible focussing mechanism is important if CD8 is to 
be utilised in adoptive transfer systems; if the copy number of the transgene controls 
expression levels, the transduced cell will be unable to alter expression levels at the 
cell surface. The potential implications if CD8 expression levels are indeed involved 
in focussing between ligands are that the cell will be unable to alter which ligands 
are best recognised. If we are able to identify the levels required for best activation 
against a given agonist, then cells expressing the desired level of CD8 may be 
selected for expansion, enabling optimal ACT. 
242 
6.1.7 Aims 
Here, I hypothesise that the level of CD8αβ expression at the cell surface can have a 
dramatic affect on T-cell antigen sensitivity. In order to examine the effect that 
different levels of cell surface CD8αβ exert on T-cell activation, I have used the 
jurkat model described in previous chapters transduced with a well-characterized 
TCR and different levels of cell surface CD8αβ. The drive of previous manipulations 
has been to identify a means by which a designer co-receptor may be used to 
augment existing ACT systems. It therefore becomes important to identify the 
optimal level of CD8αβ expression required for effective target killing by CD8+ T-
cells. It is possible that this ‘ideal level’ varies between different affinities of TCR 
agonist, and classifying these factors will enable researchers to build a designer T-
cell, fine-tuned to target cancer, and optimise ACT cancer therapies to achieve high 
success rates. 
243 
6.2 Results 
6.2.1 Cell Lines co-transfected with wild type CD8αβ and the ILA1 TCR 
co-express similar levels of TCR and broad range of the CD8αβ co-
receptor. 
The JRT3-T3.5 cell line was co-transfected with ILA1 TCR and the co-receptor CD8αβ. 
Flow cytometric analysis of these cells demonstrated co-expression of both the ILA1 
TCR and CD8αβ. Presence of the TCR was confirmed by positive staining with anti-
rCD2 antibody, with anti-CD3 antibody, and with anti-αβTCR antibody. Presence of 
the CD8αβ co-receptor was confirmed by positive staining with anti-CD8α antibody, 
and anti-CD8β antibody (Figure 6.1). Staining confirmed expression of similar levels 
of TCR in transduced cell lines (Figure 6.2A). A wide range of CD8αβ expression was 
observed, ranging from CD8αβ- to a high level of CD8αβ expression (Figure 6.2B). 
Staining confirmed similar levels of CD8α and CD8β were expressed across this range, 
suggesting expression of the heterodimer (Figure 6.1). 
6.2.2 ILA1 TCR+ CD8αβ+ lines sorted for expression of different levels of 
cell surface CD8αβ maintained their phenotype following 
sorting/enrichment. 
J.RT3-T3.5 ILA1 TCR+ CD8αβ+ cell lines stained with anti-rCD2, anti-CD8α and anti-
CD8β were sorted using a modified FACSAria flow cytometer/cell sorter, selecting for 
populations expressing either no CD8, or low, moderate and high levels of CD8αβ at 
the cell surface (Figure 6.2B). Following enrichment in this manner, the sorted cell 
populations were expanded and re-stained. J.RT3-T3.5 ILA1 TCR+ CD8αβ-, J.RT3-T3.5 
ILA1 TCR+ CD8αβlow, J.RT3-T3.5 ILA1 TCR+ CD8αβmed, J.RT3-T3.5 ILA1 TCR+ CD8αβhigh
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Figure 6.1: JRT3-3.5 ILA1 TCR+ CD8αβ+ cell 
line expresses CD8α and CD8β in equal 
proportions, suggesting expression of the 
CD8αβ heterodimer. 
The J.RT3-3.5 ILA1 TCR+ cell line was stably 
transfected with CD8αβ. The resultant cell line 
was expanded, and enriched for CD8αβ+ cells. 
These cells were stained for FACs Canto analysis 
with ViViD Live/Dead stain, APC-conjugated anti-
CD8α antibody and PE-conjugated anti-CD8β 
antibody. Live events were recorded.  
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Figure 6.2: JRT3-3.5 ILA1 TCR+ CD8αβ+ cell 
line was sorted into CD8-, CD8low, 
CD8medium, and CD8high populations.  
The J.RT3-3.5 ILA1 TCR+ CD8αβ+ cell line was 
stained with ViViD Live/Dead stain, anti-CD8β PE-
conjugated antibody and anti-rat CD2 FITC-
conjugated antibody. Cells were sorted using a 
modified FACSAriaII flow cytometer. Non-viable, 
rat CD2- events only were excluded (A) and the 
cell line was sorted into CD8β-, and CD8βlow, 
CD8βmedium, and CD8βhigh populations (B) for 
expansion.
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were found to maintain relative expression levels of both the TCR and CD8αβ at the 
cell surface (Figure 6.3A-C).  
6.2.3 Increased level of cell surface CD8αβ results in enhanced pMHCI 
tetramer staining. 
When clonal primary CD8+ T-cells (MEL5 clone) stained with tetramers loaded with 
their cognate ligand (ELA) and anti-CD8 antibody are gated upon in order to examine 
the CD8low and CD8high populations separately, the following trend can be observed; 
clones with higher levels of cell surface CD8 exhibit greater tetramer staining as 
compared to clones expressing lower levels of cell surface CD8. This trend is the 
same irrelevant of the pMHCI/CD8 interaction affinity (Figure 6.4A & B). 
6.2.4 Increasing the level of CD8αβ at the cell surface has a negative 
impact on the recognition of cognate pMHCI ligand. 
J.RT3-T3.5 ILA1 TCR+ cell lines co-expressing different levels of CD8αβ were
incubated for 24 hours with C1R A2 B-cells, which had been previously pulsed with 
the ILA peptide. Assayed cells were stained with anti-CD19 antibody in order to gate 
out the B-cell populations from analysis, and anti-CD69 antibody, and fixed before 
data capture by flow cytometry. Live, CD19- events were recorded in order to obtain 
CD69 MFI. The mean of two replicates was plotted (Figure 6.5A). The results show 
that the J.RT3-T3.5 ILA1 TCR+ line is capable of being activated via the transduced 
TCR by cognate ligand, as evidenced by increased CD69 expression as peptide 
concentration is increased. Increased activation is demonstrated in the presence of 
the CD8αβ co-receptor, indicating that the transduced co-receptor is capable of
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Figure 6.3: Sorted JRT3-3.5 ILA1 TCR+ 
CD8αβ-, JRT3-3.5 ILA1 TCR+ CD8αβlow, 
JRT3-3.5 ILA1 TCR+ CD8αβmedium, and JRT3-
3.5 ILA1 TCR+ CD8αβhigh maintain their 
phenotype following expansion.  
Following sorting (Figure 6.2) and expansion, the 
JRT3-3.5 ILA1 TCR+ CD8αβ-, JRT3-3.5 ILA1 TCR+ 
CD8αβlow, JRT3-3.5 ILA1 TCR+ CD8αβmedium, and 
JRT3-3.5 ILA1 TCR+ CD8αβhigh cell lines were 
stained with ViViD Live/Dead stain, and with anti-
CD8α APC-conjugated antibody, anti-CD8β PE-
conjugated antibody and anti-rat CD2 FITC-
conjugated antibody. Viable events were recorded, 
and the data were concatenated into histogram 
plots. Expression of CD8α (A), CD8β (B) and TCR as 
indicated by rat CD2 marker gene expression (C), 
were compared between cell lines. 
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Figure 6.4: CD8+ T-cell clones stained with 
cognate tetramer demonstrate greater 
staining where higher levels of CD8 are 
found at the cell surface.  
The MelanA-specific CD8+ T-cell clone, MEL5, was 
stained with ViViD Live/Dead stain, anti-CD8 APC-
conjugated antibody, and PE-conjugated tetramer 
loaded with cognate peptide bound to either wild 
type HLA A2 or HLA A2 bearing either the 227/8 or 
A2/Kb mutations as described previously. Data 
were recorded using a FACSCanto flow cytometer. 
Live events were recorded, and gated to show 
CD8low, CD8medium, and CD8high expressing 
populations. Tetramers staining within these gates 
were concatenated into histogram plots and 
compared for each pMHCI/CD8 affinity The MFIs 
were calculated using FlowJo software, which are 
tabulated (B) and depicted (A). 
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Figure 6.5: J.RT3-T3.5 ILA1 TCR+ CD8αβlow
demonstrated greatest response to peptide 
activation as measured by CD69 up-
regulation for all agonists.  
Peptide pulsed C1R A2 targets (either one of 5Y, 
ILA and 3G peptides), as previously described for 
the ILA system, added at the desired final 
concentration (10-4 – 10-10, and 0 M), were 
incubated together with each of the J.RT3-T3.5 
ILA1 TCR+ CD8αβlevels cell lines, overnight. Cells 
were then stained and fixed for data capture by 
flow cytometry. Viable effector T-cell (CD19-) 
events were concatenated into histogram plots in 
order to obtain the MFI of CD69, and the data 
represent the mean and standard deviation of two 
replicate samples. Data points at the origin of the 
x-axis are generated in the absence of exogenous
peptide. Data were plotted comparing the
activation of the different cell lines by the same
ligand (A). Activation by ligands at 10-4 M peptide
concentration were compared (B). These data are
representative of multiple experiments (n>4).
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acting to increase the TCR recognition of pMHCI, as it does when endogenously 
expressed in primary CD8+ T-cells. However cell lines expressing higher levels of 
CD8αβ (CD8αβmedium and CD8αβhigh) exhibited poorer activation as measured by CD69 
up regulation compared to cell lines expressing the lowest level of CD8αβ (CD8αβlow), 
indicating that optimal activation by cognate ligand is achieved at lower levels of 
CD8 expression (CD8αβlow) (Figure 6.5A). 
6.2.5 Increasing the level of CD8αβ at the cell surface has a negative 
impact on the recognition of low and high affinity pMHCI ligands. 
J.RT3-T3.5 ILA1 TCR+ cell lines co-expressing different levels of CD8αβ were
incubated for 24 hours with C1R A2 B-cells, which had been previously pulsed with 
either the low affinity 5Y- or the high affinity 3G-peptide ligand. Assayed cells were 
stained with anti-CD19 antibody in order to gate out the B-cell populations from 
analysis, and anti-CD69 antibody. Data were collected by flow cytometry. The results 
show that the J.RT3-T3.5 ILA1 TCR+ line is capable of being activated through the 
transduced TCR by cross-reactive ligands identified for the ILA system (Laugel et al., 
2007b), as evidenced by increased CD69 expression as peptide concentration is 
increased. Greater activation was observed by the high affinity 3G- ligand (Figure 
6.5B).  
For each ligand, increased activation is demonstrated in the presence of the CD8αβ 
co-receptor, as compared to CD8- cells, as with the cognate ligand. When we 
examine activation by the high affinity 3G peptide agonist, the greatest response is 
still observed in the J.RT3-T3.5 ILA1 TCR+ CD8αβlow line, however we can see 
increased response by CD8- cells as compared to the higher CD8 expressing lines 
(J.RT3-T3.5 ILA1 TCR+ CD8αβmedium and J.RT3-T3.5 ILA1 TCR+ CD8αβhigh). For all 
253 
ligands examined, cell lines expressing higher levels of CD8αβ (CD8αβmedium and 
CD8αβhigh) exhibited poorer activation as measured by CD69 up regulation compared 
to cell lines expressing the lowest level of CD8αβ (CD8αβlow), indicating that optimal 
activation for all ligands examined is achieved at lower levels of CD8 expression 
(CD8αβlow) (Figure 6.5A & B). 
6.2.6 Activation via the ILA1 TCR when CD8 binding is abrogated is 
greatest at the lowest level of CD8αβ expression. 
J.RT3-T3.5 ILA1 TCR+ cell lines co-expressing different levels of CD8αβ were
incubated for 24 hours with C1R A2 227/8 B-cells, which had been previously pulsed 
with the 5Y, ILA, or 3G- peptide ligand. Assayed cells were stained with anti-CD19 
antibody in order to gate out the B-cell populations from analysis, and anti-CD69 
antibody. Data was collected by flow cytometry. For each ligand, activation was less 
when CD8 binding was abrogated compared to the wild type C1R A2 targets, and for 
lower affinity ligands (5Y and ILA) activation was minimal at all concentrations of 
peptide, thus only data for the 3G-ligand depicted any discernable difference in 
activation, and as such, is the only data shown in Figure 6.6. As with the wild type A2 
targets, greatest activation was observed in the J.RT3-T3.5 ILA1 TCR+ CD8low cell line. 
The J.RT3-T3.5 ILA1 TCR+ CD8medium and J.RT3-T3.5 ILA1 TCR+ CD8high cell lines 
responded less well to 3G than the J.RT3-T3.5 ILA1 TCR+ rCD2+ CD8- cell line (Figure 
6.6)
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Figure 6.6: Where CD8 binding is 
abrogated J.RT3-T3.5 ILA1 TCR+ CD8medium
and J.RT3-T3.5 ILA1 TCR+ CD8high lines 
respond less well to the CD8-independent 
3G-agonist than J.RT3-T3.5 ILA1 TCR+ CD8-
. 
Peptide (3G) pulsed C1R A2 227/8 targets were 
incubated together with each J.RT3-3.5 ILA1 TCR+
CD8αβlevels line overnight. Cells were stained and 
fixed for data acquisition using a FACScanto flow 
cytometer, and analysed using FlowJo software. 
Viable effector T-cell (CD19-) events were 
concatenated into histogram plots in order to 
obtain the MFI of CD69, and the data represents 
the mean and standard deviation of two replicate 
samples. The data sets at the origin of the x-axis 
are generated in the absence of exogenous 
peptide. These data are representative of two 
assays.
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6.2.7 The J.RT3-T3.5 ILA1 TCR+ CD8med and J.RT3-T3.5 ILA1 TCR+ CD8high 
cell lines express CD8αβ at greater levels than those observed 
naturally. 
The J.RT3-T3.5 ILA1 TCR+ CD8αβvar cell lines, primary CD8+ T-cell clones (ILA1 and 
MEL5), and PBMC directly ex vivo were counted and stained with anti-CD8β antibody. 
Cells were twice washed and then fixed in 1% PFA. Live, CD8+ events were recorded 
in order to obtain MFIs. The mean of two replicates was plotted. These data 
demonstrate that the J.RT3-T3.5 ILA1 TCR+ CD8αβlow express CD8 at levels similar to, 
or slightly higher than a primary CD8+ T-cell clones, and higher than ex vivo CD8+
cells isolated from PBMC. The J.RT3-T3.5 ILA1 TCR+ CD8αβmed line expresses CD8 at a 
level approximately 5 x greater than the primary CD8+ T-cell clones examined, and 
the J.RT3-T3.5 ILA1 TCR+ CD8αβhigh line expresses CD8αβ at a level approximated 10 x 
greater than the primary CD8+ T-cell clones examined (Figure 6.7). 
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Figure 6.7: The J.RT3-3.5 ILA1 TCR+ 
CD8αβlow cell line expresses similar levels 
of CD8αβ at its cell surface as compared to 
CD8+ T-cell clones in culture. 
5 x 104 cells of each population were counted and 
stained with ViViD Live/Dead stain and anti-CD8β 
PE-conjugated antibody, before fixing for data 
acquisition by flow cytometry. LIVE, CD8+ events 
were recorded in order to obtain and MFI. These 
data are representative of n=3 replicate 
experiments.
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6.3 Discussion 
Previous chapters have concentrated on the strength of the pMHCI/CD8 
interaction, and the effect of manipulating this on the ensuing T-cell response, 
however in vivo this interaction affinity is fixed. It has also been proposed that 
alteration of absolute levels of CD8 expressed at the cell surface may be a means 
by which the cell may regulate its response to pMHCI antigen (Takada and 
Jameson, 2009b, Park et al., 2007, van den Berg et al., 2007). Moreover, it has 
been suggested by some authors that alteration of the density of CD8αβ co-
receptors available may elicit a similar effect to manipulating to pMHCI/CD8 
affinity on modulating the specific ligand focus of the TCR (van den Berg et al., 
2013). In this chapter, I have utilised a jurkat model in order to examine the effect 
of altering the level of cell surface expressed CD8 on CD8+ T-cell activation. In so 
doing, by the nature of the jurkat model, the CD8 levels present on the cell surface 
are fixed; the cell is no longer able to up- or down-regulate its co-receptor. Indeed 
demonstration of maintenance of phenotype was a key feature of experimental 
design (Figure 6.3).  
The data demonstrates enhanced tetramer staining with increased cell surface CD8 
expression, both within and outside of the normal physiological ranges for CD8 
expression. Tetramer staining is a measurement of TCR/pMHCI binding at the cell 
surface, rather than of downstream signalling, as evidenced by enhanced tetramer 
staining with enhanced pMHCI/CD8 affinity tetramers, irrelevant of the ligand 
(Wooldridge et al., 2010a), The data obtained upon peptide activation of the jurkat 
lines expressing different levels of CD8 demonstrated the greatest activation by the 
CD8low cell line for all ligands examined; low, index and high affinity. This is in 
contrast to what is seen with tetramer staining of these lines (data not shown). 
Upon comparing the CD8 levels found in these cell lines to those seen upon the 
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surface of CD8+ T-cell clones in culture, and CD8+ T-cells directly ex vivo, we see 
that only the JRT3-T3.5 ILA1 TCR CD8low line expresses CD8 at levels close to the 
apparent physiological median. The JRT3-T3.5 ILA1 TCR CD8med and JRT3-T3.5 ILA1 
TCR CD8high lines express CD8 at levels that are at least 5x and 10x respectively, 
those found in primary cells. Whilst it is possible that levels are so high as to hinder 
cell surface kinetics and movement within the cell membrane, this is unlikely, as 
evidenced by the enhanced tetramer staining seen in the JRT3-T3.5 ILA1 TCR 
CD8med and JRT3-T3.5 ILA1 TCR CD8high cell lines.  
When CD8 binds the pMHCI concurrently with the TCR, it acts to deliver kinases 
such as lck to the CD3 complex, necessary for downstream triggering (Artyomov et 
al., 2010). It seems likely that when CD8 is found at the cell surface in levels so 
much greater than those found in nature (Figure 6.7), that many of these 
molecules would not have an associated lck, indeed the CD8 levels may be far in 
excess of the lck available. CD8 binding will therefore result in enhanced tetramer 
staining owing to the greater number of CD8 molecules to stabilise and bind the 
tetrameric pMHCI molecules, however, in the absence of the cytoplasmic 
counterpart to this interaction; the delivery of lck to the CD3 ITAMs, downstream 
triggering does not take place. It could be considered that CD8 acts as a 
competitive inhibitor to itself, where CD8 binds, thus blocking the biologically 
active CD8 with lck associated (CD8-lck hereafter) from binding. Additional studies 
using lck, both free in the cytosol and fused to the CD8β tail of our trans-CD8αβ, 
would be beneficial in testing this hypothesis, and work is underway to create the 
necessary constructs. 
Another approach to examine this hypothesis could be to determine the ratio or 
absolute numbers of CD8 and lck within the cell membrane. Levels of these 
molecules could be examined with the use of antibodies by Western Blotting 
assays 
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or via immunohistochemistry, both of which detect these molecules with the use of 
mAbs. Förster Resonance Energy Transfer (FRET) could also be considered, and this 
non-invasive technique for examining molecular interactions would provide detailed 
information on the interaction of cell surface molecule. This technique may also be 
considered for fine-tuning a means of examining the differences between different 
levels of CD8 expression at the cell surface (Shrestha et al., 2015). 
It has been previously alluded to that the CD8+ T-cells transiently down-regulate 
CD8 upon antigenic stimulation via its TCR (and co-receptor binding of the pMHCI), 
thus activated CD8+ T-cells express lower levels of CD8 at the cell surface (Xiao et 
al., 2007, Paillard et al., 1990). van den Berg et al examined the polyfunctionality 
of the ILA1 CD8+ T-cell clone in response to its cross-reactive ligands (van den Berg 
et al., 2013). These data, provided by Dr. Kristin Ladell, were re-visited. The level 
of CD8 expressed by this clone following antigenic stimulation via its TCR by 
different ligands, presented in the context of C1R A2 and C1R A2 227/8 targets 
(CD8 binding abrogated) is detailed in Figure 6.8. The data evinces that CD8 
expression by the ILA1 CD8+ T-cell clone post activation is greater when the peptide 
ligand is presented in the context of HLA A2 227/8 as compared to the wild type, 
i.e. abrogation of CD8 binding of the MHCI gives rise to a lesser degree of CD8 
down-regulation at the cell surface. This is true for every peptide ligand examined, 
as is as expected: CD8 enhances the antigen specific T-cell response, thus 
abrogation of its binding engenders less activation via the TCR. With the exception 
of the 3G8T super-agonist, the general trend of the data is such that as TCR/pMHCI 
is increased, so too is CD8 down-regulation in response to activation, and this is 
true for both A2 and A2 227/8. This is as expected: increasing the strength of the 
TCR/pMHCI interaction promotes a heightened T-cell response; and, greater 
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Figure 6.8: CD8+ T-cell clones stimulated 
by peptide presented in the context of 
pMHCI that does not bind CD8 express 
higher levels of CD8 at their cell surface.  
The ILA1 clone was incubated together with C1R 
A2 and C1R A2 227/8, which had been previously 
pulsed with peptide as described (van den Berg et 
al., 2013). Cells were stained with anti-CD19, anti-
CD3 and anti-CD8, and viability stain, before lysing 
to facilitate further staining for intracellular 
markers of activation (ICS). Data were acquired 
using a modified FACSAriaII flow cytometer, and 
FCS files re-analysed in order to create the above 
figure. This figure represents CD8 expression by 
the ILA1 clone, when stimulated by different TCR 
agonists presented in the context of C1R A2 and 
C1R A2 227/8 (abrogated CD8 binding). The data 
displayed in this figure are provided by Dr. John 
Bridgeman and Dr. Kristin Ladell. Multiple 
replicates of these experiments were repeated. 
(van den Berg et al., 2013). In addition, this assay 
has been repeated multiple times against single 
peptide agonists (n>8), using this ILA CD8+ T-cell 
clone, and other CD8+ T-cell clones, and these data 
are representative.
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activation foments greater CD8 down-regulation, so lesser expression. 
Interestingly, the CD8high line still activates least well, even where CD8 binding is 
abrogated. This could suggest that CD8 exerts an effect beyond its extracellular 
interaction with the pMHCI. Another possibility is that the high levels of CD8 
remove free lck from the cytosol, making activation more difficult. 
If we further revisit the data provided by van den Berg et al (Figure 6.9) (van den 
Berg et al., 2013), an apparent change in ligand activation hierarchy when CD8 low 
versus high populations are compared is observed, similar to the ‘focussing effect’ 
observed where the strength of the pMHCI/CD8  interaction is manipulated 
(Chapter 5). It is recognised that these changes are minimal for most effector 
functions, and may be explained by the CD8low gate likely comprising the most-
activated CD8+ T-cells, however, this is also true of those activated by a weaker 
agonist, where the trend appears to be such that the CD8high gated cells 
demonstrate greater activation. This observation clearly merits further 
exploration. These data would suggest that the differences seen in the CD8+ T-cell 
clone are small. In previous chapters of this thesis, the jurkat model has proved 
very useful for creating larger differences in the system, thus garnering more 
compelling evidence, however, the jurkat model developed thus-far for this 
chapter is clearly inadequate, and further work to create a better system, such as 
the CD8-lck chimera discussed above is plainly indicated. 
It becomes apparent that aside from the strength of the pMHCI/CD8 interaction, 
the absolute numbers of CD8 molecules expressed at the cell surface represents a 
further means by which T-cell antigen sensitivity could be manipulated in order to 
facilitate a more robust response to low affinity ligands, such as cancer ligands. 
This is another aspect of CD8+ T-cell function that must be better understood in 
order to build potential novel therapies for cancer, and augment and hone existing
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Figure 6.9: The relative potencies of TCR 
ligands is re-arranged by expression of 
different levels of CD8 at the cell surface 
of CD8+ T-cell clones. 
ILA1 clones were incubated together with C1R A2, 
which had been previously pulsed with peptide as 
described (van den Berg et al., 2013). Cells were 
stained with anti-CD19, anti-CD3 and anti-CD8, and 
viability stain, before lysing to facilitate further 
staining for intracellular markers of activation 
(ICS). Data were acquired using a modified 
FACSAriaII flow cytometer, and FCS files re-
analysed in order to create the above figure. 
Experiments were repeated multiple times for 
publication (van den Berg et al., 2013). Data were 
provided by Dr. Kristin Ladell and were re-analysed 
as follows. Non-viable, CD19+ (V500+) events were 
excluded from analysis. CD3+ events were 
examined and, cells were gated into CD8-, CD8low, 
and CD8high populations. Cytokine expression was 
examined for each of these populations to obtain 
an MFI. CD8+ T-cell activation at [peptide] 10-5 M, 
as measured by cytokine expression by each CD8 
population, in response to different TCR agonists, 
is depicted. TCR agonists are displayed on the x-
axis as a product of their TCR affinity (TCR/pMHCI 
interaction affinity). 
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adoptive transfer systems. The data generated in this chapter demonstrate the 
importance of ascertaining the level of CD8 expression that engenders the optimal 
CD8 T-cell response before CD8 can be utilised in an adoptive transfer system.
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Chapter 7 
Final Discussion 
7.1 Findings and Implications 
7.1.1 Overview 
In the production of this thesis I have furthered our understanding of the role that 
the CD8 co-receptor plays in T-cell activation. Moreover I have characterised the 
effects of manipulating the affinity of the pMHCI/CD8 interaction outside of its 
normal physiological range. I have established a means of enhancing the antigen 
specific T-cell response by enhancing the strength of the pMHCI/CD8 interaction, 
and quantified the point at which this manner of manipulation results in 
widespread non-specific activation, which would be deleterious to the host. I have 
probed the dynamic kinetics of the TCR/pMHCI and pMHCI/CD8 interactions, and 
discussed the co-relationships of these, further probing the means by which the 
TCR focus may be altered. And finally, I have conducted experimental work, which 
demonstrates that it is possible to alter T-cell antigen sensitivity by altering the 
level of cell surface CD8.  
In contemplating the implications of these new aspects of T-cell biology, I have 
considered the potential therapeutic advantage of manipulation of CD8. Some 
researchers are exploring means by which increased affinity TCRs may be utilised 
in cancer immunology. This thesis examines in detail the role and function of the 
CD8 and its potential to enhance affinity and that this may help advise future 
therapeutics. 
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7.1.2 The strength of the pMHCI/CD8 interaction and its effect on T-cell 
antigen specificity 
Whilst the CD8 co-receptor functions at extremely low pMHCI/CD8 interaction 
binding affinities, the average being KD = 130 µM (Bridgeman et al., 2012), the 
strength of the pMHCII/CD4 interaction is lower still (KD >2.5 mM) (Jonsson et al., 
2016), leading us to conclude that the T-cell co-receptors have evolved to perform 
their function of augmenting the TCR/pMHC interaction at uniquely low affinities. 
It has been demonstrated that super-enhancement of the strength of the 
pMHCI/CD8 interaction results in a total loss of T-cell antigen specificity 
(Wooldridge et al., 2010a). Wooldridge et al described this as activating the T-cell 
in an ‘antibody-like manner’, when the strength of the pMHCI/CD8 interaction was 
increased 15-fold. However, Wooldridge et al had previously demonstrated that a 
small increase in the pMHCI/CD8 interaction affinity (1.5 fold) resulted in an 
enhanced T-cell response to its cognate antigen (Wooldridge et al., 2007), and it 
seemed logical that the impact of pMHCI/CD8 interaction affinities falling between 
this slight enhancement in the strength of the pMHCI/CD8 interaction (1.5 fold) 
and the super-enhanced interaction (15 fold) merited further study. 
In Chapter 3, I demonstrated that rather than a gradual loss of T-cell antigen 
specificity as the strength of the pMHCI/CD8 interaction is increased, a sudden loss 
of T-cell antigen specificity is observed at a defined threshold. I subsequently 
characterised the defined affinity threshold beyond which the pMHCI/CD8 affinity 
may not be increased without loss of the exquisite specificity of the TCR (Dockree 
et al., 2017). Enhancement of the pMHCI/CD8 interaction strength beyond this 
threshold would result in catastrophic effects in the host; in all likelihood, 
widespread autoimmunity, and the potential inducement of cytokine storms. These 
findings suggest that there is an affinity window between this threshold and the 
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typical pMHCI/CD8 interaction affinity that could be exploited in order to 
potentially enhance the antigen specific T-cell response to weaker affinity ligands, 
such as cancer antigens. 
7.1.3 The development of new tools to study cell surface CD8 
The CD8 molecule exists at the cell surface as a dimeric molecule, as the 
homodimer, CD8αα, or the heterodimer, CD8αβ. Additionally, it has been shown 
that it may (rarely) exist as a CD8ββ homodimer (Devine et al., 2000), although in 
vitro it has been shown that CD8α is absolutely required for trafficking of CD8 to 
the cell surface, thus the CD8ββ homodimer cannot be found at the surface of cells 
(Zamoyska, 1994). The heterodimer, CD8αβ, is constitutively expressed on the cell 
surface of cytotoxic T-lymphocytes, thus these are more correctly termed CD8+ T-
cells, where it acts as co-receptor to the TCR/pMHCI interaction. Structural 
biologists have long recognised the preference of CD8 to homodimerise; human 
CD8αβ has thus far proved difficult to refold, and as a consequence the crystal 
structure remains unsolved. In chapter 4, I designed and made a construct which 
when transduced into cells, enables expression of CD8αβ at the cell surface. The 
creation of a means to alter cell surface expressed CD8αβ provided me with a 
valuable research tool with which to further probe CD8 biology, allowing me to 
manipulate CD8 via both the α and β chains, and in addition to alter the levels of 
CD8 expressed at the cell surface. 
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7.1.4 High Affinity CD8αβ 
A high-affinity CD8 α-chain mutation designed by a molecular modelling approach 
was previously characterised in the form of a soluble CD8αα molecule (Cole et al., 
2007, Cole et al., 2005). The enhanced affinity of the S53>N CD8α mutant for MHCI 
was confirmed by SPR, and crystallography studies identified enhanced and 
additional contacts as compared to CD8αα wild type (Cole et al., 2007). Data 
obtained in experiments detailed in Chapter 5 clearly demonstrate that the same 
S53>N CD8α mutation inserted into the heterodimeric cell surface expressed CD8αβ 
co-receptor also exhibits enhanced affinity for the pMHCI and results in enhanced 
T-cell antigen sensitivity, even to low affinity pMHCI ligands. High affinity CD8
mediated a statistically significant enhancement of T-cell antigen sensitivity in 
multiple systems, a feature which may be of great benefit when considering means 
of enhancing the T-cell’s response to weaker affinity agonists. 
In chapter 3, increased tetramer staining as the strength of the pMHCI/CD8 
interaction was increased, was clearly demonstrated, thus it is logical to conclude 
that the enhanced staining observed with pMHCI tetramer corresponds to increased 
pMHCI/CD8 affinity. In addition, pMHCI tetramer staining with the HLA A2 mutants 
examined in chapter 3 exhibited little or no staining with the abrogated A2 227/8 
tetramer as compared to the unstained control. When the J.RT3-3.5 ILA1 TCR+
CD8var lines were stained with the CD8 null (A2 227/8) ILA tetramer, only very 
slight staining was observed in the CD8- and CD8+ lines as compared to the 
unstained control. However, a shift in staining was observed when the CD8αS53Nβ 
co-receptor was expressed at the cell surface, suggesting that in the presence of 
this high affinity co-receptor, CD8 binding is no longer entirely abrogated by this 
DT227/8>KA mutation. This would imply that this particular mutation is too great 
an enhancement to be of use in ACT systems, however points us towards a new 
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goal in identifying one which is suitable, potentially closer to the strength of the 
Q115>E mutation examined in Chapter 3.  
7.1.5 Altering the Focus of the TCR (‘CD8-Focussing’) 
The CD8αβ co-receptor serves to enhance, stabilise and tune the antigen-specific T-
cell response to specific peptide ligands, presented in the context of MHCI 
molecules expressed on the surface of target cells. Each CD8+ T-cell espresses an 
unique αβTCR, which facilitates the recognition of different peptide ligands, whilst 
the CD8αβ co-receptor is largely non-polymorphic, binding as it does the invariant 
region of the pMHCI. Moreover the unique αβTCR is highly promiscuous, and is 
capable of recognising an average of 106 different peptide ligands (Wooldridge et 
al., 2012, Sewell, 2012). In Chapter 5, the potential role of CD8 in modulating 
pMHCI recognition by the TCR, or ‘focussing’ of the TCR, was probed.  
Manipulation of the strength of the pMHCI/CD8 interaction alters the focus of the 
TCR such that as the strength of the pMHCI/CD8 interaction is increased, the focus 
of the TCR is moved away from higher affinity ligands. Moreover, lower affinity 
ligands are elevated in their potency. Indeed the augmentation of the T-cell 
response is not uniform across the board, thus CD8 appears to exert a differential 
effect on the TCR, resulting in rearrangement of the relative potency hierarchy of 
its cross-reactive ligands. This was predicted by mathematical modelling (van den 
Berg et al., 2007), however this is the first time that the strength of the 
pMHCI/CD8 interaction has been manipulated by altering cell surface CD8, thus is 
the first time that this phenomenon has been explored using this approach.  
That TCRs must be cross-reactive is taken as dogma, however the mechanism by 
which the T-cell is able to control its own degeneracy, thus avoiding autoimmunity 
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and ensuring adequate response to challenge is unclear. Every single TCR must be 
autoreactive; otherwise the T-cell would have suffered death by neglect in the 
thymus. Additionally, it has been suggested that on-going weak self-stimulation is 
very likely the means by which the resting T-cell population is maintained. When 
the T-cell encounters and recognised foreign challenge, the response is rapid and 
robust, resulting in target deletion. We must ask what is different?  
As has been mentioned, TCR ligands tend to fall within defined ranges. 
Autoimmune pMHCI are recognised with relatively weak affinities, conversely 
foreign peptide antigens are recognised far more strongly, some of these being 
CD8-independent, i.e. they do not require co-receptor help in order to facilitate 
downstream triggering and thus T-cell activation. Ligand affinity is intrinsically 
linked to on rate and thus to dwell time (Holler and Kranz, 2003, Laugel et al., 
2007b). The CD8 co-receptor has been shown to stabilise the TCR/pMHCI 
interaction and thus increase dwell time of the ligand by over 2-fold (Holler and 
Kranz, 2003, Luescher et al., 1995), and in doing so increase the probability of full 
ITAM phosphorylation, thus initiating downstream signalling (Szomolay et al., 
2013).  
Complete-cell activation requires serial TCR triggering (Valitutti et al., 1995), so in 
order for T-cell activation to occur the triple structure must dissociate before the 
TCR can be re-cycled to allow the process to occur again. High affinity TCR ligands 
have a longer dwell time, and as a consequence do not absolutely require CD8 co-
receptor help in order for downstream signalling to occur. Indeed, for very high 
affinity super-agonists, their ability to bring about serial triggering may be 
hampered by the CD8 co-receptor because the triple structure is now too stable 
and fails to dissociate. Conversely, the short dwell time of a weak affinity agonist 
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means that triggering cannot occur without CD8 co-receptor assistance because the 
TCR/pMHCI interaction is too fleeting for full ITAM phosphorylation to occur. 
The data that I have presented in Chapter 5 supports this. Furthermore, if the 
pMHCI/CD8 affinity is enhanced by manipulation of either the CD8 molecule itself, 
or the CD8 binding region of the MHCI, then the triple structure is further stabilised 
and takes longer to dissociate. The probability of downstream signalling before 
dissociation is increased, however the focus of the TCR is moved away from high 
affinity agonists because they are now unable to bring about the serial triggering 
required. This novel aspect of CD8 biology may open up new means of enhancing 
the CD8+ T-cell response to cancer ligands, which tend to be of weaker affinity 
than those pertaining to foreign challenge. 
7.1.6 The effect of the level of CD8αβ expression on T-cell activation 
I have convincingly demonstrated the manner in which the focus of the TCR may be 
altered by manipulation of the strength of the pMHCI/CD8 interaction. Whilst it has 
been considered likely for sometime that the CD8 co-receptor may control cross-
reactivity (Wooldridge et al., 2010b), it should be evident, given the non-
polymorphic nature of the CD8 molecule, that this is not the means by which the T-
cell is able to focus between its degenerate ligands. When van den Berg et al 
predicted the phenomenon of CD8 mediated TCR ‘focussing’, manipulation of the 
absolute levels of CD8 expressed by the cell at the cell surface was postulated as 
the means by which focussing may be brought about in vivo. Whilst I have been 
unable to generate a jurkat model robust enough to allow me to probe this aspect 
of CD8 biology in more detail, I have re-analysed an existing activation dataset, 
and the findings may go some way to support this theory.  
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It has been recognised for sometime that upon activation, CD8+ T-cells down 
regulate cell surface CD8. I put forward the hypothesis that this is because they are 
focussing the TCR. High affinity ligands with a longer dwell time form stable 
TCR/pMHCI complexes, and as such require minimal CD8 co-receptor help. Indeed, 
in order for serial triggering to occur, they require the structure to dissociate. To 
this end CD8 is down-regulated resulting in a reduced probability of CD8 co-
receptor co-engagement owing to its reduced density at the cell surface. Weaker 
ligands absolutely require this co-receptor help in order to stabilise the TCR/pMHCI 
interaction for long enough to initiate triggering, consequently CD8 expression 
must remain high. If one considers that weaker affinity ligands are potentially self-
reactive, thus a low level of signal propagation in order to maintain the T-cell 
population is all that is required, since robust activation would result in 
autoimmune disease, then it makes sense that this should be so. It also goes some 
way to explain why those cancer agonists that fall between these two extremes 
may be missed by the immune system. 
The mechanism by which the cell may achieve this is unclear, however it seems 
likely that this should be in response to activation, as it is evident that the cell 
could have no way of pre-determining the nature of the peptide ligand which the 
TCR engages. The T-cell’s response to TCR triggering is to down-regulate CD8 at 
the cell surface. I suggest that the cell surface CD8 levels will continue to fall until 
the TCR becomes focussed, thus in the case of strong TCR ligands low levels of CD8 
are observed. These lower levels provide less CD8 co-receptor help to the 
TCR/pMHCI interaction and so stabilisation of the TCR/pMHCI is afforded, however 
in the instance of stronger ligands, this is sufficient for triggering, thus serial 
engagement may rapidly and efficiently occur. Weaker agonist require more co-
receptor help; the TCR must remain engaged with the pMHCI for sufficiently long 
for full iTAM phosphorylation (Szomolay et al., 2013), which owing to the less 
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stable TCR/pMHCI interaction, requires increased co-receptor help to stabilise the 
triple complex. If cell surface CD8 levels fall too far then triggering cannot occur. 
At this point, CD8 levels stop falling. An increase in CD8 levels at this point will 
result in the correct level of CD8 to provide optimal co-receptor help, i.e. the TCR 
is ‘focussed’ upon this ligand. 
7.1.7 The level of cell surface CD8 must be maintained within a 
defined range for normal T-cell function 
It is apparent that the levels of CD8αβ present of the surface of a T-cell do indeed 
affect T-cell function, as evidenced by the existence of sub-types expressing 
different levels of CD8; the CD8high and CD8low phenotypes. These two CD8+ T-cells 
subsets have been shown to have differing function with the CD8low expressers 
being of low cytotoxicity as compared to the CD8high phenotype (Kienzle et al., 
2004). Whilst the jurkat model which I created in order to explore the effect of 
manipulating the level of CD8 at the cell surface did not allow me to do so 
comprehensively, I believe that I have used this data to demonstrate the need for 
maintaining cell surface CD8 levels within a defined range, similar to that which 
has evolved in nature. Increasing the level of cell surface CD8 outside of this 
“normal” range, resulted in reduced T-cell antigen sensitivity. I believe that the 
most probable explanation for this observation is that the CD8 co-receptor acts to 
deliver lck to the TCR-CD3 complex, thus if the level of cell surface CD8 greatly 
outstrips that of lck within the cell, then co-receptor function is hampered. In 
future, building a chimeric CD8-lck molecule would allow me to explore the effects 
of increasing cell surface CD8 levels outside of the physiologically range. I have 
designed a construct whereby the lck is fused to the tail of CD8α by means of a 
serine linker, although this remains to be tested in vitro. 
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7.1.8 The β-chain Splice variants 
The β-chain of CD8 has been touched upon as another potential means of 
manipulating the T-cell response, but has not been probed in great depth. Human 
CD8β has been shown to exist in four possible alternatively splice variants (M-1 – M-
4), which differ in their cytoplasmic tails (Thakral et al., 2013, Thakral et al., 
2008, Giblin et al., 1989, DiSanto et al., 1993). These have been shown to originate 
from two additional exons acquired during recent evolution through a common 
human and chimpanzee ancestor (Nakayama et al., 1992). The M1 isoform is 
homologous to murine CD8β, and is therefore considered to be the wild type. It 
predominates in naïve T-cells, where expression of the corresponding mRNA for 
these isoforms is shown to be M-1 > M-4 > M-2 > M-3. The M-4 isoform has been 
demonstrated to be up-regulated in effector memory populations, where it appears 
to enhance response to APC at least 2-fold when compared to the wild type 
(Thakral et al., 2013). The exact mechanism by which the CD8β gene is controlled, 
creating the various transcripts, and the relative expression and role of each of 
these splice variants, is poorly understood. 
Differential expression of the β-chain splice variants across different T-cell subsets 
would suggest that they may act differently and thus play different roles in CD8+ T-
cell activation, as evidenced by enhanced cytokine production observed by CD8+ T-
cells with increased expression of the M-4 isoform (Thakral et al., 2013). Thus the 
β-chain splice variants may represent another means by which the antigen-specific 
T-cell response may be manipulated in order to create the most robust response to
a given antigen. The information could be utilised for patient benefit in order to 
tailor an optimal ACT by combining the TCR with a fully optimised co-receptor for 
the cancer target. The β-chain may also be considered as a potential target for 
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manipulation. Although, SPR studies to classify and examine mutations in vitro via 
SPR studies would be more difficult owing to the fact that as discussed above, 
refolding of human CD8αβ is extremely challenging. 
Other authors have noted enhanced T-cell response with β-chain mutations in the 
extracellular domain which are presumed to enhance the affinity of the pMHCI/CD8 
binding interaction (Devine et al., 2006). The stalk-region of the β-chain is also 
considered to confer better co-receptor function to the CD8αβ molecule. Whilst it 
is possible that this could be further explored in our quest for a ‘designer co-
receptor’, it seems more likely to the author that this is further evidence for the 
need for a heterodimeric co-receptor, rather than as potential area for 
manipulation or improvement.  
The alternatively spliced transcripts, which result in the β-chain splice variants, 
are differentially expressed in different populations, thus it seems likely that they 
have different effects on cell function. Whilst their expression and prevalence in 
primary cells has been explored, a fully robust understanding of the effect which 
they exert upon CD8+ T-cell function, and how they may act differently as co-
receptors needs to be fully understood. Whilst these splice variants differ in their 
cytoplasmic tails, and cannot therefore be classified and examined by in vitro SPR 
studies, I have demonstrated that they can be transduced into cells, where they 
are capable of acting as co-receptor to a transduced TCR. However, time 
limitations and limitations with the equipment to measure effector responses from 
the J.RT3-3.5 NFAT GLuc cell lines precluded an analysis of how these splice 
variants affect antigen specific T-cell activation, but did serve to demonstrate that 
this is an avenue which merits further exploration in future. Preliminary data is 
detailed in Appendix E. 
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7.1.9 Optimisation of the CD8 co-receptor 
When we talk about wishing to optimise a response, to a molecule, we need to first 
consider why this is not optimal in the first place? Why has CD8 evolved the way 
that it has if the response is not ‘optimal’? The answer is simple. CD8 has multiple 
roles in T-cell biology. It has a role in the thymic selection of TCRs. It must also 
provide co-receptor help when required, augmenting the CD8+ T-cell response, 
where necessary, enabling the immune system to mount a robust response to both 
foreign pathogens and dysregulated cells. Additionally, it must maintain a low-
grade recognition of self-ligands, whilst avoiding autoimmune disease. I would 
argue that if we consider all of these roles, and the areas where they may 
contradict one another, then the CD8αβ molecule is already fully optimal. 
However, I would argue that the main thrust of discussions in this thesis has been 
the potential to optimise the T-cell response by means of manipulating CD8, in 
order to augment the T-cell response to cancer ligands; ligands that require a full 
and robust response however are of lower affinity than those associated with 
foreign challenge. To this end, it seems important from the results generated that 
any attempts to utilise such a manipulated CD8 molecule for therapeutic gain 
should be robustly tested, and the effect on cross-reactivity in the host fully 
probed. 
7.1.10 Engineering CD8 as a potential means of augmenting ACT 
strategies 
CD8+ T-cells are capable of recognizing cancer antigens presented in the context of 
MHCI on neoplastic cells. In addition to the various strategies that tumours employ 
in order to evade the immune system, the TCR/pMHCI interaction itself is 
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sometimes sub-optimal in the case of cancer antigens, which is probably due to 
their similarity to self-antigens. Some cancer antigens are recognised by the TCR 
with a much weaker affinity than those of pathogen-derived antigens, typically 
with a KD of 10-100 µM, as compared to 8 µM, respectively (Bridgeman et al., 
2012), although there is overlap meaning that for some ligands this is not always 
the case. This discrepancy in TCR recognition of foreign vs. neoplastic-self pMHCI 
goes some way to explain why the immune system is capable of effectively clearing 
many pathogens, but appears to be far less efficient at eliminating cancer. The 
‘ideal’ TCR/pMHCI interaction affinity has been suggested to be around 10 µM 
(Zhong et al., 2013), and whilst there do exist cancer epitopes which when 
presented by the MHCI have an affinity for the TCR of this order, they are far less 
common than weaker cancer ligands. The potential for enhancement of the T-cells 
response to cancer ligands as a means of improving ACT has been demonstrated by 
the creation of ‘designer TCRs’, which recognise the cancer pMHCI with enhanced 
affinity. 
The failure of peptide vaccines to induce an adequate immune response to clear 
tumours would suggest that endogenous TCRs are inadequate for this challenge. 
Various ACT strategies to overcome this failing have already been discussed; ex 
vivo priming and expansion of TILs, genetic engineering with ‘designer TCRs’ or the 
creation of CARs, along with the potential problems and inadequacies in each 
system. It has been previously mentioned that for many of these systems, the 
approach must be tailored to the individual tumour in order to avoid toxicity due 
to the attack of other tissues. The CD8 co-receptor is a largely non-polymorphic 
molecule in man, and binds the invariant region of every pMHCI, acting to stabilise 
and enhance the CD8+ T-cell response (Wooldridge et al., 2005). It has been 
discussed how this feature of CD8 could make this molecule an ideal target for 
manipulating the CD8+ T-cell response, and as such a system would be globally 
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applicable. Although data generated with the S53>N CD8α mutant in Chapter 5 
provides proof of principle data that increasing the strength of the pMHCI/CD8 
interaction by manipulating cell surface CD8 can result in enhanced T-call antigen 
sensitivity, the fact that the affinity of this mutant is near to the affinity threshold 
beyond which non-specific T-cell activation is observed means that this mutant is 
not suitable for incorporation into ACT strategies. However, if a mutation could be 
generated which has a pMHCI/CD8 affinity similar to that of the MHCI Q115>E 
mutation, then data suggests that this would be of value in augmenting the T-cell 
response, whilst still maintaining T-cell antigen specificity.  
The data presented suggests that manipulation of the CD8 molecule may afford a 
means by which the T-cell response may be manipulated, however thus far this has 
only been examined in a jurkat model, and robust testing in primary cells is 
required before the value of this approach could be considered further. 
7.2 Future Work with enhanced affinity CD8 
7.2.1 SPR Studies 
The mutation examined in this thesis, S53>N, was identified by Cole et al by 
computational design, and was examined in the context of solubilised extracellular 
α-chain homodimers (Cole et al., 2007, Cole et al., 2005). The S53>N mutation 
provides a larger side chain, enhancing contacts between the MHCI α3 domain and 
the mutation, which is located in the CDR-like loops of CD8α. Enhanced affinity of 
CD8αα for HLA A2 of 30 µM was demonstrated using SPR, compared to a KD of 
127µM for the wild type CD8αα. Assumptions are made that CD8αα and CD8αβ 
interact with pMHCI with comparable affinities, based upon this being the case in 
the murine system, however it is uncertain whether this true, or if the mutation 
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may affect this. In the absence of structural studies of wild type CD8αβ, SPR 
studies of the heterodimer possessing this mutation are unlikely in the near future. 
It is recognised that SPR studies with the CD8αβ heterodimer would be a far more 
accurate means of assessing the affinity of this molecule of its pMHCI ligand in 
vitro, and that the refolding of soluble CD8αβ remains a goal for structural 
biologists studying T-cell cell surface interactions. 
The data presented in this thesis suggest that this mutation greatly enhances the 
pMHCI/CD8 interaction. Enhanced tetramer staining in the presence of CD8αS53Nβ 
compared to wild type CD8αα suggests that Kon is enhanced by this mutation. 
Tetramer decay studies will provide information with regards to the off rate 
(Laugel et al., 2007b, Holmberg et al., 2003). Preliminary experiments (data not 
shown) demonstrated greater stability of tetramer binding in the presence of the 
CD8αS53Nβ co-receptor, although this experiment requires repetition, and thus 
was not included in this thesis. 
7.2.2 Primary Cells 
A goal for this thesis was the examination of this mutation in primary cells. This 
would enable the quantification of this mutation and its effect on cross-reactivity 
with self. A combinatorial peptide library (CPL) screen can be used to examine the 
cross-reactivity of the TCR (Wooldridge et al., 2012), thus comparison of screens 
obtained where the wild type co-receptor is present will enable quantification of 
the effect of this mutation on TCR promiscuity. The jurkat model has not proved 
sufficiently robust to enable this kind of screening. 
Unfortunately, efforts to transduce primary cells with both TCR and CD8, resulted 
in a cell population which failed to undergo more than a single expansion before 
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crashing, meaning cell numbers were too small to facilitate the use of a CPL 
screen. 
Many strategies had been employed in efforts to infect primary cells with both 
lentiviral particles, and results are improving, and it is hoped that revisiting this in 
future will enable the generation of these primary cells.  
A further goal for these cells is to use them in experiments with tumour banks. For 
example, can primary cells transduced with the Mel TCR and with CD8αS53Nβ 
recognise Melanoma tumour cells? Can they target and kill these cells, and, most 
importantly, can they do so better than the wild type? The jurkat model could have 
been used with these tumour banks to prove enhanced recognition of ‘real’ tumour 
antigens in vitro, thus further demonstrating the potential value of this study. 
7.2.3 An ‘Ideal’ Affinity for CD8 to enhance T-cell function. 
A 1.5 fold enhancement in pMHCI/CD8 affinity has been shown to enhance the T-
cell response without the loss of specificity of the TCR probed in Chapter 3 
(Wooldridge et al., 2007, Dockree et al., 2017), thus it follows that a mutation in 
CD8 of a similar order is more likely to be of value for the enhancement of the T-
cell response to weaker affinity agonists in a clinical setting. Indeed, the Q115>E 
mutation of the MHCI heavy chain has been utilised by researchers for the 
identification of low avidity T-cell populations (Wooldridge et al., 2009, Melenhorst 
et al., 2008). Such a mutation could be useful in a clinical setting in any setting 
where enhancement of T-cell response is desirable, however, as has been 
discussed, many cancer agonists are recognised by TCRs with affinities lower than 
that which would give rise to the most robust response. Whilst it is recognised that 
there are numerous other reasons why cancers escape the immune system, and 
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that some cancer agonists are demonstrably of suitably high affinity to induce a 
cytotoxic response from the CD8 T-cell, the success of some enhanced affinity TCR 
ACT systems to treat some cancers demonstrates that, at least in some settings, 
this approach may be beneficial to the patient. 
7.2.4 Murine Models 
Following the identification of a potentially useful CD8 mutation resulting in only 
mild enhancement in T-cell function, and robust of this in vitro, a translational 
model to further test this novel approach is required. Murine models are frequently 
used prior to therapeutic trials. Owing to the vast species differences in CD8 
biology between these two species, this would need to be carefully considered. 
Murine CD8 recognises murine MHCI with an affinity approximately 5x greater than 
its human counterpart (Hutchinson et al., 2003, Kern et al., 1998, Willcox et al., 
1999, Gao et al., 1997a). The reason for this is uncertain, however it is assumed 
that murine CD8+ T-cells must be more cross-reactive than in man in order to 
provide a sufficient T-cell repertoire, owing to the fact that the number of TCRs 
available must be reduced due to differences in their size. For this reason, a fully 
humanised mouse model would need to be considered. 
7.2.5 Patient Safety 
It has been discussed in some detail the need for further examination of this 
system, particularly in primary cells, largely due to the concerns of the affect of 
such an approach on the cross-reactivity of the TCR, meaning that the generation 
of autoimmune disease in the host is a potential cause for concern. 
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Whilst I have stated that one benefit of the use of CD8 to enhance the T-cell 
response is that such a molecule could be globally applicable, individual testing of 
the effect in each specific host would be an essential part of any pre-clinical 
suitability screening. T-cells destined for ACT would need to be screened, however 
the simplest means of doing so against the hosts unique tissue type, would be by 
the use of directly ex vivo PBMC as targets. 
One of the greatest concerns with the enhancement of the T-cell response to 
tumour antigens is the potential for ‘on-target, off-tumour’ toxicity; whereby the 
engrafted T-cell successfully target the tumour cells, however activity against 
normal self tissues bearing similar (or autoreactive antigens) is also enhanced, 
leading to toxicity in the host. Some toxicities in patients are tolerated where the 
side effects are considered to be preferable to the disease, however it is 
recognised that sometimes in these systems, despite rigorous testing, unexpected 
toxicities occur; deaths have been reported following the use of high-affinity 
designed TCRs (Linette et al., 2013), and the enhancement of pMHCI/CD8 affinity 
as a means of enhancing the T-cell response would pose similar concerns for 
patient safety. 
Further safety features may be built into transduced cells. Cells can be made 
incapable of division, thus any deleterious effects would cease with the life of the 
cells, however this is a poor solution in the case of anti-cancer therapy, where one 
is hoping that the T-cells will persist and continue immune surveillance to control 
the tumour or prevent its return, thus perpetuating remission.  
Another approach is to introduce into the cell a gene switch as a means by which 
the T-cell’s activity may be controlled. Engrafted cells may be designed such that 
their activity may be initiated or terminated by administration of, for example, 
antibiotics such as tetracycline (Stieger et al., 2009, Jin et al., 2014). Transgene 
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expression in engrafted cells may be controlled in this manner, enabling the 
clinician to control the function and behaviour of the engrafted cells in vivo, 
meaning that the harmful activity of these cells may be ceased if deleterious 
bystander activity or autoimmunity occurs.  
Suicide genes have also been used as a means of enhancing the safety of ACT 
systems (Straathof et al., 2003, Griffioen et al., 2009). Inducible caspase, 
inducible Fas and CD20 have been considered as a means of controlling overgrowth 
transplanted cells, leading to induced apoptosis of the engrafted cell populations 
in the event of over-proliferation and over-activity. 
Potential enhancement of the activity of the endogenous TCR by enhanced affinity 
trans-CD8 is another potential cause for concern as effects could be hugely 
unpredictable and vary from patient to patient, as well as from one engrafted cell 
to another. Mis-pairing of trans-TCR with the endogenous can also add a further 
dynamic to the unpredictability of activity of transduced cells for adoptive 
transfer, and the addition of an enhanced affinity CD8 to the system may very well 
cause further problems. To this end, the removal of the endogenous TCR may be 
necessary to improve safety. TALENs have been used in some CAR systems to 
remove the endogenous α-chain, thus (along with CD52 removal) rendering the 
engrafted T-cells less sensitive to the lymphodepleting agent Alemtuzumab which 
may be administered concurrently in lymphoma therapy (2017, Qasim et al., 2017), 
however a similar strategy could be considered to remove the endogenous TCR is 
enhancement of the endogenous TCR is proved to be a cause of concern for patient 
safety.
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7.3 Summary and future directions 
The data presented in this thesis has implications for the development of a novel 
way of augmenting ACT systems. A better understanding of the means by which 
modulation of the CD8+ T-cell response can be achieved and how we can fine tune 
its response to alternate ligands will enable the development of future systems 
whereby the TCR may be tuned or ‘focussed’ to target ligands, enabling us to 
ensure ACT systems remain focussed to the cancer target of choice, as opposed to 
other cross-reactive ligands within the spectrum of TCR agonists which the CD8+ T-
cell is potentially able to recognise. Whilst the examples examined within this 
thesis are far from ready to be taken forward, further exploration in this area has 
great potential for identification and design of a model which may become ready 
to be taken forward to aid in design of novel ACT systems for patient benefit. 
Future studies need to focus on a detailed examination of a range of CD8 mutations 
falling between the wild type, and defined loss of specificity threshold (KD ≤ 
30µM). A robust examination of this system over such a range would enable a 
better quantification of the effects that increasing the strength of the pMHCI/CD8 
interaction has on T-cell antigen sensitivity, and the effects that this is likely to 
have on TCR focus. Furthermore, this system still requires testing in primary cells, 
and doing so would enable probing of the effects that these mutations have on 
cross-reactivity with self.  
The effect exerted by altering levels of cell surface CD8 upon the antigen specific 
T-cell response requires probing in more detail. Whilst it is predicted that altering
the levels of CD8 at the cell surface and in so doing the receptor density, is likely 
the means by which the cell alters the focus of its TCR in vivo, this hypothesis has 
not been examined. The effect of drastically increasing cell surface CD8 expression 
has been shown to be inhibitory to T-cell activation, thus it remains to either probe 
285 
this effect within a much narrower window, something which proved impossible in 
the jurkat model used in this thesis, or to pursue alternative strategies, such as the 
CD8-lck chimera. It is anticipated that more detailed examination of this area of 
CD8 biology will equip us with the tools necessary to build a designer co-receptor 
to augment sub-optimal ACT systems.
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Appendix A 
Primers Used in this thesis 
Name Sequence 
IRES for 5' GGC CAA AAG CCA CGT GTA TAA GAT AC 3' 
pELN seq rev 5' CAT AAA GAG ACA GCA ACC AG 3' 
Xba kozac for 5' GCT AGC TCT AGA GCC GCC ACC ATG 3' 
IRES rev 5' CTG GGG TTG TGC CGC CTT TGC AGG TG 3' 
CD8α int for 5' GAG TTG CTC AGG GCG 3' 
CD8α int rev 5' CAG CGC CCT GAG CAA 3' 
pMK seq for 5' CAG TCA CGA CGT TGT AAA AC 3' 
T2A for 5' GGC GAC GTC GAG GAA AAC CCC GGG 3' 
T2A rev 5' GCT TCC GCG TCC CTC GCC AGA TCC GG 3' 
pcDNA3.1 F 5' CTG GCT AGC GTT TAA ACG GGC CC 3' 
pcDNA3.1 R 5' AAT TCT GCA GAT ATC CAG CAC AGT G 3' 
T7 for 5' TAA TAC GAC TCA CTA TAG GG 3' 
CD8α F48Q sense 5' GCT GCC AGC CCC ACC CAG CGT CTG TAC CTG AGC 3' 
CD8α F48Q antisense 5' GCT CAG GTA CAG CAG CTG GGT GGG GCT GGG AGC 3' 
CD8α Q2K sense 5' GCC GCC AGA CCT AGC AAA TTC AGA GTC TCC CCC 3' 
CD8α Q2K antisense 5' GGG GGA CAC TCT GAA TTT GCT AGG TCT GGC GGC 3' 
CD8α S53N sense 5' CAC CTT CCT GCT GTA CCT GAA CCA GAA CAA GCC 3' 
CD8α S53N antisense 5' GGC TTG TTC TGG TTC AGG TAC AGC AGG AAG GTG 3' 
m Q2K mt for 5' GCT GCT GCA CGC CGC CAG ACC TAG CAA A 3' 
m Q2K mt rev 5' GTC CGG TCC AGG GGG GAC ACT CTG AA 3' 
m S53N mt for 5' AAC CAG AAC AAG CCC AAG GCC GCC 3' 
m S53N mt rev 5' CAG GTA CAG CAG GAA GGT GGG G 5' 
Table A.1: Primer sequences 
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Name -mer Application(s) Vector Plasmid(s) 
IRES for 
26 Sequencing Colony PCR CD8β.IRES.α pMK, pELN 
pELN seq rev 
20 Sequencing Colony PCR CD8β.IRES.α pMK, pELN 
Xba kozac for 
24 Sequencing Colony PCR CD8β.IRES.α pMK, pELN 
IRES rev 
26 Sequencing Colony PCR CD8β.IRES.α pMK, pELN 
CD8α int for 
15 Sequencing CD8β.IRES.α pMK, pELN 
CD8α int rev 
15 Sequencing CD8β.IRES.α pMK, pELN 
pMK seq for 
20 Sequencing CD8β.IRES.α pMK, pELN 
T2A for 
24 Sequencing TCRα.2A.β pMK, pELN 
T2A rev 
26 Sequencing TCRα.2A.β pMK, pELN 
pcDNA3.1 F 
23 Sequencing pcDNA3.1 
pcDNA3.1 R 
25 Sequencing pcDNA3.2 
T7 for 
20 Sequencing pGMT7 
CD8α F48Q sense 
33 SDM CD8β.IRES.α pMK 
CD8α F48Q 
antisense 
33 SDM CD8β.IRES.α pMK 
CD8α Q2K sense 
33 SDM CD8β.IRES.α pMK 
CD8α Q2K 
antisense 
33 SDM CD8β.IRES.α pMK 
CD8α S53N sense 
33 SDM CD8β.IRES.α pMK 
CD8α S53N 
antisense 
33 SDM CD8β.IRES.α pMK 
m Q2K mt for 
28 SDM CD8β.IRES.α pELN 
m Q2K mt rev 
26 SDM CD8β.IRES.α pELN 
m S53N mt for 
24 SDM CD8β.IRES.α pELN 
m S53N mt rev 
22 SDM CD8β.IRES.α pELN 
Table A.2: Primer names and applications 
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Appendix B 
Protein Biology Supplementary Data 
 
Figure B.1: Ion exchange MHCI. 
The FPLC trace obtained for ion exchange (IE) of a typical HLA A2 monomer. 
Retained fractions (A11 – A15 inclusive) to be taken forward for concentration, 
biotinylation, and gel filtration (GF) are indicated. 
  
 27092012 hla a2qe ela b2m ie:10_UV  27092012 hla a2qe ela b2m ie:10_Cond  27092012 hla a2qe ela b2m ie:10_Cond%  27092012 hla a2qe ela b2m ie:10_Conc
 27092012 hla a2qe ela b2m ie:10_Flow  27092012 hla a2qe ela b2m ie:10_Temp  27092012 hla a2qe ela b2m ie:10_Fractions
 27092012 hla a2qe ela b2m ie:10_Logbook
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Figure B.2: Gel Filtration of MHCI. 
The FPLC trace obtained for GF of a typical HLA A2 monomer. Retained fractions 
(A14 – B2 inclusive) to be taken forward for use in experiments are indicated. 
 
  
 HLA A2kb ELA B2M rpt gf 17072012:10_UV  HLA A2kb ELA B2M rpt gf 17072012:10_Cond  HLA A2kb ELA B2M rpt gf 17072012:10_Cond%
 HLA A2kb ELA B2M rpt gf 17072012:10_Conc  HLA A2kb ELA B2M rpt gf 17072012:10_Flow  HLA A2kb ELA B2M rpt gf 17072012:10_Temp
 HLA A2kb ELA B2M rpt gf 17072012:10_Fractions  HLA A2kb ELA B2M rpt gf 17072012:10_Inject  HLA A2kb ELA B2M rpt gf 17072012:10_Logbook
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Figure B.3: Ion exchange TCR. 
The FPLC trace obtained for IE of the MEL5 αβTCR monomer. Retained fractions 
(A15 – B11 inclusive) to be taken forward for concentration and GF are indicated. 
  
 mel 13 tcr 180712 ie 2:10_UV  mel 13 tcr 180712 ie 2:10_Cond  mel 13 tcr 180712 ie 2:10_Cond%  mel 13 tcr 180712 ie 2:10_Conc
 mel 13 tcr 180712 ie 2:10_Flow  mel 13 tcr 180712 ie 2:10_Temp  mel 13 tcr 180712 ie 2:10_Fractions  mel 13 tcr 180712 ie 2:10_Logbook
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Figure B.4: Gel Filtration of TCR. 
The FPLC trace obtained for GF of an αβTCR (MEL5) monomer. Retained fractions 
(A11 – A1 inclusive) to be pooled and taken forward for use in experiments are 
indicated. 
 
  
 01082012 5th gf mel5 tcr part 1001:10_UV  01082012 5th gf mel5 tcr part 1001:10_Cond  01082012 5th gf mel5 tcr part 1001:10_Cond%
 01082012 5th gf mel5 tcr part 1001:10_Conc  01082012 5th gf mel5 tcr part 1001:10_Flow  01082012 5th gf mel5 tcr part 1001:10_Temp
 01082012 5th gf mel5 tcr part 1001:10_Fractions  01082012 5th gf mel5 tcr part 1001:10_Inject  01082012 5th gf mel5 tcr part 1001:10_Logbook
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Figure B.5: Ion exchange CD8. 
The FPLC trace obtained for IE of the CD8αα monomer. Retained fractions (B9 – B6 
inclusive) to be taken forward for concentration and GF are indicated. 
  
 31082012 cd8aa caction exchange:10_UV  31082012 cd8aa caction exchange:10_Cond  31082012 cd8aa caction exchange:10_Cond%
 31082012 cd8aa caction exchange:10_Conc  31082012 cd8aa caction exchange:10_Flow  31082012 cd8aa caction exchange:10_Temp
 31082012 cd8aa caction exchange:10_Fractions  31082012 cd8aa caction exchange:10_Logbook
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Figure B.6: Gel Filtration of CD8. 
The FPLC trace obtained for GF of CD8αα monomer. Retained fractions (B15 – B11 
inclusive) to be pooled and taken forward for use in experiments are indicated. 
 
 01092012 gf cd8aa001:10_UV  01092012 gf cd8aa001:10_Cond  01092012 gf cd8aa001:10_Cond%  01092012 gf cd8aa001:10_Conc
 01092012 gf cd8aa001:10_Flow  01092012 gf cd8aa001:10_Temp  01092012 gf cd8aa001:10_Fractions  01092012 gf cd8aa001:10_Inject
 01092012 gf cd8aa001:10_Logbook
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Appendix C 
Sequence CD8α and α-chain Mutations
T CTAGAGCCG CCACCATGCG GCCCAGACTG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
T GGCTGCTGC TGGCCGCT CA GCTGACAGTG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CTGCACGGCA ACAGCGTGCT GCAGCAGACC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CCCGCCTACA T CAAGGTGCA GACCAACAAG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ATGGT CATGC TGAGCTGCGA GGCCAAGAT C
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AGCCTGAGCA ACATGCGGAT CTACTGGCTG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CGGCAGAGAC AGGCCCCCAG CAGCGATAGC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CACCACGAGT T T CTGGCCCT GTGGGACAGC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1
CGGCTGCCCA GACCCGAGAC ACAGAAAGGC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CCCCTGTGCA GCCCCAT CAC ACTGGGACTG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CTGGTGGCTG GCGTGCTGGT GCTGCTGGTG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
T CT CTGGGAG TGGCCAT CCA CCTGTGCTGC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AGAAGAAGAA GGGCGCGCCT T CGGT T CATG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AAGCAGT T CT ACAAGTGACT CGAGGCCCCT
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CT CCCT CCCC CCCCCCTAAC GT TACTGGCC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GAAGCCGCT T GGAATAAGGC CGGTGTGCGT
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3
GCCAAGGGCA CAAT CCACGG CGAGGAAGTG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GAACAGGAAA AGAT CGCCGT CT T T CGGGAC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GCCAGCCGGT T CAT CCTGAA CCTGACCAGC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GTGAAGCCCG AGGACAGCGG CAT CTAT T T C
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
T GCATGAT CG TGGGCAGCCC CGAGCTGACC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
T T CGGCAAGG GCACACAGCT GAGCGTGGTG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GACT T CCTGC CCACCACCGC CCAGCCCACC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AAGAAGT CCA CCCTGAAGAA AAGAGTGTGC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2
T TGT CTATAT GT TAT T T T CC ACCATAT TGC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CGT CT T T TGG CAATGTGAGG GCCCGGAAAC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CTGGCCCTGT CT T CT TGACG AGCAT T CCTA
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GGGGT CT T T C CCCT CT CGCC AAAGGAATGC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AAGGT CTGT T GAATGT CGTG AAGGAAGCAG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
T T CCT CTGGA AGCT T CT TGA AGACAAACAA
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CGT CTGTAGC GACCCT T TGC AGGCAGCGGA
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ACCCCCCACC TGGCGACAGG TGCCT CTGCG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4
GCCAAAAGCC ACGTGTATAA GATACACCTG
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Appendix D
Best Fit Curves Used to generate pEC50s 
Figure D.1: J.RT3-T3.5 ILA1 TCR+ CD8var 
neg = CD8-
WT = CD8αβ+ 
Mut = CD8αS53Nβ+
Best fit curves were applied to the data presented in Figure 5.1. The group were 
treated as a single batch (assumptions discussed in the main body of this thesis), 
and the curves used to generate pEC50s (Table 5.2), which were then scaled 
relative to each other in order to generate Figure 5.2. 
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Figure D.2: H9 ILA1 TCR+ CD8var 
neg = CD8-
WT = CD8αβ+ 
Mut = CD8αS53Nβ+
Best fit curves were applied to the data presented in Figure 5.3. The group were 
treated as a single batch (assumptions discussed in the main body of this thesis), 
and the curves used to generate pEC50s (Table 5.3), which were then scaled 
relative to each other in order to generate Figure 5.4. 
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Figure D.3: MEL5 CD8+ T-cell clone, C1R A2 (or mutant) targets. 
Best fit curves were applied to the data presented in Figure 5.5 & 5.7. The group 
were treated as a single batch (assumptions discussed in the main body of this 
thesis), and the curves used to generate pEC50s (Table 5.4 and Figure 5.6), which 
were then scaled relative to each other in order to generate Figure 5.6. 
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Appendix E
Supplementary Figures; The β-chain Splice Variants 
Figure E:1: CD8 β-chain splice variants: 
Four alternatively spliced variants have been described in man, resulting from 
alternative transcription of two exons, acquired in a common human/chimpanzee 
ancestor (DiSanto, Smith et al. 1993, Thakral, Dobbins et al. 2008, Thakral, Coman 
et al. 2013). The alternative transcriptions result in four distinctly different mRNA 
transcripts, giving rise to four different β-chain alleles, which differ in their 
cytoplasmic domain as detailed above. 
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β-chain 
M-1 M-2 M-3 M-4
α-chain 
wild type α β α β α β α β 
S53>N α β α β α β α β 
Table E.1 
CD8αβ co-receptor variants utilised in this thesis. 
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Figure E.2: The J.RT3-3.5 NFAT gluc. cell line was transduced with 
the both MEL5 TCR, and a CD8αβ co-receptor as detailed in table F.1. 
Following expansion, the resultant cell lines were stained to demonstrate 
expression of the TCR and the co-receptor.  
5 x 104 cells of each line were counted and re-suspended in 40 µl PBS and stained 
with fixable violet fluorescin amine dye (ViViD)(Life Technologies) at 1 in 800 
dilution for 5 minutes in the dark, and at room temperature. Cells were then 
washed and re-suspended in 40 µl PBS and stained with 0.5 µl anti-rat CD2 antibody 
(FITC-conjugated), 2 µl anti-CD8α antibody (APC-conjugated), and 2 µl anti-CD8β 
antibody (PE-conjugated) for 20 minutes at 4°. Cells were washed twice and fixed 
in 100 µl 1% paraformaldehyde. Data were acquired using a FACSCanto flow 
cytometer, and analysed using FlowJo software. The data plotted represent the 
live, singlet populations, concatenated into dot plots showing presence of TCR (as 
demonstrated by rCD2 staining) and CD8αβ (as demonstrated by CD8β staining). 
The double positive (Q2) populations for each line were selected for enrichment 
before further expansion and re-staining to confirm phenotype was maintained. 
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Figure E.3: JRT3-3.5 NFAT GLuc MELTCR rCD2+ CD8αβspl.var. cells are 
capable of responding to peptide through their TCR. 
C1R A2 target cells, pre-pulsed with ELA, 3T, or FAT peptides at a final 
concentration of 10-4 – 10-7 M, were incubated together with each of the J.RT3-3.5 
NFAT GLuc MELTCR+ CD8αβspl.var.  lines, at 37 °C for 24 hours. The supernatant was 
harvested, and assayed for luciferase protein by bioluminescence as per 
manufacturer’s instructions. The data plotted represent the mean of two replicate 
assays, and these data are representative of two identical experiments.  
These data show that these cell lines are capable of activating through their TCR in 
response to peptide, moreover that there appear to be differences between 
different species, however experimental design limits the usefulness of this 
interpretation. 
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Figure E.4: 
The same data shown is figure E.3 is re-plotted in order to examine activation by 
different affinity TCR agonists, where co-receptor help is provided by each β-chain 
splice variant. Differential activation is observed by the M3 variant, suggesting that 
further exploration of this system is indicated.  
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